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CHAPTER 1 
 
 
BACKGROUND AND RESEARCH OBJECTIVES 
 
 
HIV and AIDS 
 
 Over 33 million people in the world are thought to be infected with the human 
immunodeficiency virus (HIV) which is the causative agent of acquired immune 
deficiency syndrome (AIDS).  AIDS has now become a worldwide epidemic with a death 
toll estimated at over 25 million people (UNAIDS/WHO, 2008). Sub-Saharan Africa 
accounts for 67% of HIV/AIDS cases worldwide; however, recent epidemiological 
studies detailed in the 2008 UNAIDS report indicate rapid spread of HIV in developed 
and developing countries such as Russia and India, respectively. In 2007 an estimated 2.7 
million people contracted HIV, half of these people were under the age of 25. 
Approximately 2 million people died as a result of HIV infection in 2007, with 13.5% of 
these deaths being children.  Rising rates of HIV infection has considerable negative 
economic and social effects. HIV infection frequently affects people of working age, 
resulting in losses in worker productivity and GNP. Children of parents with HIV are 
frequently called on to care for infected individuals, resulting in an escalating cycle of 
poverty. In poorer countries, both parents are often infected, and this frequently results in 
the children of these parents becoming orphaned. It is estimated that Africa alone has 
11.6 million children orphaned as a result of AIDS. In many developing nations parents 
without access to adequate medical care often transmit the virus to their children through 
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child-birth or breastfeeding, resulting in numerous persons in the family becoming 
infected. 
 There are currently numerous drug treatments available for persons infected with  
HIV-1, but as these drugs do not eliminate infection, they must be continuously 
administered in order to be effective. Anti-retroviral treatments (ART) are also limited in 
their effectiveness in that the virus has the capability to rapidly mutate to escape 
suppression (Goetz et al., 2006; Tozzi et al., 2008). The drugs can also have significant 
toxic side effects, some of which can be exacerbated by long term use (Je van Schalkwyk, 
2008; McKoy et al., 2009). The high costs of these drugs also limit their application in 
countries lacking the medical and economic infrastructure required to afford them. An 
estimated 9.7 million people in developing countries require drugs to combat HIV-1 
infection but only 3 million actually receive them (UNAIDS/WHO, 2008). This limited 
overall coverage of infected persons along with the requirement for lifelong treatment has 
resulted in considerable resources being applied to the search for an effective vaccine 
against HIV-1. Unfortunately, these efforts have so far failed to provide significant 
protection from infection. These combined issues of a difficulty in treating so many HIV-
1 infected persons and the limited effectiveness of the existing drug therapies has led to 
continuous searches for new aspects of the viral life cycle to target for interdiction. It is 
thought that insight gained from these efforts could lead to more effective treatments and 
limit the spread of the virus to new persons.  The early stages of HIV-1 infection 
following viral fusion are one of the least understood aspects of the viral lifecycle yet 
appear to be one of the best targets for inhibition. Recent work from several groups has 
identified host factors that block retroviral infection by interfering with the early stages of 
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the viral lifecycle after the virus has entered the cell (Best et al., 1996; Sheehy et al., 
2002; Nisole et al., 2004; Sayah et al., 2004; Stremlau et al., 2004; Wolf and Goff, 2007).  
My doctoral research, described herein, is directed towards determining which host 
cellular proteins are involved in, and how these proteins mediate, the block to viral 
infection mediated by one of these host factors, TRIM5α. 
 
HIV-1 Infection and Progression of AIDS 
 HIV is transmitted through direct contact with bodily fluids from an infected 
individual. Infectious virus has been isolated from blood, semen, vaginal secretions, 
breast milk, and tears (Fujikawa et al., 1985; Wofsy et al., 1986). The primary mode of 
transmission is through direct sexual contact (Royce et al., 1997). Alternate sources of 
transmission include: sharing of needles for intravenous drug use, blood transfusions, and 
transmission of virus from mother to child during childbirth or subsequent breastfeeding. 
HIV enters the host by crossing mucosal surfaces where it is picked up by dendritic cells, 
which in turn transmit it to the main target cells: macrophages and CD4 positive T-cells 
(Niedecken et al., 1987).The progression of HIV infection to AIDS occurs in three phases: 
acute infection, clinical latency, and severe immune compromise or AIDS. The timeline 
from initial infection to the onset of AIDS is typically between 8 to 10 years (Figure 1-1). 
Acute infection is marked by a rapid rise in viral load and significant depletion of the 
host’s CD4+ T-cell population and can be associated with flu-like symptoms. This 
increase in viral replication results in viral dissemination to all lymphoid cell reservoirs 
and establishment of a persistent ongoing infection. Clinical latency follows the initial  
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Figure 1-1. Diagram of the clinical progression of HIV-1 infection. The CD4+ T cell 
levels are represented in blue while the viral RNA levels are shown in red. Primary 
infection leads to an acute viremia and dissemination of the virus throughout the host. 
Following this initial stage the immune system controls but does not eliminate the 
infection leading to a clinical latency stage which can last for many years. Viral 
replication proceeds and eventually the hosts CD4+ T cells are depleted to sufficient 
levels to permit the emergence of opportunistic infections. The emergence of these 
types of infections or depletion of CD4+ T cells below 200 cells per milliliter of blood 
results in the patient being classified as having AIDS. Once a patient is diagnosed as 
having AIDS they are considered seriously immunocompromised and frequently 
succumb to death from various infections (from www.microbiologybytes.com). 
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immune response to infection and the host’s immune cell population rebounds as the host 
begins to mount a defense against the disseminated HIV-1 infection, resulting in a 
decrease in detectable virus in the blood, but viral replication persists. The patients 
develop detectable antibodies targeting HIV epitopes in the blood, which is termed 
seroconversion. During this stage the host is typically asymptomatic and viral load is 
maintained at a lower, manageable level. Persistent viral replication leads to progressive 
depletion of CD4+ T cells due both directly to viral infection and indirectly from immune  
disregulation resulting from chronic immune activation (Shearer, 1998a; Shearer, 1998b). 
Loss of CD4+ T cells impairs the host immune system’s ability to respond to new 
infections or to suppress replication of previously acquired pathogens. As time progresses 
the host begins to become increasingly susceptible to infections such as Kaposi's 
sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV), Pneumocyctis jiroveci, 
and Mycobacterium Tuberculosis. Thes “opportunistic infections” do not normally cause 
disease in healthy, immunocompetent individuals (Johnson, 1985; Suttmann et al., 1988; 
Castro, 1995; Whitby et al., 1995). Patients experiencing these types of opportunistic 
infections or having CD4+ T-cell levels below 200 per milliliter of blood are classified as 
having AIDS (CDC, 1992). Late stages of AIDS are typically associated with the 
presentation of severe opportunistic infections, HIV-1 associated dementia, and overall 
wasting. Death of the patient generally results from eventually succumbing to one or 
more uncontrolled infections rather than directly from HIV-1 infection. 
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Host Genus Virus Species 
Humans Lentivirus 
Deltaretrovirus 
Human immunodeficiency virus 1 and 2 (HIV-1 and HIV-2) 
Human T-lymphotropic virus 1 and 2 (HTLV-1 and HTLV-2) 
Monkeys Lentivirus 
Betaretrovirus 
Spumavirus 
Simian immunodeficiency virus (SIV) 
Mason-Pfizer monkey virus (MPMV) 
Simian foamy virus (SFV) 
Felines Gammaretrovirus 
Lentivirus 
Feline leukemia virus (FeLV) 
Feline immunodeficiency virus (FIV) 
Puma lentivirus (PLV) 
Domestic 
cattle 
Deltaretrovirus 
Lentivirus 
Bovine leukemia virus (BLV) 
Bovine immunodeficiency virus (BIV) 
Jembrana disease virus (JDV) 
Chicken Alpharetrovirus Avian leukosis virus (ALV) 
Rous sarcoma virus (RSV) 
Equids Lentivirus 
Spumavirus 
Equine infectious anemia virus (EIAV) 
Equine foamy virus (EFV)  
Sheep Betaretrovirus Jaagsiekte sheep retrovirus (JSRV) 
Mouse Betaretrovirus 
Gammaretrovirus 
Mouse mammary tumor virus (MMTV) 
Murine leukemia virus (MLV) 
Fish Epsilonretrovirus Walleye dermal sarcoma virus (WDSV) 
 
 
 
HIV-1 Virus Classification and Structure 
HIV-1 is a member of the Retroviridae family of viruses, subfamily Lentiviridae (Table 
1-1). The members of the Lentiviridae family infect a narrow host range, implying that a 
critical level of host-viral interactions is required to support viral infection. The 
HIV-1 virion is an enveloped viral particle that is studded on the outer surface by trimers 
of the envelope proteins gp120 (SU) and gp41 (TM) (Figure 1-2). The envelope is 
derived from the host cell plasma membrane and contains numerous host cellular proteins 
(Kolegraff et al., 2006). The gp120 and gp41 proteins mediate attachment and fusion 
with the target cell. The matrix protein (MA) lines the inner leaflet of the viral membrane 
with a small portion incorporated into the viral capsid. The internal portion of the virion  
Table 1-1. Organization of the Retroviridae family. Viruses are classified according to 
predominant host organism and the genuses of each retrovirus that is capable of 
infecting that host (Modified from (Leroux and Mornex, 2008) 
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Figure 1-2. Diagram of a mature HIV-1 particle. The HIV-1 particle is surrounded 
by a lipid bilayer membrane derived from the host cell. The membrane is studded 
with trimeric forms of the envelope proteins gp120 and gp41 on the outer surface.  
Inside the virion is the conical viral core or “capsid” which is composed entirely 
of the viral protein CA. The capsid houses all replication proteins that will be 
required following fusion with the target cell as well as two copies of the RNA 
genome. Numerous host cellular proteins are located in the lipid bilayer as well as 
inside and outside the viral capsid. The standard two-letter abbreviations for the 
viral proteins are shown in parentheses ((Dismuke, 2006) Reprinted with 
permission). 
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Figure 1-3. Diagram of the HIV-1 genome. HIV-1 encodes the gag, pol, and env 
genes common to all members of the retroviridae family with the exclusion of 
spumaviruses. The regulatory genes tat and rev control viral expression. Additionally, 
HIV-1 encodes the accessory genes vif, vpr, vpu, and nef. These genes are dispensable 
for growth in culture but are required for infection in the host. The genome is 
approximately 9.7 kb long and is flanked by the long terminal repeat (LTR) 
sequences. The 5’ LTR contains numerous regulatory elements that promote 
transcription of the HIV-1 genome. The standard two-letter abbreviations for the viral 
proteins are capitalized. 
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Figure 1-4. Overview of the HIV-1 lifecycle. Upon attachment (1) and fusion (2) the 
viral capsid is released into the target cell cytoplasm where it begins the process of 
disassembly (3). The RNA genome is converted to DNA (4) and associates with viral 
and host proteins to form the PIC (5). The PIC is then transported into the nucleus (6) 
where it integrates into the host cell genome (7). Early transcripts (8) produce the 
regulatory proteins Tat and Rev (9) which return to the nucleus (10) and upregulate 
transcription and export of incompletely spliced RNAs respectively (11). Unspliced 
or partially spliced RNAs encode the structural proteins and viral accessory proteins 
respectively (12). The structural proteins traffic to the cell membrane (13) where the 
rendezvous with the envelope proteins (not shown). The structural proteins drive 
budding of immature virions and upon release (14), protease cleaves them to facilitate 
formation of a new mature virion (15), ((Scherer et al., 2007) Reprinted with 
permission from Nature Publishing Group). 
 10 
 
contains the viral capsid core composed entirely of the p24 protein (CA). The capsid 
houses the viral replication proteins and the viral RNA genome. Viral proteins inside the 
capsid include the reverse transcriptase protein (RT), integrase (IN), viral protein R (Vpr), 
nucleocapsid (NC), along with two copies of the 9.2kb (+) positive strand RNA genome. 
Numerous host-derived cellular proteins are also present in the capsid. The RNA genome 
includes 9 different genes that encode a total of fifteen proteins (Figure 1-3). The viral 
proteins that are enclosed within the capsid are responsible for converting the RNA 
template into DNA and integration of the viral genome into the host cell’s DNA.  
 
HIV-1 Lifecycle 
 The HIV-1 lifecycle begins when the surface protein gp120 binds to its target, the 
cell-surface protein CD4 (Figure 1-4), (Freed, 2001). This binding induces a 
conformational change in gp120 that exposes a cryptic loop, which in turn binds to one of 
two coreceptors: CCR5 or CXCR4. Binding of both CD4 and coreceptor results in release 
of the gp41 fusion peptide into the target cell membrane and brings the virus and cell 
membranes into close apposition (Gallo et al., 2001). The fusion peptide of gp41 then 
folds back upon itself forming a highly stable six-helix bundle structure. At this point, the 
membranes of the virion and target cell merge and the viral capsid is released into the 
target cell’s cytoplasm. Upon entering the host cell, the capsid begins a process of 
disassembly that has been termed “uncoating” (Aiken, 2006). Disassembly results in 
release of the viral ribonucleo-protein (RNP) complex which is responsible for reverse 
transcription of the viral RNA genome to DNA. Reverse transcription is a discontinuous  
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Figure 1-5. Diagram of HIV-1 reverse transcription. Reverse transcription products 
are labeled as follows: grey for viral RNA, red for viral DNA. The tRNA primer is 
labeled in black. Synthesis of the viral DNA from the RNA template results in 
degradation of the RNA template via the RNaseH domain on RT. PBS is the primer 
binding site where reverse transcription is initiated. The PPT is the polypurine tract 
which is resistant to degradation by RT and serves as the initiation point for positive 
strand DNA synthesis ((Sarafianos et al., 2001) Reprinted with permission from 
Nature Publishing Group. 
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process that occurs in multiple stages (Figure 1-5). Upon completion of reverse 
transcription, the viral DNA is part of a complex of viral and host cellular proteins that is 
referred to as a preintegration complex or PIC. This PIC is then brought into the nucleus 
via active transport through a nuclear pore in a mechanism that remains undefined. 
Following entry into the nucleus, the viral DNA is inserted into the host cell genome by 
the IN protein and the DNA is resealed using host DNA repair proteins.  
 After integration, the 5’ end of the long terminal repeat (LTR) of the HIV-1 viral 
genome binds several cellular transcription factors that upregulate transcription of the 
viral genome. The initial viral mRNAs are multiply spliced to produce the viral proteins 
Tat, Rev, and Nef. Tat potently upregulates transcription of the viral genome by 
recruiting host cellular factors to the nascent viral RNA transcripts that modify RNA 
polymerase II, thereby enhancing transcription efficiency (Wei et al., 1998). Viral 
transcripts are exported from the nucleus and translated by the host cell translation 
machinery. Nef is responsible for preparing the host cell for infection utilizing a variety 
of functions including down-regulation of CD4 and MHC class I molecules from the cell 
surface, and interaction with multiple cellular kinases that enhance HIV replication in 
various ways (Baur, 2004). The Rev protein regulates viral expression by allowing 
unspliced or incompletely spliced viral transcripts to exit the nucleus. As the level of Rev 
increases in the cell, unspliced transcripts that encode the viral structural proteins begin to 
exit the nucleus. The major viral structural protein of HIV-1 is p55Gag (Gag). Gag 
contains all of the structural proteins; MA, CA, and NC, required for HIV-1 viral 
formation as well as the p6 late domain region. Upon translation, Gag traffics to the cell 
membrane where it localizes via an N-terminal myristylation modification. Expression of 
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the Gag protein alone is sufficient to drive viral budding from the host cell (Gottlinger et 
al., 1989). The unspliced viral transcripts also encode a second viral structural protein, 
Gag-Pol, which results from a -1 ribosomal frameshift that occurs during translation. The 
Gag-Pol protein contains all of the HIV-1 structural proteins along with the viral protease 
(PR) and the replication enzymes RT and IN. Gag-Pol also traffics to the host cell 
membrane where it is incorporated into budding virions through Gag-Gag interactions. 
Gag is responsible for recruiting the viral RNA for viral incorporation via its interaction 
with a 3-dimensional structure formed by the nascent HIV-1 RNA transcripts known as 
the packaging (ψ) element (Aldovini and Young, 1990). Gag also binds and incorporates 
numerous cellular mRNAs in a nonspecific manner through their interaction with the NC 
region of Gag (Muriaux et al., 2001). These mRNAs provide a critical structural 
component of budding virions as mutations that prevent RNA binding result in 
abolishment of viral production. 
At the surface of the cell Gag interacts with the viral Env proteins gp120 and 
gp41 that are cotranslationally inserted into the endoplasmic reticulum (ER) and brought 
to the cell surface via the host cell’s endosomal transport systems. Accumulation of Gag 
on the cell surface results in recruitment of host cell ESCRT machinery through the p6 
domain of Gag (von Schwedler et al., 2003). The ESCRT machinery facilitates viral 
budding and pinching off of the newly formed virion. At this time, the protease in Gag-
Pol undergoes an intramolecular catalysis resulting in cleavage and freeing of the viral 
PR protein (Pettit et al., 2004). PR then proceeds to cleave Gag and Gag-Pol, freeing the 
individual viral proteins and resulting in reorganization of the internal viral structure from 
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the immature to the mature form. Only after this reorganization to the mature form is the 
virion capable of infecting the next target cell. 
  
The HIV-1 Capsid and Uncoating 
 During maturation by the viral protease, the Gag polypeptide is cleaved into its 
individual subunits of MA, CA, NC, and p6. The CA protein then associates through 
intermolecular interactions to form the mature viral capsid. Electron micrographs of  
cell free, intact virions show an electron dense, fullerene cone that is not present in cell-
associated virions (Figure 1-6). Impairment of Gag cleavage via mutation or addition of 
pharmaceutical inhibitors results in a failure to complete maturation and leads to an 
almost complete loss of viral infectivity. This indicates that formation of the capsid is a 
critical aspect of the viral lifecycle (Nitschko et al., 1991; Wiegers et al., 1998). The 
HIV-1 capsid is composed entirely of units of the CA protein organized into hexameric 
repeating units with 12 pentameric “defects” incorporated to allow proper cone formation 
(Ganser et al., 1999). Studies utilizing electron microscopy have led to an estimate of 
approximately 5000 Gag molecules incorporated into a budding virion but analysis of the 
cores has shown they are composed of only 1200-1500 CA monomers indicating there is 
a considerable excess of CA present in a maturing virion (Briggs et al., 2003; Briggs et 
al., 2004). The CA protein contains all of the determinants necessary to organize core 
formation. In vitro assembly reactions containing HIV-1 CA purified from bacteria result 
in tube-like structures composed of hexameric repeats analogous to the hexameric 
organization of CA in the viral core (Li et al., 2000). These reactions can also contain 
cones and some spheres and analysis has shown that these structures are also composed  
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A 
B 
Figure 1-6. Picture and diagram of HIV-1 capsid (A) Electron micrographs of 
cell free virions. Mature virions contain the electron dense fullerene capsid 
surrounded by the lipid bilayer (Lanka, 1995). (B) Structural model of a 
mature HIV-1 capsid. The capsid is composed entirely of CA protein arranged 
in hexameric repeats with approximately 12 pentameric “defects” included to 
allow curvature. The six vertices of each hexamer represent 6 independent CA 
proteins. Pentamers are shaded darkly ((Ganser et al., 1999) Reprinted with 
permission from AAAS). 
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Β-hairpin loop 
CTD 
NTD 
CypA-binding loop 
Figure 1-7. Ribbon diagram of the HIV-1 CA protein. Structure is based upon 
data from Gitti, et al., 1996 and Gamble, et al, 1997. Generated with Swiss-
Pdb software. 
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of CA organized into hexameric repeats (Ehrlich et al., 1992; Gross et al., 1997; Gross et 
al., 1998; Ganser et al., 1999). 
The organization of CA into hexameric lattices is thought to be a general feature 
of retroviruses (Campbell and Vogt, 1995; Mortuza et al., 2004; Mortuza et al., 2008). 
Impaired core formation, via mutations in Gag cleavage sites or in the viral protease, 
results in a significant loss of viral infectivity. The HIV-1 CA protein is highly helical in 
nature with 11 overall helices, 7 in the N-terminal domain (NTD), (Figure 1-7) and 4 in 
the C-terminal domain (CTD), (Gamble et al., 1996; Gitti et al., 1996; Momany et al., 
1996; Gamble et al., 1997). The NTD also contains 2 β-hairpins and an exposed loop that 
is rich in proline. Residues in this loop have been shown to bind the host cellular protein 
cyclophilin A (CypA), (Franke et al., 1994). In 2005, the crystal structure of hexameric 
lattice of the N-terminal domain of the gammaretrovirus N-tropic MLV was determined 
and was remarkably similar to the model of the HIV-1 CA hexamer (Li et al., 2000; 
Mortuza et al., 2004). Overlays of the respective capsid structures show high levels of 
structural similarity between the two NTDs of the HIV-1 and MLV CA proteins despite 
limited sequence homology at the amino acid level. CA proteins derived from various 
other retroviruses have also been shown to adopt very similar capsid structures. 
While insight into the mechanism of self assembly of mature CA into a capsid of 
hexameric lattice structure has increased substantially, the process of HIV-1 uncoating in 
the target cell remains one of the most poorly understood aspects of the viral lifecycle. 
Electron microscopy studies of cells infected with high levels of incoming virus have 
failed to detect intact viral capsids, suggesting that uncoating occurs rapidly (Grewe et al., 
1990). Analysis of subviral particles derived both in vitro and in vivo show a rapid loss of 
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CA as the viral lifecycle progresses (Bukrinsky et al., 1993; Miller et al., 1997; Fassati 
and Goff, 2001). In contrast, analysis of particles derived from MLV-infected cells shows 
that the subviral particles retain most of their capsid even after completion of viral DNA 
synthesis (Bowerman et al., 1989). The difference in the requirement of capsid shedding 
is postulated to play a role in why lentiviruses are capable of infecting quiescent cells 
while other retroviruses require the cell to divide to gain access to the nucleus.  
A considerable amount of what is known about HIV-1 uncoating has been 
obtained from the studies of alterations to CA. The CA protein has been extensively 
mutagenized and these mutants have been intensely studied for effects on viral assembly, 
viral release, and infectivity. In 2002, a large panel of HIV-1 CA mutants was analyzed 
for the ability to form stable cores and the overall impact of the mutations on viral fitness 
(von Schwedler et al., 1998; Forshey et al., 2002). Capsids composed of these mutant CA 
proteins were isolated from concentrated virions by equilibrium density centrifugation 
and then assayed for the rates of disassembly using an in vitro uncoating assay. The study 
identified numerous mutants that resulted in decreased stability of the cores formed by 
the mutant CA proteins (unstable). Several other mutants were shown to have cores that 
were more stable than wild-type (hyperstable). When these mutants were tested for 
infectivity, it was found that both unstable and hyperstable CA mutants were poorly 
infectious in target cells. Analysis of real-time PCR transcripts (qPCR) of the reverse 
transcription products of both types of mutant viruses showed an impairment of the virus 
to complete early stages of reverse transcription. These findings led to the conclusion that 
the HIV-1 capsid exists as a metastable structure that must disassemble at an appropriate 
rate in order for the virus to be infectious. Why the rate of disassembly is so critical is 
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currently a matter of considerable research interest in the HIV-1 field. Numerous theories 
have been proposed as to why the core must uncoat at a specific rate including: a 
requirement of the capsid for viral trafficking through the cytoplasm following fusion, a 
requirement for certain concentrations of RT for efficient reverse transcription, or 
coupling of disassembly to nuclear entry of the viral PIC (McDonald et al., 2002; Arhel 
et al., 2007). While the exact mechanism of why the rate of uncoating is so critical to 
viral infection remains uncertain, the requirement for uncoating is highly consistent. CA 
mutants that are overly stable are very poorly infectious. Studies by David Dismuke in 
our lab using the unstable mutant Q63A/Q67A have shown that this virus undergoes 
reverse transcription but is impaired for both nuclear entry and integration (Dismuke and 
Aiken, 2006). Analysis of purified PICs from cells infected with this mutant virus 
showed elevated levels of CA compared to wild-type HIV-1, suggesting that failure to 
completely shed the viral capsid impairs subsequent steps in the viral lifecycle. Overall, 
the implications for study of HIV-1 uncoating are very clear: as the rate of capsid 
shedding is critical for viral infectivity, understanding how the virus uncoats may provide 
potential avenues for new therapies designed to disrupt the uncoating process, possibly 
providing a new target for therapy. 
 
HIV-1 and Cyclophilin A 
 In 1994, a yeast-two hybrid screen identified the members of the human 
peptidylprolyl isomerase family, specifically CypA, as a binding partner to HIV-1 Gag 
(Luban et al., 1993). The CypA protein catalyzes the cis-trans isomerization of proline 
residues on proteins facilitating proper protein folding (Nieba-Axmann et al., 1997). 
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CypA is specifically incorporated into virions via interactions with the HIV-1 CA protein 
on the exposed proline rich loop (Franke et al., 1994; Thali et al., 1994). The Gag 
proteins of the closely related HIV-2 or SIV derived from rhesus macaques (SIVmac
As CypA is incorporated into virions via its interaction with Gag, it was a matter 
of debate as to whether the CypA provided by the cell producing the virus was more or 
less important than the CypA present in the target cell. Studies from several groups 
employing knockdown or knockout of CypA in either producer or target cells eventually 
identified the target cell CypA as being of primary importance in HIV-1 infection 
(Sokolskaja et al., 2004; Hatziioannou et al., 2005). Collectively, these findings have led 
) do 
not bind to CypA and these viruses do not incorporate CypA into budding virions 
(Braaten et al., 1996c). HIV-1 infection in the presence of the immunosuppressive drug 
Cyclosporin A (CsA) or in cells which lack CypA is severely impaired (Franke and 
Luban, 1996). Mutation at position 89 on the loop of the CA protein results in a failure of 
CA to bind CypA and similar infectivity defects as virus passaged in the presence of CsA 
(Braaten et al., 1996b). The importance of CypA in enhancement of HIV-1 infection was 
further highlighted by the finding that addition of CsA to Owl monkey kidney (OMK) 
cells resulted in a dramatic increase in viral infection (Towers et al., 2003). It was thus 
postulated that CypA mediates an important step in either capsid assembly or 
disassembly that enhances infectivity of HIV-1. Extended passage of HIV-1 in the 
presence of CsA results in mutations near the CypA binding domain of CA that render 
the emergent virus dependent on the presence of CsA for full infectivity (Braaten et al., 
1996a; Franke and Luban, 1996). This effect is observed in certain cell lines but not in 
others.  
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to the theory that CypA plays a critical role in HIV-1 uncoating. As the CypA binding 
loop is exposed to the outer capsid surface and the loop contains multiple proline residues, 
it is thought that cis-trans isomerization of these residues may play a role in capsid 
disassembly. Analysis of CA by NMR has shown that the majority of CA exists in trans 
conformation at the Gly 89-Pro 90 position, but an understanding of how catalysis of 
isomerization of this loop by CypA impacts viral infectivity has remained elusive (Bosco 
et al., 2002). Despite the identification of the interaction of CypA with CA over 15 years 
ago and considerable research into CypA effects on viral infectivity, the role of CypA in 
HIV-1 infection remains poorly understood.  
 
Post-Entry Restriction 
 In the 1970’s studies of the differential susceptibilities of various inbred mouse 
strains led to the identification of several host cell factors that restrict infection by 
differing strains of the Friend Murine Leukemia Virus (MLV), (Lilly, 1967; Pincus et al., 
1971, 1975). One of these factors, Fv1, targets viral replication at a point in the lifecycle 
after fusion but prior to integration (Pryciak and Varmus, 1992). This factor is dominant 
in cells transfected with yeast artificial chromosomes (YACs) derived from the murine 
genome, indicating the presence of a specific inhibitory molecule present in restrictive 
cells (Frankel et al., 1989; Stoye et al., 1995). MLV viruses that infect cells expressing a 
restrictive Fv1 complete reverse transcription but fail to integrate into host cell genome 
(Jolicoeur and Rassart, 1980). The target of Fv1 was shown through genetic evidence to 
be the CA protein of MLV, and restriction was later mapped to a single amino acid 
residue on the surface of the viral capsid at position 110 (Boone et al., 1983; 
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DesGroseillers and Jolicoeur, 1983; Kozak and Chakraborti, 1996). Restriction of MLV 
infection by Fv1 can be overcome by infecting target cells with high levels of incoming 
MLV virions (saturation) or by the addition of virus like particles (VLPs) that contain the 
properly assembled, restricted viral capsid (Pincus et al., 1975; Boone et al., 1990). 
Addition of unrestricted virions or particles lacking a mature capsid does not saturate 
restriction by Fv1 (Bock et al., 2000). Fv1 was identified by positional cloning in 1996 
and was shown to be derived from an endogenous murine retrovirus, possessing ~60% 
homology to the viral capsid protein (Best et al., 1996). Despite having been identified 
for over a decade, the mechanism by which Fv1 inhibits viral infection remains 
undetermined. 
 Studies begun late in the 1990’s identified the presence of an activity in cells of 
other mammalian species that was also capable of restricting infection of N-tropic MLV 
following entry (Towers et al., 2000). This restriction activity also targets the incoming 
viral capsid but differs from Fv1 restriction in that it blocks infection prior to completion 
of reverse transcription. Humans do not encode an Fv1 protein, which suggested another 
host cell protein was responsible for the restrictive activity which was termed restriction 
factor 1 (Ref1). Ref1, like Fv1, was also saturable by high levels of incoming virus or 
pretreatment of cells with mature VLPs. The restriction activity was also dominant in 
heterokaryons, suggesting the presence of a molecule that was specifically blocking MLV 
infection.  
 It had been known that African monkeys were susceptible to infection by SIV but 
did not support infection by HIV-1. Identification of incongruities between cellular 
coreceptors and subsequent expression of these on target cells did not relieve the block to 
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infection (Chen et al., 1997; Hofmann et al., 1999; Munk et al., 2002). Pseudotyping the 
virus with the pantropic envelope from vesicular stomatitis virus (VSV-G) also failed to 
overcome the block to HIV-1 infection in the monkey cells, indicating the block occurred 
following fusion of the virus with the target cell (Hofmann et al., 1999). Studies utilizing 
primate cells from Africa and South America found significant differences in the ability 
to restrict both HIV and SIVmac. A generalized pattern emerged in that cells derived from 
African monkeys (old world monkeys) are more likely to restrict HIV-1 while cells 
derived from South American monkeys (new world monkeys) are more likely to restrict 
SIVmac, but there are numerous exceptions to this pattern. Analysis of infected cells 
showed that the incoming virions failed to complete reverse transcription in a manner 
analogous to restriction by Ref1 and the activity was thus termed Lentivirus restrictive 
factor 1 (Lv1), (Besnier et al., 2002; Cowan et al., 2002). Genetic swapping of HIV and 
SIVmac gene segments showed that the target of Lv1 restriction also mapped to the CA 
protein of the incoming virus as SIVmac, possessing a capsid derived from HIV-1, was 
potently blocked for infection in rhesus macaque cells (Owens et al., 2003). Also similar 
to Fv1 and Ref1, restriction by Lv1 could be overcome by saturating levels of infection or 
by pretreatment of target cells with restricted VLPs (Kootstra et al., 2003). In 2004, the 
cellular protein responsible for the Lv1 activity in rhesus macaque cells was identified 
through a genetic screen as TRIM5α (Stremlau et al., 2004). Expression of the rhesus 
allele of TRIM5α (TRIM5αrh) in human cells or in permissive Crandel feline kidney 
(CrFK) cells renders them potently restrictive to infection by HIV-1.  It was later shown 
that the human allele of TRIM5α (TRIM5αhu) is responsible for the Ref1 activity in 
human cells (Hatziioannou et al., 2004b; Keckesova et al., 2004; Perron et al., 2004; Yap 
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et al., 2004). Polymorphic differences between primate species determine the restriction 
range of TRIM5α, and the viruses restricted by various primates can widely differ (Song 
et al., 2005; Stremlau et al., 2005; Yap et al., 2005; Ylinen et al., 2005). 
Shortly after the identification of TRIM5α, a second HIV-1 specific, restriction 
factor was identified in Owl monkey cell lines (Sayah et al., 2004). This gene is a result 
of a LINE1 retrotransposition event in which the entire CypA mRNA was inserted into 
the TRIM5 locus. This insertion resulted in a functional fusion protein that possesses the 
N-terminal portion of TRIM5α attached to the full CypA protein. Expression of this 
protein, named TRIMCyp, in nonrestrictive cells renders them highly restrictive to 
infection by HIV-1. TRIMCyp derived from OMK cells is only capable of restricting 
HIV-1 and is blocked from restriction by addition of CsA during viral infection or by a 
mutation of the G89 position of the viral capsid. Analogs of CsA that bind CypA but are 
not immunosuppressive also block restriction by TRIMCyp, indicating that the effect of 
CsA on restriction is most likely through steric inhibition rather than related to an 
immunosuppressive effect. Recent investigations have identified other TRIMCyp 
proteins present in certain African and Indian-derived macaques (Liao et al., 2007; 
Brennan et al., 2008; Newman et al., 2008; Virgen et al., 2008; Wilson et al., 2008). The 
varied location of the insertion site of the CypA coding sequence into the TRIM5 locus 
indicates these insertion events have occurred independently of the LINE1 insertion event 
that generated OMK TRIMCyp. These new TRIMCyp proteins display different 
restriction profiles as compared to OMK TRIMCyp as they are capable of restricting SIV. 
This finding is mysterious as the CA protein of SIV does not appear to bind CypA.  
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Host Activity Protein Restricts Does Not Restrict 
Mouse (NIH) Fv1 Fv1N N B-MLV N-MLV, NB-MLV 
Mouse (Balb/c) Fv1 Fv1B B N-MLV B-MLV, NB-MLV 
Mouse 
(M.dunni) 
Fv1 N/A 0 N/A N-MLV, B-MLV, NB-MLV 
Human Ref1 TRIM5α N-MLV, EIAV, FIV B-MLV, NB-MLV, HIV-1, 
HIV-2, SIVmac, SIVagm 
Rhesus monkey Ref1, 
Lv1 
TRIM5α HIV-1, N-MLV B-MLV, SIVmac 
Owl monkey Lv1 TRIMCyp HIV-1 N-MLV, B-MLV, SIVmac 
Pig tail 
macaque 
Lv1 TRIMCyp HIV-2, FIV HIV-1 
African green 
monkey 
Ref1, 
Lv1 
TRIM5α 
TRIM1 
HIV-1, HIV-2, 
SIVmac, EIAV, N-
MLV 
B-MLV, SIVagm 
Pindak monkey Lv1 TRIM5α SIVmac N-MLV, B-MLV, HIV-1 
 
 
 
 
 
 
Table 1-2. Table of restriction activities and restrictive proteins. The proteins are 
listed according to the host animal they were derived from. The activity is listed as the 
original term for the restriction potential that was defined in the particular host.  
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However, the independent nature of insertions of CypA into the TRIM5 coding locus 
indicates a strong selective pressure towards the expression of a restrictive protein with a 
C-terminal CypA fusion. 
The discovery of TRIMCyp, along with studies involving restriction of chimeric 
HIV and SIV mutants by TRIM5α, indicated that the viral capsid contained the genetic 
determinant that was the target of post-entry restriction by TRIM5α (Cowan et al., 2002; 
Kootstra et al., 2003). Analysis of restriction patterns using a panel of HIV-1 capsid point 
mutants further advanced the hypothesis that the outer surface of the viral capsid was the 
target of direct binding by both TRIM5α and TRIMCyp (Hatziioannou et al., 2004a). As 
the tertiary structures formed by the divergent capsids of MLV and HIV are quite similar, 
it seemed logical that this explained the ability of a single protein to restrict widely 
divergent retroviruses. Additionally, superimposing structures of CA molecules of 
both viruses shows that amino acid 110, the position that determines restriction of N-
MLV by Fv1 and TRIM5α, lies in an exposed extended loop analogous to the CypA 
binding loop in HIV-1 CA. The failure of TRIMCyp to restrict HIV-1 with the G89V CA 
mutation or in the presence of CsA indicated that restriction of HIV-1 by TRIMCyp was 
mediated by direct contact of the restriction factor with the incoming viral capsid. The 
same requirement for direct binding is thought to exist for TRIM5α; however, some 
groups have proposed that one or more secondary cellular cofactors may be required 
(Berthoux et al., 2005; Hatziioannou et al., 2005). 
 While the binding of CA by the restriction factor was thought to be direct, it 
remained to be determined if the restrictive TRIM5 proteins bound to CA alone or if the 
recognition was of a three dimensional structure presented on the surface of the mature 
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viral capsid. Treatment of target cells with large doses of incoming virus results in 
saturation of restriction mediated by TRIM5α and TRIMCyp and can be measured in 
titration curves as a ratio of infected cells to input virus. An alternative method to  
analyze restriction is by using a set amount of a reporter virus (GFP or luciferase) and 
adding increasing levels of a tester virus which is termed an abrogation assay (Kootstra et 
al., 2003). Prior to my investigations into the mechanism of TRIM5α function, another 
graduate student in our lab, Brett Forshey, conducted a series of experiments analyzing 
the capacity of several of previously characterized CA mutants to abrogate restriction by 
TRIMCyp (Forshey et al., 2005). His experiments demonstrated that CA mutants that 
formed unstable cores also fail to abrogate restriction in OMK cells. CA mutants that 
form hyperstable cores are capable of abrogating restriction at levels equal to wild-type 
viruses. Previous experiments had shown that mutation of the cleavage site between CA 
and NC results in virions that had spherical core-like structures composed of hexagonally 
organized CA-NC protein. This mutation restores stability to the previously unstable CA 
mutants but the virus is noninfectious. When viruses containing mutations in CA that 
render the cores unstable are further mutated to abolish CA-NC cleavage, the unstable 
mutants are now fully capable of abrogating infection. A technician in the lab, Jiong Shi, 
later observed similar effects in the rhesus macaque cell line FRhK-4 (Shi and Aiken, 
2006). Another study showed that expression of Gag or CA in cells that are then infected 
with HIV-1 does not affect post-entry restriction by TRIM5α. Taken together these 
studies indicate that TRIM5α and TRIMCyp are capable of interacting only with a 
maturely cleaved, polymeric form of capsid which exists in a mature assembled core.   
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TRIM5α and TRIMCyp 
 TRIM5 is one of fifty one members the TRIM family of proteins present in the 
human genome. All members of the TRIM family possess a common N-terminus of a 
RING (Really interesting new gene) domain, one or two B-box domains, and a coiled-
coil domain (Figure 1-8). This grouping of domains is referred to as a “tripartite motif” 
and is the origin of the protein family name. TRIM5 is located on chromosome 11 of the  
human genome in a cluster of several TRIM family proteins. Alternative splicing of the 
mRNA transcript of TRIM5 results in at least 3 splice isoforms, of which TRIM5α is the  
longest. All isoforms contain the common N-terminal domain but only the α-isoform 
encodes the C-terminal PRY/SPRY domain. Multiple lines of genetic evidence have 
shown that the PRY/SPRY domain is responsible for recognition of the incoming viral 
core (Nakayama et al., 2005; Perez-Caballero et al., 2005a; Stremlau et al., 2005; Ohkura 
et al., 2006; Zhang et al., 2006).  Sequence alignment of TRIM5α alleles from numerous 
primate species show considerable heterogeneity, with the greatest differences existing at 
the C-terminal portion of the protein encoding the PRY/SPRY domain. The coiled-coil 
domain is responsible for protein multimerization and is required for restriction by 
TRIM5α (Perez-Caballero et al., 2005a). The function of the B-box remains unclear but it 
is also required for restriction activity (Javanbakht et al., 2005). The RING domain is 
required for full restriction activity by TRIM5α as proteins in which it is deleted or in 
which folding is compromised are severely impaired for restriction potential (Stremlau et 
al., 2004; Perez-Caballero et al., 2005a). The RING domain of TRIM5δ, which is 
identical to that in TRIM5α, possesses E3-ubiquitin ligase and autoubiquitylation 
activities in vitro (Xu et al., 2003; Yamauchi et al., 2008). This activity is abolished 
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Full cyclophilin A protein Coiled-Coil Domain B-Box 2 RING Domain 
RING Domain B-Box 2 Coiled-Coil Domain PRY/SPRY Domain 
A 
B 
TRIM5α 
TRIMCyp 
Figure 1-8. Schematic representation of TRIM5α and TRIMCyp. A. The three 
N-terminal domains of TRIM5α (RING, B-Box, and coiled-coil), make up the 
tripartite motif conserved in all TRIM proteins. The TRIM5 transcript 
generates three splice isoforms α, γ, and δ; of which only TRIM5α contains 
the fourth domain, the B30.2 PRY/SPRY domain. B. TRIMCyp results from 
in-frame fusion of the cyclophilin A mRNA into the TRIM5 locus that has 
occurred in several primate species. The cyclophilin A domain is colored 
purple for clarity. 
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by mutations that impair the proper folding of the TRIM5δ RING domain. TRIM5α is 
ubiquitinated in vivo, but the role for this modification, if any, is not known and the 
relationship of ubiquitin and E3-ligase activity to retroviral restriction by TRIM5α 
remains unclear (Diaz-Griffero et al., 2006; Yamauchi et al., 2008).  
Many TRIM proteins, including TRIM5α, adopt a punctuate staining pattern 
when over-expressed in cells (Reymond et al., 2001). When the punctae localize to the 
nucleus they are termed “nuclear bodies” and when they localize to the cytoplasm they 
are termed “cytoplasmic bodies”. Over-expression of TRIM5α results in the appearance 
of cytoplasmic bodies. The exact nature of these bodies remains controversial and their 
relevance in a physiological setting as well as their role in post-entry restriction remains 
undetermined. Cytoplasmic bodies contain numerous other proteins that are found in 
close association and the nature of these associations as to function or physiologic 
relevance is also unclear.  
 
Ubiquitin and the Proteasome 
 Ubiquitin is a small 8.5kD protein that is present in all eukaryotic cells. Ubiquitin 
plays multiple roles in the cell including protein targeting, endocytosis, and degradation 
of damaged or misfolded proteins (Mukhopadhyay and Riezman, 2007). Ubiquitin is 
conjugated onto lysines of target proteins through a series of enzymatic reactions by three  
different families of proteins: E1, E2, and E3 (Figure 1-9). Humans encode a single E1 
protein (Uba1) that is responsible for transferring free ubiquitin onto a conserved cysteine 
residue on one of several E2 proteins (UBCs) via a trans(thio)esterification reaction. 
These E2 proteins then in turn interact with one of numerous E3 proteins that mediate  
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Figure 1-9. Schematic representation of the ubiquitin-proteasome pathway. 
Free ubiquitin is transferred onto the E1 activating protein through hydrolysis 
of ATP. The E1 protein in turn transfers the single ubiquitin onto the E2 
protein. The E2 then interacts with an E3-ubiquitin ligase to transfer the 
ubiquitin moiety onto the target protein. Repeated addition of ubiquitin to a 
protein targets the protein for degradation by the proteasome, the result of 
which is the release of the polyubiquitin chain to be broken down to free 
ubiquitin and hydrolysis of the target protein into peptides 7-8 amino acids in 
length. The proteasome is displayed in the 26S form which consists of the 
main 20S catalytic core capped by two 19S subunits (from www.boston 
biochem.com). 
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transfer of the ubiquitin moiety onto the target protein. There are two main classes of E3  
proteins; RING proteins and HECT-domain (Homology to E6-AP carboxyl terminus) 
proteins. These proteins differ in the mechanism of transfer in that HECT domains form a 
thioester intermediate where the ubiquitin is first transferred to the E3 then onto the target,  
while RING domain proteins facilitate the transfer of the E2-associated ubiquitin moiety 
directly to the target protein in most, but not all, cases (Fang et al., 2000).  The 
mammalian genome encodes approximately 30-40 UBCs and several hundred potential 
E3-ubiquitin protein ligases. This increasing diversity allows for an enormous potential 
number of interactions and the ability to cover a vast spectrum of potential targets.  
 Ubiquitin contains seven lysine residues and is capable of being ubiquitylated 
itself in a reaction known as polyubiquitylation. The fate of a polyubiquitinated protein  
varies based upon which of the lysines in the ubiquitin molecule the other ubiquitin 
moieties are attached to.  Attachment of a single ubiquitin residue to a target is most often 
utilized for targeting of the protein to distinct positions within the cell. Polyubiquitylation, 
typically with high levels of K48-linked chains, most often results in targeting of the 
protein to the cellular proteasomes (Ciechanover, 1994; Sigismund et al., 2004). There 
are several other ubiquitin-like molecules present in cells that also serve to alter the 
localization or fate of proteins within the cell. One of these moieties is known as small 
ubiquitin-like modifier (SUMO). SUMO modification is conducted exclusively by the E2 
Ubc9 and typically results in changes in cellular localization or enhanced stabilization of 
the target protein (Desterro et al., 1997; Buschmann et al., 2000; Mao et al., 2000).    
The proteasome is a cellular organelle responsible for degradation and turnover of 
cellular proteins. The proteasome consists of a proteolytic core (20S) that can be 
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associated with one or two regulatory subunits (19S, 11S). The 20S core is composed of 
4 stacked heptameric rings. The inner two rings are referred to as the β-rings and are 
composed of identical sets of 7 distinct subunits. When docked together these two rings 
create the central cavity which houses the main catalytic activity. The inner β-rings are 
flanked by two outer rings which are composed of seven different α-subunits each. These 
α-rings facilitate interaction with the various regulatory subunits and organize 
translocation of the protein targeted for degradation into the main catalytic chamber. The 
makeup of the α and β subunits is subject to change depending on the status of the cell. 
Exposure to type I interferons upregulates specific sets of subunits that result in an altered 
proteolytic capacity (Aki et al., 1994). The most common form of the proteasome for the 
degradation of ubiquitinated proteins is the 26S form, which consists of the 20S core 
capped by two 19S subunits at either end.  The 19S subunits recognize extended chains of 
ubiquitin and direct linearization and internalization of the peptide into the 20S core in an 
ATP-dependent manner. This process releases the polyubiquitin chain, which is then 
broken down to free ubiquitin by deubiquitinating enzymes. Once inside the core the 
peptide is subjected to peptide hydrolysis resulting in degradation of the protein into 
small peptides. While most proteasomal degradation requires polyubiquitination, a 
growing number of examples of ubiquitin-independent proteasome degradation have 
been identified, and the rules for targeting of proteins for hydrolysis by the proteasome 
have become increasingly less static (Hoyt and Coffino, 2004). Further complicating the 
situation has been the identification of several E3-ligases that are degraded along with 
their target proteins as a result of polyubiquitination (Ohta et al., 1999; Fang et al., 2000; 
Boutell et al., 2005; Lu et al., 2007). While these cases are typically the exception rather 
 34 
 
than the rule, their role in the ubiquitin-proteasome pathway has added a new level of 
complexity to a field that is already highly intricate. 
Proteasome function is required for all aspects of the cellular lifecycle as well as 
for facilitating immune responses through degradation of peptides from pathogens for 
antigen presentation (Goldberg et al., 2002).  Blockade of proteasome function by 
various pharmaceutical agents leads to impairment of numerous cellular processes due to 
a lack of free ubiquitin and buildup of toxic or misfolded proteins, which eventually leads 
to cell death (Shinohara et al., 1996; Dick et al., 1997) The most common inhibitor of 
proteasome function is the peptide-aldehyde carbobenzoxyl-leucinyl-leucinyl-leucinal-H 
(MG132). This peptide binds reversibly to the internal 20S core non-specifically and 
impairs the chymotrypsin-like activity of the β-subunits. While relatively specific, when 
used in high doses (25µM) MG132 can inhibit the function of endosomal cathepsins and 
calpains required for the initial stages of protein degradation by the lysosome (Sasaki et 
al., 1990). Other inhibitors such as lactacystin or epoxomicin are more specific and can 
be used at concentrations low enough to avoid endosomal protease inhibition, but these 
inhibitors are irreversible and frequently kill the cell after a period of several hours 
(Meng et al., 1999).    
 
HIV-1, the Proteasome, and Post-Entry Restriction 
Several lines of evidence have shown that the proteasome plays a critical role in the HIV-
1 lifecycle. HIV-1 encodes the Vpu and Vif proteins that are responsible for the 
proteasomal degradation of the host-cell proteins CD4 and APOBEC3G proteins 
respectively (Fujita et al., 1997; Conticello et al., 2003; Marin et al., 2003; Sheehy et al., 
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2003). Both of these host proteins impair the production of infectious virus in cells 
producing HIV-1. Paradoxically, the proteasome can also impair the ability of HIV-1 to 
infect target cells. Inhibition of proteasome function with MG132 or lactacystin enhances 
HIV-1 infectivity 2-3 fold (Schwartz et al., 1998). Thus, the proteasome appears to have 
both positive and negative effects on the ability of HIV-1 to replicate in cells, the theme 
being that proteasome function seems to be critical for viral production but deleterious 
for viral infection. 
 The observation that TRIM5δ possesses E3-ligase activity led to immediate 
speculation that TRIM5α may function to inhibit viral infection by binding to the 
incoming capsid and ubiquitinating it, thus targeting it for degradation via the proteasome. 
This theory was deemed unlikely based upon subsequent studies that demonstrated that 
the presence of proteasome inhibitors during HIV-1 infection does not abrogate 
restriction by TRIM5α, and restriction is not impaired in cells that lack a functional 
ubiquitin pathway (Perez-Caballero et al., 2005b). These observations led to the 
speculation that restriction by TRIM5 proteins does not require proteasome function. This 
view was modified when it was demonstrated that, while treatment of cells expressing 
TRIM5α rh with proteasome inhibitors does not abrogate restriction, it does result in a 
change in the timing in the viral lifecycle at which it occurs (Wu et al., 2006). When 
TRIM5α- expressing cells are treated with MG132 during viral infection, levels of late 
stage reverse transcription (late-RT) products increase, indicating the completion of viral 
DNA synthesis. This accumulation of late-RT products without an increase in viral 
infection is analogous to the effects of Fv1 expression on MLV replication in murine 
cells. Similar results are obtained when human cells are infected with N-tropic MLV in 
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the presence of MG132 (Anderson et al., 2006). In both cases, the target cells fail to 
accumulate nuclear forms of viral products indicating a block to nuclear import and 
further paralleling Fv1 restriction. These results have led to the speculation that TRIM5α 
was capable of mediating two blocks to infection. While the CA protein is the target of 
both blocks, the first block is dependent on proteasome function in order to inhibit viral 
infection. In the event of a loss of proteasome function, a secondary, post-RT block exists 
that prevents nuclear entry of the viral PIC. 
 
Research Objectives 
 After the identification of TRIM5α as the host cellular protein responsible for 
both Ref1 and Lv1 activities, numerous theories were proposed to explain how TRIM5α 
might function to block viral infection. The lack of accumulation of early-RT products 
and the knowledge that the intact viral capsid was the target of restriction suggested at 
least two possible mechanisms about how TRIM5 proteins could restrict retroviral 
infection: (1) TRIM5α binds to the outer surface of the incoming viral capsid and 
mediates an accelerated uncoating event that renders the virus uninfectious or (2) 
TRIM5α  
 Additionally, though TRIM5α
binds to the incoming viral capsid and prevents the capsid from properly 
uncoating and impairs viral infection. Either of these hypotheses is consistent with the 
observations from Brett Forshey that increases or decreases in core stability have 
negative impacts on viral infectivity, but the precise mechanism remained unknown 
(Forshey et al., 2005). 
 was identified as the protein responsible for post-
entry retroviral restriction, it remained to be determined if other proteins were required 
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for retroviral restriction. As the RING domain of TRIM5δ possesses an E3-ligase activity 
and mutation or deletion of the RING domain of TRIM5α  
 The goal of my dissertation research was to identify the mechanism of restriction 
of HIV-1 by TRIM5α
results in significant loss of 
restriction potential (Stremlau et al., 2004; Yamauchi et al., 2008), the relevance of the 
ubiquitin pathway in terms of post-entry restriction is of considerable interest. The 
observation that numerous other proteins are associated with cytoplasmic bodies also 
suggests a complex interaction of host pathways may be necessary for TRIM5α-mediated 
restriction.  
. To achieve this goal, I used three separate approaches. The first 
approach was to study the relative stability of TRIM5α in cells in the context of a natural 
infection. To do this, I employed immunoblotting to quantify TRIM5α protein levels in 
infected cells. My findings, described in Chapter II, indicate that infection of a TRIM5α 
or TRIMCyp expressing cell with a restricted retrovirus results in a rapid loss of TRIM5α 
in the target cells. This loss is highly specific to restriction and is observed when 
TRIM5α is expressed exogenously or endogenously. Second, I sought to study the role of 
the RING domain and proteasome function on post-entry restriction by TRIM5α. I 
utilized proteasome inhibitors and deletion mutants to assay the stability of TRIM5α 
during HIV-1 infection. The results, described in Chapter III, show stabilization of 
TRIM5α by inhibition of cellular proteasome function or deletion of the RING domain in 
cells without an increase in overall viral infection. These data combined with previous 
findings support a proposed mechanism for restriction by TRIM5α. My data is consistent 
with a model where TRIM5α blocks infection by binding to incoming retroviral cores, an 
event which is followed by proteasomal recruitment and degradation of TRIM5α, 
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resulting in aberrant capsid uncoating and abortive infection. Lastly, I analyzed a panel of 
several E2 proteins to determine if over-expression of mutant forms or silencing of 
endogenous levels of the E2 proteins impaired restriction by TRIM5α . My findings, 
described in Chapter IV, indicate that inhibition of restriction does occur in the presence 
of over-expressed levels of nonfunctional E2 proteins. These data provide preliminary 
evidence for a role of the UbcH5 family of proteins in post-entry restriction of 
retroviruses by TRIM5α. Collectively, my data indicate that the proteasome plays a 
critical role in post-entry restriction by TRIM5α and that a functional RING domain is 
required to mediate pre-RT restriction by TRIM5α. In addition, my data provide an 
alternative hypothesis for the mechanism of saturation of TRIM5α by incoming virus and 
provide evidence for a mechanism of retroviral restriction by TRIM5α
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CHAPTER II 
 
 
DESTABILIZATION OF TRIM5α IN RESPONSE TO RESTRICTED RETROVIRAL 
INFECTION 
 
 
Introduction 
The early stages of viral infection are arguably the least understood aspect of the 
HIV-1 lifecycle. The process of uncoating, reverse transcription, assembly of the PIC, 
and transport of this particle through the densely crowded cytoplasm entail numerous, 
complicated protein-protein interactions as well as complex enzymatic reactions 
facilitated by both host and viral proteins. Studies utilizing cellular fractionation and 
differential centrifugation have resulted in isolation of subviral particles from inside 
infected cells. Analysis of the protein composition of these particles has identified several 
viral and host proteins utilized by the virus for infection (Miller et al., 1997; Chen and 
Engelman, 1998; Kotov et al., 1999; Forshey and Aiken, 2003; Lin and Engelman, 2003). 
However, these results do not explain what role these proteins play during the early 
stages of viral replication or to what extent they are required. 
 The process of capsid shedding, known as uncoating, has been of considerable 
interest due to the significant effects that mutations altering core stability have on viral 
infectivity (Forshey et al., 2002). While biochemical purification of cores has permitted 
the study of core disassembly in vitro, the relevance of these studies to what occurs in 
vivo was questionable. Extensive fractionation of cellular lysates and study of the effects 
these fractions have on the rate of viral uncoating has identified fractions that have both 
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positive and negative effects on uncoating rates. The factors responsible for these 
activities have remained elusive (Forshey and Hout, unpublished data). These 
problematic issues and the difficulty of the techniques involved in the experiments 
resulted in a very slow rate of advancement in our understanding of how uncoating 
occurs inside cells. Thus, the identification of a dominant factor in cells that interferes 
with HIV-1 infection by targeting the capsid after viral fusion led to a considerable effort 
to discover the molecule responsible (Hofmann et al., 1999; Besnier et al., 2002; Cowan 
et al., 2002; Munk et al., 2002). Identification of the putative host factor offered the 
possibility of significant advancement in the study of retroviral uncoating, the theory 
being that by understanding how the factor impairs viral uncoating it would be possible to 
extrapolate what steps are important for the virus to complete its lifecycle. 
Early studies that identified the restrictive activities later attributed to TRIM5α 
found that the restriction was saturable by high levels of incoming virus. It was also 
observed that saturation is stable for a period of several hours. Saturation of restriction is 
not dependent on the ability of the virus to complete the lifecycle as the addition of VLPs 
lacking all viral proteins except Gag and protease is also capable of saturating restriction. 
Cross-saturation is observed in cells that are capable of restricting infection by more that 
one type of virus (Hatziioannou et al., 2003). Despite the limited sequence homology that 
exists between the various members of the Retroviridae family, extensive biochemical 
analysis of the capsids of various retroviruses indicates that structural homology is 
maintained even amongst different families of retroviruses (Li et al., 2000; Mortuza et al., 
2004; Ganser-Pornillos et al., 2007; Mortuza et al., 2008). The conserved nature of this 
viral structure, despite limited sequence conservation, explains how the restrictive factors 
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are capable of inhibiting such highly divergent retroviruses and suggested that TRIM5α 
interacts with the incoming core following fusion with the target cell. 
Numerous genetic experiments suggested the interaction of TRIM5 proteins with 
the incoming capsid was most likely to be direct. Restriction of N-MLV by TRIM5αhu is 
determined by a single amino acid on the outer surface of the viral capsid (Yap et al., 
2004). This amino acid is located on the same exposed loop of the CA protein that 
determines restriction of MLV by Fv1. Mutations or pharmacologic agents that block 
CypA binding to HIV-1 capsid also block restriction by TRIMCyp (Towers et al., 2003). 
TRIMCyp from OMK cells only restricts HIV-1, and HIV-1 is the only lentivirus known 
to incorporate CypA through binding to capsid. Insertion of the flexible loop of the CA 
protein of SIVmac
While binding of the incoming capsid by TRIM5α explained how restriction was 
initiated, it did not explain how this results in a failure to complete reverse transcription. 
Recognition of the capsid is through interaction with the PRY/SPRY domain, while the 
coiled-coil domain facilitates oligomerization of TRIM5α, presumably providing an 
overall enhancement through an increased avidity of a multimerized TRIM5α. The RING 
 into the CA protein of HIV-1 also blocks restriction (Hatziioannou et 
al., 2004a). Biochemical evidence of a direct capsid-TRIM5α interaction has also been 
obtained using in vitro assembled capsids and lysates of cells expressing TRIM5α 
(Stremlau et al., 2006; Perron et al., 2007). These studies providing evidence for direct 
interaction of TRIM5α with capsids offered a potential explanation of why restriction is 
saturable. It was thought that high levels of incoming capsid eventually bound up all of 
the restriction factor, which allowed excess virus to complete the normal progression of 
infection.   
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domain of TRIM5δ, identical to TRIM5α, has E3-ligase activity in vitro (Xu et al., 2003; 
Yamauchi et al., 2008). Based on this observation, I hypothesized that TRIM5α binds to 
an incoming viral complex and targets one or more viral proteins for ubiquitylation. As 
the E3 activity of TRIM5δ was autoubiquitylation, I chose to examine changes in 
TRIM5α resulting from infection. I found that infection of TRIM5αrh-expressing cells 
with HIV-1 leads to depletion of TRIM5α itself. This depletion specifically occurs in 
response to infection by a restricted retrovirus and is dependent on virus dose. 
Experiments utilizing TRIM5α proteins derived from multiple primate species showed 
that depletion in response to infection is a broad feature of post-entry restriction, with one 
notable exception. I conclude that infection of cells expressing TRIM5α by a restricted 
retrovirus results in a rapid destabilization of the protein. These findings suggest an 
alternate explanation for the saturation of restriction by incoming retroviruses, depletion 
of the restrictive factor itself. 
 
Results 
 
Destabilization of Rhesus macaque TRIM5α  
 293T cells expressing TRIM5α
upon challenge with HIV-1 
rh are 100-fold more restrictive to infection by 
HIV-1 as compared to the parental cell line 293T (Figure 2-1C). I inoculated these 
TRIM5αrh–expressing cells with a saturating level of VSV-G pseudotyped HIV-1 and 
harvested the cells at various timepoints afterwards. This viral challenge was sufficient to 
infect >90% of the cells. All of the cells were treated with cycloheximide both before and  
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Figure 2-1. Destabilization of TRIM5α upon challenge of cells with HIV-1.            
(A) Immunoblot analysis of TRIM5α in cells challenged with HIV-1. 293T cells 
expressing HA-tagged TRIM5αrh were pretreated for 1 hour with cycloheximide at 
370C. Cells were then challenged with stock solutions of HIV-1(VSV) or media 
alone (Mock). (B) Quantitation of TRIM5α levels utilizing Odyssey Band imaging 
software. The TRIM5α levels are expressed as a percentage of the ratio of 
TRIM5α:actin signal to the zero hour sample TRIM5α:actin signal. Shown are the 
mean values and standard deviations obtained in four independent experiments. (C) 
Titration of HIV-GFP virus on 293T cells expressing HA-tagged TRIM5αrh or 
TRIM5αhu. Shown is a representative example of at least 4 experiments. h.p.i. = 
Hours post infection. 
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during the infection in order to arrest protein synthesis and allow quantitation of TRIM5α 
in response to viral infection. I analyzed the levels of TRIM5α in the post-nuclear lysates 
by quantitative immunoblotting.  In control cells not exposed to virus, the loss of 
TRIM5α occured at a slow rate eventually leveling off to 55% of the original level after 4 
hours (Figure 2-1A). Infection of the cells with HIV-1 induced a much more rapid rate of 
depletion which resulted in loss of 85% of the protein after the same interval. These 
experiments were repeated using HeLa cells, and similar results were observed indicating 
that HIV-induced loss of TRIM5αrh is not a cell-type dependent effect (data not shown).  
 
Rhesus macaque, but not human TRIM5α, is less stable in cells challenged with 
HIV-1 
 
 I considered the possibility that depletion of TRIM5αrh in response to HIV-1 
infection may have been caused by the high levels of infection rather than being related 
to restriction. TRIM5αhu does not efficiently restrict HIV-1 (Figure 2-1C), and I reasoned 
that if the depletion of TRIM5α was specific to post-entry restriction, than infection of 
cells expressing TRIM5αhu by HIV-1 would not result in depletion. To test this, I 
analyzed the lysates of 293T cells expressing either TRIM5αrh or TRIM5αhu following 
HIV-1 challenge for changes in TRIM5α stability. 293T cells, while of human origin, do 
not express a measurable quantity of TRIM5αhu. Infection of the TRIM5αrh-expressing 
cells with HIV-1 induced the previously observed rapid depletion of the restriction factor 
as compared to mock-infected cells (Figure 2-2A). TRIM5αhu was intrinsically less stable 
than TRIM5αrh
 
, as indicated by the rates of decay in the mock-infected cells. However,  
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Figure 2-2. Rhesus macaque, but not human TRIM5α, is less stable in cells 
challenged with HIV-1. (A) 293T cells expressing HA-tagged TRIM5αrh or TRIM5αhu 
were pretreated for 1 hour with cycloheximide then exposed to VSV-G pseudotyped 
HIV-1 or media alone as in Figure 1. TRIM5α was detected by immunoblotting with 
HA-specific antibody.  Integrated intensity values for the individual bands are shown 
in Figure S1. (B and C) Quantitation of TRIM5αrh (B) and TRIM5αhu levels utilizing 
Odyssey imaging software. Data shown are from one representative of three 
independent experiments. 
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infection with HIV-1 did not result in a further increase in the rate of depletion of 
TRIM5αhu in the cells. These data indicate that the loss of TRIM5αrh in response to 
infection was related to the ability of the protein to restrict HIV-1 rather than a 
nonspecific cellular response to infection. 
 
Human TRIM5α is destabilized upon challenge with N-Tropic MLV 
 While TRIM5αhu does not restrict infection by HIV-1, it is capable of restricting 
infection of N-tropic but not B-tropic-MLV. I sought to determine if degradation of 
TRIM5α in response to retroviral infection was specific to the TRIM5αrh, allele or was a 
broader attribute of other TRIM5α proteins. I infected TRIM5αhu-expressing cells with 
stocks of VSV-G pseudotyped N or B-tropic MLV in the presence of cycloheximide and 
measured levels of TRIM5α in response to infection. The capsids of N and B-MLV are 
highly homologous, differing by only a few amino acids. To ensure I was adding equal 
amounts of each virus to the infection, I titered the viral stocks on the nonrestrictive cell 
line CrFK that is equally infected by both N and B-tropic MLV (Figure 2-3C). 
Expression of TRIM5αhu in 293T cells rendered the cells highly restrictive to N-MLV but 
not B-MLV. Analysis of the lysates from the infected cells showed that TRIM5αhu was 
relatively stable in the mock treated cells (t1/2~ 2.5h; Figure 2-3A). Infection with B-
MLV did not significantly alter the rate of TRIM5α depletion. In contrast, cells 
challenged with the equivalent level of N-MLV showed an accelerated loss of TRIM5α 
(t1/2~ 1h). These data demonstrate that TRIM5αhu is destabilized in response to infection 
by a restricted retrovirus and indicate that depletion resulting from restriction is a feature 
shared by differing TRIM5α alleles. 
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Figure 2-3. Human TRIM5α is destabilized upon challenge of cells with N-tropic but 
not B-tropic MLV. (A) 293T cells expressing HA-tagged TRIM5αhu were pretreated 
for 1 hr with cycloheximide and exposed to stocks of VSV-G-pseudotyped N- or B-
tropic MLV or media alone (Mock). Integrated intensity values for the individual 
bands are shown in Figure S3. (B) Quantitation of TRIM5α levels utilizing Odyssey 
Band imaging software. Data shown are from one representative of three independent 
experiments. (C) Titration of N and B-tropic MLV on CrFK and 293T cells 
expressing HA-tagged TRIM5αhu. Shown is one example of 3 experiments. 
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  TRIMCyp is destabilized in cells challenged with HIV-1 
 Owl monkey cells encode the restriction factor TRIMCyp that restricts HIV-1 
infection by interacting with the CypA-binding loop on the surface of CA. Restriction can 
be abolished by addition of CsA to cells during infection or by infecting cells with  
HIV-1 containing a capsid with a mutation in CA that prevents CypA binding 
(HIV.G89V-GFP). I sought to determine if TRIMCyp was also destabilized in cells 
infected with HIV-1. I challenged a cycloheximide treated-monoclonal 293T cell line 
expressing TRIMCyp (3C2) with VSV-G pseudotyped HIV-1 in the presence or absence 
of CsA and analyzed the effect of the infection on TRIMCyp levels. Expression of 
TRIMCyp renders this cell line potently restrictive to infection by HIV-1, and this 
restriction is abolished by addition of CsA or infection with HIV.G89V-GFP (data not 
shown). In mock-infected cells, TRIMCyp was stable over a period of six hours (Figure 
2-4A). Challenge with HIV-1 resulted in accelerated loss of TRIMCyp, which was not 
observed when CsA was present during infection. 
 I considered the possibility that CsA may have altered cellular metabolism, thus 
providing an alternate explanation for the restoration of TRIMCyp levels in the infected 
cells. To address this possibility I infected parallel cultures of cycloheximide treated-
293T cells expressing either TRIMCyp or TRIM5αrh with equivalent quantities of either 
HIV-GFP or HIV.G89V-GFP virus particles (as determined by p24 assay). HIV.G89V-
GFP is not restricted by TRIMCyp but is fully restricted by TRIM5αrh. Exposure to wild- 
type HIV-1 induced accelerated loss of both TRIMCyp and TRIM5αrh (Figure 2-4C). In 
contrast, exposure to the HIV.G89V-GFP mutant particles resulted in loss of TRIM5αrh 
but not TRIMCyp. Viruses containing the G89V mutation are less infectious than 
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Figure 2-4. TRIMCyp is destabilized in cells challenged with HIV-1. (A) 293T 
cells expressing the myc-His6 tagged TRIMCyp were pretreated for 1 hour with 
cycloheximide. Cells were then challenged with HIV-1(VSV) and either ethanol 
carrier (HIV-1) or CsA (HIV-1+CsA), or with media alone (Mock). All stocks 
contained cycloheximide. (B) Quantitation of TRIMCyp levels as described in the 
legend to Figure 1B. Data in this figure are from one of two independent 
experiments. (C) 293T cells expressing either myc-His6 tagged TRIMCyp or HA-
tagged TRIM5αrh were pretreated for 1 hour with cycloheximide. Cells were then 
challenged for 5 hours with stock solutions of VSV-G pseudotyped HIV-GFP 
(WT), VSV-G pseudotyped HIV-GFP with the G89V capsid mutation (G89V), or 
medium alone (M).  (D) Quantitation of TRIMCyp and TRIM5α levels as 
described in legend to Figure 1B. Data in (D) are expressed as the mean values of 
four determinations from two experiments, with error bars representing one 
standard deviation. 
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wild-type viruses, which could account for the failure of the HIV.G89V-GFP to deplete 
TRIMCyp; however, similar results were obtained when the virus was normalized by 
GFP titration on nonrestrictive cells (data not shown). These data indicate that HIV-1 
infection destabilizes TRIMCyp in cells and that this destabilization is associated with the 
ability of TRIMCyp to be able to recognize the incoming core.  
 
Virus-induced destabilization is correlated with lentiviral restriction in old and new 
world monkeys 
 
 TRIM5α proteins from various primates differ in their ability to restrict specific 
lentiviruses. For example, tamarin monkey TRIM5α (TRIM5α tam) restricts SIVmac but 
not HIV-1, while spider monkey TRIM5α (TRIM5αsp) restricts both viruses. I chose to 
further test the correlation between virus-induced loss of TRIM5α and antiviral 
specificity of the primate from which it was derived. To do this, I stably expressed the 
TRIM5α tam and TRIM5αsp proteins in 293T cells and challenged them with equivalent 
titers of VSV-pseudotyped HIV-1 and SIVmac239 GFP reporter viruses (as determined by 
titration on permissive CrFK cells). The cell lines were found to restrict the respective 
viruses by at least ten-fold (data not shown).  Immunoblot analysis of post-nuclear lysates 
revealed that TRIM5αrh was specifically destabilized when challenged with HIV-1 but 
not SIVmac (Figure 2-5A).  In contrast, the SIV-restrictive TRIM5αtam was destabilized 
only in response to SIVmac challenge. TRIM5αsp
amongst TRIM5α proteins from widely divergent primates. 
, which restricts both viruses, was 
depleted in response to challenge with either virus. These results strengthen the 
correlation between the specificity of retrovirus restriction and virus-induced 
destabilization of TRIM5α and indicate that this destabilization is a feature common 
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Figure 2-5. Destabilization of primate TRIM5α proteins is correlated with 
restriction of HIV-1 and SIVmac239. (A) 293T cells expressing HA-tagged 
TRIM5αrh, TRIM5αtam (tamarin monkey), TRIM5αsp (spider monkey), and were 
pretreated for 1 hour with cycloheximide then exposed to stocks of VSV-G 
pseudotyped HIV-GFP, SIV-GFP, or media alone (Mock). (B). Quantitation of 
relative TRIM5α levels. Data shown are from one representative of three 
independent experiments. 
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TRIM5α from squirrel monkeys is not degraded during retroviral restriction 
 Once TRIM5α was identified as the Lv1 factor, numerous groups screened alleles 
of TRIM5α proteins isolated from various primate species to determine the restriction 
profile of each animal. Many of these were also tested for their ability to restrict infection 
of HIV or SIVmac prior to completion of reverse transcription (pre-RT). These studies 
found that all of the TRIM5α proteins restricted infection by these viruses pre-RT with 
one exception; the TRIM5α protein encoded by the Bolivian squirrel monkey 
(TRIM5αsq), (Ylinen et al., 2005). The protein encoded by this allele restricts infection 
by SIVmac but analysis of SIVmac-infected cells expressing this TRIM5α protein show 
normal levels of viral DNA synthesis despite strong restriction of infection. This type of 
restriction is analogous to the restriction of MLV infection by Fv1. Additional 
experiments found that cells expressing TRIM5αsq also do not have that restriction 
saturated by pretreatment of the cells with VLPs. When I originally began my 
investigation into the destabilization of TRIM5α proteins derived from primates, I was 
not aware of unique nature of restriction by TRIM5αsq. I conducted the experiments in 
Figure 2-5 and had included cells expressing TRIM5αsq in the panel of primate proteins I 
had assayed. These cells were capable of restricting infection of SIVmac by a value of ~7-
fold (Figure 2-6C). Immunoblot analysis of the lysates from these cells showed that 
TRIM5αsq was not depleted in response to infection by a concentration of SIVmac that was 
sufficient to cause degradation of both TRIM5αsp and TRIM5αtam (Figure 2-6A). I found 
the coincidence of the lack of degradation of TRIM5αsq during SIV infection and the fact 
that TRIM5αsq was the only TRIM5α allele that did not restrict pre-RT to be intriguing 
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Figure 2-6. Squirrel monkey TRIM5α is not depleted in response to challenge 
with SIVmac239. (A). 293T cells expressing HA-tagged TRIM5αsq were 
pretreated for 1 hour with cycloheximide then exposed to stocks of VSV-G 
pseudotyped HIV-GFP, SIV-GFP, or media alone (Mock). (B). Titration curves of 
either transduced 293T cells expressing HA-tagged TRIM5αsq or untransduced 
cells (293T) infected with HIV or (C) SIVmac239. Data shown are representative 
of three independent experiments. 
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and considered the implications of this finding in relation to a mechanism of how 
TRIM5α might function to block retroviral infection. Studies I have conducted 
investigating this anomaly will be discussed in further detail in the next chapter. 
 
Virus-induced depletion of rhesus macaque TRIM5α is dose-dependent 
 Exposure of target cells to saturating levels of virus or VLPs can overcome 
restriction by TRIM5α. While saturation can occur in a laboratory, the relevance of this 
observation to infection in natural settings is questionable. All of my previous 
experiments had utilized large doses of virus for challenge in order to induce the maximal 
possible degradation. This created the possibility that destabilization of TRIM5α was not 
related to restriction per se, but rather the result of superinfection of target cells with a 
saturating quantity of virus. This possibility was less likely in light of the lack of 
depletion observed in TRIM5α-expressing cells infected by an unrestricted virus, but I 
sought to more fully investigate this possibility.  
 To determine whether the decay of TRIM5αrh was related to saturation of 
restriction, I inoculated TRIM5αrh-expressing cells with decreasing doses of a GFP- 
encoding virus in the presence of cycloheximide for a fixed period of time and harvested 
the cells to quantify TRIM5α levels. To probe the relationship between saturation of 
restriction and TRIM5αrh degradation, a portion of the harvested cells were replated and 
cultured for 48 hours, and the extent of infection determined by flow cytometric analysis 
of GFP expression.  These experiments showed that the ability to detect degradation of 
TRIM5α rh was strongly dependent on the dose of virus used (Figure 2-7A).  Furthermore,  
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Figure 2-7. Destabilization of TRIM5α by HIV-1 challenge is dose-dependent. 
(A) Immunoblot analysis of TRIM5α in cells challenged with HIV-1. 293T cells 
expressing HA-tagged TRIM5αrh were pretreated for 1 hour with cycloheximide at 
370C. Cells were then challenged with media alone (Mock) or the indicated 
amount of pseudotyped HIV-GFP expressed as quantity of p24 (CA) for a period 
of three hours. (B) Relationship of TRIM5α level to permissivity of target cells. A 
portion of the cultures harvested in (A) were recultured for 48 hours and 
subsequently analyzed for GFP expression by flow cytometry. Shown are the 
mean values for the two replicates for both TRIM5α levels and extent of infection.  
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the TRIM5αrh level following inoculation was inversely related to the overall extent of 
infection (Figure 2-7B).  These results indicate that HIV-1-induced degradation of  
TRIM5α rh is correlated with saturation of restriction, likely due to a requirement to 
engage most of the restriction factor to detect the loss of the protein. These data also 
suggest an alternate explanation of how saturation of restriction may occur: depletion of 
the restriction factor as a result of infection. 
 
HIV-1 induced destabilization of TRIM5α in a rhesus macaque cell line 
 The majority of work studying TRIM5α by myself and others had, up to this point, 
used exogenously-expressed, epitope-tagged forms of the TRIM5α protein. Due to the 
extensive number of TRIM proteins encoded by the human genome as well as other 
proteins that contained RING or PRY/SPRY domains, antibodies developed against 
purified TRIM5α frequently cross-reacted with other proteins in western blots and in 
intracellular stains making interpretation considerably more difficult. My previous studies 
had indicated that infection with a restricted retrovirus induced depletion of TRIM5α 
proteins, but these assays were all performed using transduced 293T or HeLa cell lines in 
which TRIM5α was detected by virtue of a hemagglutinin epitope tag. In this setting, it 
was necessary to treat the cells with cycloheximide to detect virus-induced degradation of 
the restriction factor, potentially leading to artifacts due to general inhibition of protein 
synthesis. Virus titration experiments demonstrated markedly greater restriction in the 
transduced cells versus a rhesus macaque cell line (FRhK-4), indicating that the 293T 
cells overexpressed TRIM5αrh. Furthermore, while cycloheximide treatment had only a  
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Figure 2-8. Cycloheximide treatment decreases restriction in cells exogenously 
expressing TRIM5α. 293T-TRIM5αrh (A and C) and FRhK-4 (B and D) cultures 
were pre-treated for one hour with vehicle (DMSO) or cycloheximide (CHX), 
followed by inoculation with the indicated quantities of HIV-1 (A and B) or SIV 
(C and D) reporter viruses containing polybrene (5 μg/mL) and the respective 
drugs at concentrations identical to those used in the pretreatment.  Four hours 
later, the cultures were washed and replenished with fresh media.  Two days later, 
cells were harvested and analyzed for GFP expression by flow cytometry.  Data 
shown are from one representative of two independent experiments. 
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minor effect on restriction in FRhK-4 cells, the drug markedly reduced restriction in the 
293T cells (Figure 2-8). 
 To probe the physiological relevance of my observations made using 293T cells, I 
sought a means to detect endogenous TRIM5α protein in rhesus macaque cells.  Using a 
monoclonal antibody against native TRIM5α for immunoblotting, I was able to detect a 
band that was consistent in terms of molecular weight with TRIM5αrh that was also 
absent in cells lacking TRIM5αrh (data not shown). Though this observation was 
promising, I wanted to confirm that the band detected was, in fact, TRIM5α. To do this I 
transfected both FRhK-4 cells and 293T cells expressing the epitope-tagged TRIM5αrh 
with either a TRIM5αrh -specific siRNA duplex or a non-targeting control siRNA duplex 
and quantified the intensity of this band by immunoblotting. Transfection of FRhK-4 
cells with TRIM5αrh-specific siRNA resulted in a 72% decrease in intensity of the 
relevant band versus FRhK-4 cells treated with the non-targeting control (Figure 2-9A). 
Cells treated with the TRIM5αrh-specific siRNA also exhibited an eighteen fold increase 
in permissiveness to infection with HIV-1 (Figure 2-10). HIV-1 infection of FRhK-4 
cells was not altered by treatment with the non-targeting siRNA control.  As expected, 
treatment with either siRNA duplex did not affect permissiveness to the unrestricted SIV-
GFP (Figure 2-10), an observation consistent with previous reports (Stremlau et al., 
2004). These results indicate that the monoclonal antibody is capable of detecting 
endogenous TRIM5αrh in FRhK-4 cells. They further demonstrate that the transduced 
293T cells expressed a 3.3 fold higher level of TRIM5α than the FRhK-4 cells (Figure 2-
9B).  
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Figure 2-9. HIV-1 specifically induces destabilization of TRIM5α in rhesus 
macaque cells. (A) Duplicate cultures of 293T-TRIM5αrh and FRHK-4 cells were 
transfected on two consecutive days with siRNAs specific for TRIM5αrh 
(TRIM5α) or a non-targeting control siRNA (NTC). 72 hours after the second 
transfection, proteins were extracted and analyzed by immunoblotting with a 
TRIM5α–specific monoclonal antibody. (B) Quantitation of TRIM5αrh levels in 
siRNA-transfected cells by Odyssey imaging software. TRIM5αrh levels following 
siRNA knockdown are expressed as the average of the duplicate determinations 
with the error bars depicting the range of values. (C) FRhK-4 cells were 
challenged with HIV-GFP (VSV) or media alone (Mock). Zero hour timepoint 
represents TRIM5αrh levels in uninfected cells. (D) Quantitation of TRIM5αrh 
levels. Results shown are from one representative of three independent 
experiments. 
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Figure 2-10. Transfection of TRIM5α siRNA duplexes enhances HIV-1 infection 
in FRhK cells. A subset of cultures of 293T-TRIM5αrh and FRHK-4 cells 
transfected with the siRNA duplexes in Figure 2-9 along with a set of untreated 
cells were replated 48 hours after the second transfection. The next day the cells 
were infected with 10-fold dilutions of HIV-GFP (A) or SIV-GFP (B). The cells 
were cultured for 48 hours and then analyzed for GFP expression by flow 
cytometry. Results shown are from one representative of two independent 
experiments. 
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I next sought to determine if endogenous TRIM5αrh was destabilized by HIV-1 in 
rhesus macaque cells.  FRhK-4 cultures were inoculated with HIV-1 in the presence or 
absence of cycloheximide, and the stability of TRIM5αrh in response to infection was 
analyzed by immunoblotting.  Initial experiments showed no effect of cycloheximide 
treatment on TRIM5αrh levels in HIV-1-exposed cells (data not shown); therefore, the 
drug was removed in all subsequent experiments.  I observed that TRIM5αrh levels were 
stable in FRhK-4 cells over the 4 hour period (Figure 2-9C).  Infection with HIV-1 
resulted in accelerated depletion of endogenous TRIM5α rh in rhesus macaque cells 
without any requirement for inhibition of protein synthesis.   
 I wished to exclude the possibility that the loss of TRIM5αrh was not specifically 
due to restriction but was rather a non-specific effect resulting from viral infection. In the 
absence of cycloheximide, I infected FRhK-4 cells with equivalent titers of HIV-1 or 
SIVmac239 GFP reporter viruses.  Infection with HIV-1 resulted in a potent loss of 
TRIM5α rh, while infection with the unrestricted SIV resulted in only a slight loss of 
TRIM5α rh as compared to the control cells (Figure 2-11). Collectively, these data 
demonstrate that challenge with a restricted retrovirus induces depletion of TRIM5αrh in 
cells where TRIM5α is expressed at normal levels. The fact that this depletion is 
observed in the absence of cycloheximide indicates that depletion of the restriction factor 
is not likely due to a nonspecific effect of the inhibition of protein synthesis.  These data  
also suggest that depletion of TRIM5α in response to retroviral challenge is likely a 
common feature of restriction of lentiviruses by primate cells. 
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Figure 2-11. HIV-1-induced turnover of TRIM5α in primate cells is specific to 
restriction. (A) Duplicate cultures of FRhK-4 cells were exposed to stocks of 
VSV-G-pseudotyped HIV-GFP (HIV), SIV-GFP (SIV), or media alone (Mock) 
for a period of 4 hours then harvested and TRIM5αrh levels quantified by 
immunoblotting.  The zero hour sample corresponds to uninfected cells. (B) 
Quantitation of TRIM5αrh levels in (A) utilizing Odyssey imaging software. Data 
in this figure are expressed as the average of two independent determinants with 
the error bars spanning the range of values. 
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Discussion 
Initial studies that described restrictive activities in various cells lines, later 
attributed to TRIM5α, were extensively focused on the conditions that resulted in 
increased levels of infection by a restricted virus. These studies typically used increasing 
doses of virus to eventually overcome the block to infection but this method did not 
indicate how the restrictive factor inhibited viral replication or exactly what viral protein 
was targeted. The only things known relating to how post-entry restriction occurred was 
that it happened quickly after fusion and the end result was a decrease in the 
accumulation of viral DNA in target cells (Jolicoeur and Rassart, 1980; Perez-Caballero 
et al., 2005b). The identification that CA was the viral determinant provided the first clue 
about how restriction might be occurring (Besnier et al., 2002; Cowan et al., 2002; 
Owens et al., 2003). CA has only one demonstrated function in the retroviral lifecycle, 
formation of the capsid. Studies of HIV-1 subviral particles have found CA in association 
with reverse transcription complexes (RTCs) but little to no CA present in the PICs, 
suggesting that complete shedding of the viral capsid is important for HIV-1 infection 
(Bukrinsky et al., 1993; Miller et al., 1997; Fassati and Goff, 2001; Dismuke and Aiken, 
2006). Studies showing mature VLPs or viruses with a hyperstable capsid are efficient at 
saturating restriction provided strong evidence that it is the intact capsid that is the target 
of the restriction factors (Owens et al., 2003; Forshey et al., 2005). The identification of 
TRIMCyp provided major insight into the possible mechanisms of restriction. It was well 
established that CypA bound to CA, is associated with virions, and blockage of this 
interaction with CsA in OMK cells results in a significant increase in infection (Franke et 
al., 1994; Towers et al., 2003). It seemed clear that the restriction factor had to be able to 
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bind to the outer surface of the incoming core. This hypothesis has now been extensively 
proved through both biochemical and genetic studies (Li et al., 2006; Stremlau et al., 
2006; Perron et al., 2007). However, the knowledge that TRIM5α binds to the core does 
not explain how it inhibits viral infection. Clearly, binding is only the first stage in the 
process of post-entry restriction and the question becomes: what happens next? 
In these studies I sought to identify changes in the state of TRIM5α following 
viral challenge. I observed that inoculation with HIV-1 results in an accelerated turnover 
of the restriction factor TRIM5αrh. Similar effects were observed in both 293T and HeLa 
cells, suggesting that TRIM5αrh destabilization is not specific to a unique cell type.  HIV-
1 challenge resulted in destabilization of TRIM5αrh but not TRIM5αhu. Likewise, 
TRIM5αhu was destabilized by inoculation of cells with restriction-sensitive N-MLV 
particles but not by unrestricted B-MLV.  Similar results were seen in cells expressing 
the HIV-1-specific restriction factor TRIMCyp. Treatment of target cells with CsA, 
which blocks TRIMCyp restriction of HIV-1, or infection with virus containing 
mutations that prevent CypA binding did not affect TRIMCyp stability. Specific loss of 
TRIM5α from cells expressing different primate alleles of the protein also correlated with 
the ability of those alleles to restrict HIV or SIV, with one interesting exception.  
Destabilization of TRIM5α rh by HIV-1 was also observed in a primate-derived cell line 
without the need of cycloheximide to inhibit protein synthesis. This destabilization was 
specific for the restricted HIV-1 and was not observed in cells infected with an 
unrestricted virus. Viral-induced TRIM5α destabilization is dose-dependent and inversely 
correlates with infection in target cells. 
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How does depletion of cellular TRIM5α relate to the process of post-entry 
restriction and how does it fit in the extensive studies on saturation? My finding that viral 
challenge leads to depletion of the restriction factor and that this depletion is inversely 
correlated with restriction provides a better understanding of why post-entry restriction is 
saturable. Prior to the presentation of my findings, saturation was considered to simply be 
an overwhelming number of incoming cores binding up all of the available TRIM5α in 
the cell. While binding by itself indicates that an interaction is required, it does little to 
provide insight into the subsequent steps that are required to inhibit infection. The 
observation that binding of the incoming capsid induces TRIM5α loss indicates 
possibilities for the fate of both the TRIM5α protein as well as the incoming virus. This 
difference between the two interpretations is subtle but in light of findings from studies I 
present in Chapter III, has a critical impact on my interpretation of the mechanism of 
restriction of HIV-1 by TRIM5α.   
 The observation that TRIM5αsq is not depleted from cells in response to SIVmac 
infection presented an interesting quandary. The fact that the cells are restrictive to 
infection indicates that the protein is capable of targeting the incoming capsid, but it is 
also possible that TRIM5αsq could be targeting an entirely different aspect of SIVmac 
replication.  Data from previous studies had indicated that the mechanism of TRIM5αsq 
restriction may be different as it is not saturable by VLPs and imposes a block to 
infection at a later timepoint in the viral lifecycle (Ylinen et al., 2005). Analysis of the 
primary sequence of TRIM5αsq indicates numerous amino acid codon changes exist in 
the RING domain as compared to TRIM5αrh and TRIM5αhu. Individual mutation of the 
lysines in TRIM5αrh to arginine did not alter the ability of these mutants to restrict HIV-1 
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(data not shown). These findings suggested a possible connection with the ability of a 
TRIM5α protein to restrict prior to completion of reverse transcription and its depletion 
in cells in response to viral challenge. My efforts towards exploring this connection will 
be discussed in the next chapter.
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CHAPTER III 
 
 
THE ROLE OF THE RING DOMAIN AND THE CELLULAR PROTEASOME IN 
RETROVIRAL RESTRICTION BY TRIM5α 
 
 
Introduction 
Extensive genetic evidence implicated the capsid as the target of TRIM5α, and 
failure of the incoming virus to complete reverse transcription indicated that the block to 
infection occurred during the poorly defined “uncoating” phase. Formation of the capsid 
is critical to viral fitness, as impairment of Gag cleavage or protease function blocks viral 
infectivity (Nitschko et al., 1991; Wiegers et al., 1998). Mutations in CA that increase or 
decrease the stability of capsids have universally negative effects on viral infectivity, 
indicating that the stability of the viral capsid is properly balanced for productive 
uncoating in target cells (Forshey et al., 2002).  
When the cumulative evidence indicated the target of TRIM5α was the uncoating 
phase of the viral lifecycle, two theories emerged as to how TRIM5α may function to 
block viral infection. The first theory posited that TRIM5α recognized the highly 
repetitive nature of the incoming viral capsid and bound to the outer surface through 
interaction via the PRY/SPRY domain and triggered premature capsid disassembly 
(premature decapsidation) resulting in abortive infection. In this model, TRIM5α, perhaps 
with one or more cofactors, promotes a physical decapsidation of the virus core 
independently of proteolysis. Studies of HIV-1 CA mutants indicated that mutants with 
unstable capsids are impaired for viral DNA synthesis, suggesting that premature 
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uncoating is detrimental to reverse transcription (Forshey et al., 2002). The similar 
impairment to HIV-1 viral DNA synthesis in cells expressing TRIM5αrh
While the exact mechanism by which TRIM5α functioned remained in debate, so 
too did the question of which specific regions of the protein were required for full 
function. Researchers favoring the first model maintained that loss of the RING domain 
resulted in little loss of restriction activity (Javanbakht et al., 2005), while another study 
found that deletion of the RING domain resulted in significant loss of restriction potential 
(Perez-Caballero et al., 2005a). The latter study also found that inhibition of proteasome 
function with MG132 did not enhance infection in restrictive cells and that restriction 
was not affected by inactivation of the ubiquitin pathway. Cumulatively, these findings 
 made this theory 
appealing. Studies designed to test this possibility observed that TRIM5α restriction is 
associated with decreased recovery of sedimentable CA protein in lysates of acutely-
infected cells (Stremlau et al., 2006; Perron et al., 2007). However, these studies fell 
short of demonstrating that the sedimentable CA protein was associated with intact viral 
cores. The second hypothesis suggested a model in which TRIM5α binds to the outer 
surface of the capsid and stabilizes the structure. This enhanced stabilization would 
prevent the incoming capsid from uncoating and in turn, all subsequent aspects of the 
viral lifecycle. Support for this model was provided by studies of HIV-1 CA mutants that 
contained increased levels of CA in PICs and the observation that these mutants are 
impaired for both nuclear import and integration (Dismuke and Aiken, 2006). This 
observation, coupled with the finding that viruses with hyperstable capsids are not 
infectious, made this theory equally plausible.   
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implied that post-entry restriction by TRIM5α, might require the RING domain, but did 
not require the ubiquitin proteasome pathway. 
The breakthrough occurred when it was discovered that, while inhibition of the 
proteasome does not alter the magnitude of restriction by TRIM5α, it does result in a 
change in the nature of the block to infection (Wu et al., 2006). TRIM5αrh-expressing 
cells treated with MG132 contain accumulated levels of viral DNA products equivalent to 
unrestrictive cells infected with the same quantity of virus. The DNA products that 
accumulate in the MG132 treated TRIM5αrh
Considering my previous findings in relation to the data from these studies, I 
sought to investigate the possibility that depletion of TRIM5α that occurs in response to 
viral infection might be due to degradation of the restriction factor by the proteasome. 
Using a panel of TRIM5α chimeras and deletion mutants I also investigated the role of 
the RING domain in virus-induced degradation of TRIM5α. Based on the results of these 
studies, along with those of my colleagues (Campbell et al., 2008), I conclude that 
 cells fail to enter the nucleus, reminiscent of 
the block to infection imposed on MLV by Fv1. This study was the first to provide 
evidence for a role of the cellular proteasome in retroviral restriction by TRIM5α, a 
finding confirmed in several different primate cell lines (Anderson et al., 2006). These 
studies proposed that TRIM5α is capable of mediating two blocks to retroviral infection. 
The first block is dependent on proteasome function and is capable of preventing 
infection by retroviruses prior to completion of reverse transcription (pre-RT block). The 
second block occurs in the absence of proteasome function and impairs the ability of the 
viral particle to fully shed the capsid, inhibiting transport to or entry into the nucleus 
(post-RT block). 
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recognition of the incoming core by TRIM5α results in recruitment of the cellular 
proteasome, resulting in destruction of TRIM5α. This recruitment and destruction is 
dependent on both a functional RING domain as well as the proteasome. These studies 
provide evidence for a mechanism of restriction of retroviruses by TRIM5α. 
 
Results 
 
Inhibition of the proteasome restores stability of TRIM5α in HIV-1 infected cells 
 The observation that the cellular proteasome has a role in TRIM5α-mediated 
restriction led me to hypothesize that the depletion of TRIM5α I observed in cells 
infected with a restriction-sensitive retrovirus was due to proteasomal degradation. 
Previous studies had shown that the turnover of TRIM5α is dependent on cellular 
proteasome activity (Diaz-Griffero et al., 2006), supporting this possibility. To answer 
this question I infected TRIM5αrh-expressing cells with HIV-1 in the presence or absence 
of the proteasome inhibitor MG132. Consistent with previous studies (Anderson et al., 
2006; Diaz-Griffero et al., 2006; Wu et al., 2006), addition of MG132 resulted in 
increased accumulation of viral DNA in TRIM5αrh-expressing cells (Figure 3-1) as well 
as accumulation of the TRIM5α protein (Figure 3-2A). MG132 prevented the HIV-1-
induced destabilization of TRIM5αrh in comparison to the carrier DMSO. Additional 
studies revealed that epoxomicin, a more specific proteasome inhibitor, also blocked the 
HIV-1-induced degradation of TRIM5αrh (data not shown). By contrast, infection by 
HIV-1 in the presence of the cysteine protease inhibitor E64 did not prevent 
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A 
Figure 3-1. MG132 increases levels of viral DNA in TRIM5α-expressing cells 
infected with HIV-1. 293T cells expressing either HA-tagged TRIM5αrh (A) or 
TRIM5αhu (B) were cultured for 1 hour with DMSO, MG132, or AZT then exposed 
to HIV-1 in the presence of the same drug for a period of 5 hours. After 5 hours virus 
and drug were washed away and cells were either harvested or cultured for another 5 
to 10 hours. Cells treated with AZT were cultured in the presence of drug for the 
entire 16 hour period. Harvested cells were frozen then lysed and DNA isolated via 
standard Qiagen DNA column. Real time PCR reactions were analyzed for 30 cycles 
using primers and probe targeting Gag sequence of the HIV-1 genome. Quantities of 
viral DNA were calculated against a standard curve generated by dilution of a known 
concentration of plasmid containing the HIV-1 genome. Values displayed are the 
average of three independent wells. Error bars for rhDMSO (A) are included but not 
visible.  
 
 
 
B 
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Figure 3-2. HIV-1-induced destabilization of TRIM5α is blocked by the 
proteasome inhibitor MG132. (A and B) 293T cells expressing HA-tagged 
TRIM5αrh were cultured for 1 hour with cycloheximide and DMSO (Mock) or 
MG132 then exposed to HIV-1(VSV) with DMSO or MG132 (open or filled 
circles, respectively) or D10 media containing DMSO or MG132 (open or filled 
diamonds, respectively). Panel B shows quantitation of TRIM5α levels utilizing 
Odyssey imaging software. Data in this figure are from one of two independent 
experiments. (C). 293T cells expressing myc-His6-tagged TRIMCyp were 
cultured for 1 hour with cycloheximide and DMSO or MG132. The cells were 
then exposed for 5 hours to; VSV-G-pseudotyped HIV GFP with either DMSO or 
MG132, VSV-G-pseudotyped HIV-GFP with the G89V capsid mutation (G89V) 
with either DMSO or MG132, or media alone containing DMSO or MG132 
(Mock). (B) Quantitation of TRIMCyp levels utilizing Odyssey imaging software. 
Data in this figure are expressed as the average of the duplicate determinations, 
with the error bars depicting the range of values. 
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HIV-1-induced TRIM5αrh degradation (data not shown), suggesting that endosomal 
proteases are not responsible for TRIM5αrh destabilization.  
To determine whether HIV-1-induced destabilization of TRIMCyp is dependent 
on proteasome activity, I challenged TRIMCyp-expressing 293T cells with either 
restricted HIV-GFP or unrestricted HIV.G89V-GFP in the presence or absence of 
MG132. Addition of MG132 prevented the HIV-1-induced loss of TRIMCyp (Figure 3-
2C). Infection with the unrestricted HIV.G89V-GFP virus did not alter TRIMCyp 
stability, while addition of MG132 stabilized the restriction factor.  Thus, restriction of 
HIV-1 by TRIMCyp also results in degradation of the restriction factor by the 
proteasome. 
 
Role of proteasome function in post-entry restriction of HIV-1 in primate cells 
 While the effects of proteasome inhibition on restriction of HIV-1 in cells 
exogenously expressing TRIM5α were seen as minimal, the data from my previous 
studies indicate that restriction in this context was less than ideal for measuring what 
might be minor effects on restriction if proteasome function were to be inhibited in cells 
expressing TRIM5α at endogenous levels. The data demonstrating that TRIM5α was 
significantly over-expressed in transduced cell lines (Figure 2-9B) indicated that changes 
in restriction due to a loss of proteasome function could easily be masked by the relative 
abundance of restriction factor to facilitate the secondary late block to infection. It was 
thus possible that in cells expressing lower levels of TRIM5α that inhibition of 
proteasome function might have a greater impact. To test this hypothesis, I pretreated 
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Figure 3-3. MG132 enhances restriction of HIV-1 in primate cell lines. OMK (A 
and C) and FRhK-4 (B and D) cultures were pre-treated for one hour with the 
vehicle DMSO or MG132 (25μM), followed by inoculation with the indicated 
quantities of HIV-1 (A and B) or SIV (C and D) reporter viruses containing 
polybrene (5 μg/mL) and the respective drugs at concentrations identical to those 
used in the pretreatment.  Four hours later, the cultures were washed and 
replenished with fresh media.  Two days later, cells were harvested and analyzed 
for GFP expression by flow cytometry.  Data shown are from one representative 
of two independent experiments. 
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cultures of OMK and FRhK-4 cells with MG132 or DMSO for 1 hour, then infected the 
cells with VSV-pseudotyped HIV-1 and SIV-GFP reporter viruses in the presence of drug, 
and analyzed the effect on post-entry restriction (Figure 3-3). Addition of MG132 to 
OMK and FRhK-4 cells enhanced post-entry restriction of HIV-1 by 6- and 3-fold 
respectively while the effect of the drug on infection by the unrestricted SIV virus was 
unchanged. These data indicate that while inhibition of proteasome function impairs 
restriction of an incoming virus when TRIM5α (or TRIMCyp) are in abundance, 
inhibition of proteasome function in the context of normal levels of TRIM5α expression 
actually enhances the potential of the target cell to block infection. 
 While the effects of proteasome inhibition did enhance restriction of HIV-1 in 
primate cell lines, these experiments did not demonstrate that this effect was due to 
changes in viral-induced degradation of TRIM5α as opposed to a non-specific effect of 
the MG132 treatment. To confirm my results were relevant to restriction in an 
endogenous setting, I exposed the rhesus macaque cell line FRhK to HIV-1 in the 
presence or absence of MG132 for a period of four hours and measured the levels of 
TRIM5α by immunoblotting. In FRhK-4 cells infected with HIV-1, the addition of 
MG132 stabilized TRIM5α compared to cells infected with HIV-1 in the presence of 
carrier alone (Figure 3-4A). Flow cytometric analysis of GFP signal in a small subset of 
the infected cells showed no difference in infection levels resulting from inhibition of 
proteasome function, which is consistent with previously published results (Perez-
Caballero et al., 2005b; Wu et al., 2006). These results indicate that HIV-1-induced 
destabilization of TRIM5αrh in rhesus macaque cells requires proteasome activity. Based 
on the results from these experiments, I conclude that the virus-induced depletion of  
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Figure 3-4. HIV-1-induced turnover of TRIM5α in primate cells is blocked by the 
proteasome inhibitor MG132. (A) Duplicate cultures of FRhK-4 cells were treated for 
1 hour with DMSO or MG132, then exposed for 4 hours to: VSV-G-pseudotyped 
HIV-GFP with either DMSO or MG132, or media alone containing DMSO or 
MG132 (Mock).  (B) Quantitation of TRIM5αrh levels utilizing Odyssey imaging 
software. Data in this figure are expressed as the averages of the two determinations, 
with the error bars spanning the range of values. 
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TRIM5α and TRIMCyp is due to destruction of the restriction factor as a result of 
binding to the incoming virus and that this destruction is dependent on proteasome 
function. 
 
The RING domain is required for viral-induced degradation of TRIM5α 
 Having identified the proteasomal degradation of TRIM5α as a result of 
restriction of an incoming retrovirus, I sought to identify the region of the TRIM5α 
protein responsible for this effect. To address this problem, I utilized the previously 
discussed allele of TRIM5α that was not degraded by TRIM5α in response to viral 
infection, TRIM5αsq. Using this protein I generated a panel of chimeric domain swaps 
between TRIM5αrh and TRIM5αsq to identify which segments of the protein correlated 
with degradation in response to infection. To ensure that the results would not be clouded 
by having to use different viruses in order to induce degradation, I replaced the 
PRY/SPRY domain of all the constructs with the CypA domain from OMK-derived 
TRIMCyp. This rendered all of the constructs HIV-1 restrictive (Figure 3-5C). I 
expressed this panel of chimeras in 293T cells, selected single cell clones, and analyzed 
them for degradation in response to HIV-1 infection. In cells expressing TRIMCyprh with 
the RING domain from TRIM5αsq (SRRRCyp), degradation of the protein no longer 
occured (Figure 3-5A). The reciprocal chimera, TRIMCypsq with the RING domain of 
TRIM5αrh (RSSSCyp) was degraded in response to infection. These data suggest that the 
RING domain is responsible for viral-induced degradation of TRIM5α. 
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Figure 3-5. Transfer of the RING domain of TRIM5αrh confers viral-induced 
degradation. (A). Duplicate cultures of SRRRCyp or RSSSCyp cells were exposed 
to stocks of VSV-G-pseudotyped HIV-GFP (HIV), SIV-GFP (SIV), or media 
alone (Mock) for a period of 4 hours then harvested and TRIMCyp levels 
quantified by immunoblotting.  The zero hour sample corresponds to uninfected 
cells. (B) Quantitation of TRIM5αrh levels in (A) utilizing Odyssey imaging 
software. Values shown are the average of the two replicates and are 
representative of two independent experiments. Results are representative of two 
independent experiments. Titration curve of HIV-GFP (C) or SIV-GFP (D) on 
cultures of SRRRCyp, RSSSCyp, or 293T cells. 
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 During this process I obtained cells expressing wild-type TRIM5αrh or a 
TRIM5α rh mutant in which the RING domain had been deleted (TRIM5αrh ΔRING) from 
a collaborator. I infected these cells with HIV-1 and quantitated the changes in TRIM5α  
levels following infection. Deletion of the RING domain rendered the cells less 
restrictive than wild-type TRIM5αrh, but the cells still restricted HIV-1 infection 
compared to the parental cell line (Figure 3-6C). When these cells were challenged with 
HIV-1 there was a considerable reduction in the extent of TRIM5α degradation compared 
to the cells expressing wild-type TRIM5αrh (Figure 3-6A). Results communicated to me 
by our collaborator have shown that the cells expressing TRIM5αrh ΔRING, while being 
restrictive, contain elevated levels of viral DNA transcripts, indicating that the block to 
infection was a late block (Felipe Diaz-Griffero, personal communications). This type of 
block is analogous to restriction of SIVmac by TRIM5αsq or restriction of HIV-1 by 
TRIM5α rh in the presence of proteasome inhibitors. Taken together, these findings 
indicate that the TRIM5α RING domain is required for the degradation induced by viral 
challenge and that the ability of a TRIM5α protein to be degraded correlates with its 
ability to restrict viral infection prior to completion of reverse transcription. 
 
Discussion 
 Following the identification of TRIM5α as the protein responsible for retroviral 
restriction in primates, there was an intense effort to elucidate the mechanism of how 
TRIM5α was able to block infection. The models proposed at the time suggested that 
either TRIM5α binding induces a premature decapsidation (Figure 3-7) or prevented the 
shedding of the capsid preventing the virus from proceeding to reverse transcription. 
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Figure 3-6. Viral-induced degradation of TRIM5αrh requires the RING domain. 
(A). Duplicate cultures of TRIM5αrh or TRIM5αrhΔRING cells were exposed to 
stocks of VSV-G-pseudotyped HIV-GFP (HIV), SIV-GFP (SIV), or media alone 
(Mock) for a period of 4 hours then harvested and TRIM5α levels quantified by 
immunoblotting.  The zero hour sample corresponds to uninfected cells. (B) 
Quantitation of TRIM5αrh levels in (A) utilizing Odyssey imaging software. 
Values shown are the average of the two replicates. Results are representative of 
two independent experiments. (C) Titration curve of HIV-GFP on cultures of 
TRIM5αrh, TRIM5αrhΔRING, or the parental Cf2 cell line. 
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Studies showing decreased levels of pelletable capsid in restrictive cells following 
infection provided the initial evidence for premature decapsidation (Stremlau et al., 2006; 
Perron et al., 2007). This finding was considered to be convincing, and many considered 
that TRIM5α was capable of inhibiting viral replication independently of any other 
cellular pathway. While the theory of premature capsid uncoating was appealing, several 
groups began to conduct studies that generated data inconsistent with this theory. The 
observation that treatment of restrictive cells with proteasome inhibitors results in 
increased viral DNA accumulation indicated that the TRIM5α-capsid interaction might 
be far less transient than would be expected if TRIM5α simply caused the capsid to 
disassemble (Anderson et al., 2006; Wu et al., 2006). As such, there remained 
considerable debate about how TRIM5α functions and why the presence of proteasome 
inhibitors results in such a drastic change in the timing of restriction. The observation that 
proteasome function is required for restriction prior to reverse transcription implied that 
something in the complex is being degraded, but the identity of that protein was unknown. 
My observation of viral-induced loss of TRIM5α from cells resulting from restriction 
suggested that this protein was an excellent candidate. 
 The series of experiments performed in this study were designed to determine if 
degradation of TRIM5α is dependent on the cellular proteasome and if so, which domain 
of TRIM5α is responsible for this degradation. My findings demonstrate that degradation 
of both TRIM5α and TRIMCyp in response to HIV-1 infection is proteasome-dependent 
and that this degradation is observed whether the TRIM5α protein is expressed 
exogenously or endogenously. Lastly, I found preliminary evidence for a correlation  
 82 
 
 
 
 
 
 
 
 
 
 
 
A B 
D C 
Figure 3-7. Diagram of the model of premature decapsidation. (A) The incoming 
retrovirus containing a restricted capsid binds to the cell and (B) deposits the 
capsid into the cytoplasm. (C) TRIM5α in the cell binds to the incoming core 
through interaction with the PRY/SPRY domain. This binding results in a change 
in the conformation of CA molecules, rendering the structure unstable and causing 
the capsid to uncoat prematurely resulting in abortive infection. 
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between the ability of a TRIM5α protein to restrict retroviral infection pre-RT and the 
RING domain of that TRIM5α protein.    
 My data coupling the proteasomal dependence of the depletion of TRIM5α from 
the cytoplasm of target cells and my previous observation that this depletion is inversely 
correlated with infection provide key points in any potential interpretation of the 
mechanism of post-entry restriction by TRIM5α. A common feature of restriction by 
almost all TRIM5α alleles is that it is saturable. As infection with virus induces the 
degradation of TRIM5α my findings provide a satisfying explanation of why saturation 
occurs: loss of the restrictive protein. My results also potentially explain why 
pretreatment of cells with virus can efficiently saturate restriction for several hours: the 
requirement of synthesis of new TRIM5α. Considering this, the degradation of TRIM5α 
as a result of restriction makes the model of premature decapsidation as the mechanism of 
post-entry restriction appear less likely to be correct. 
 If the model of a proteolysis-independent, premature decapsidation were true, 
then why would restriction be saturable? If binding of the restriction factor to the 
incoming capsid and subsequent uncoating of the capsid was all that occurred, than it 
would be predicted that the TRIM5α protein would then be free to target the next capsid 
and therefore there should be no decrease in the ability of the cell to block infection. It 
could be possible that a large concentration of incoming capsids coming into the cell 
simply overwhelms the concentration of TRIM5α present in the cell, but this answer does 
not explain why saturation is stable for a period of several hours (Besnier et al., 2002). 
Assays analyzing the kinetics of restriction by the TRIMCyp protein indicate that it 
occurs very rapidly in the target cell, most often within the first hour following fusion 
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(Perez-Caballero et al., 2005b). Addition of CsA after this timepoint does not enhance 
infection of viruses inside the cell, indicating the restrictive function that TRIMCyp 
facilitates has already taken place. Considering this, if restriction is rapid and does not 
involve proteasomal degradation, then the pretreatment of cells with virus to saturate 
restriction should only be stable for a short time period (~1 hour), but this is not the case.  
 It is possible that the premature decapsidation of an incoming virus results in a 
molecular modification of TRIM5α that causes it to become destabilized and the 
degradation occurs independently of restriction, but this argument does not reconcile with 
the findings related to the timing of the block to infection (early vs. late) in the presence 
of proteasome inhibitors. If the theory of premature decapsidation of the incoming viral 
core was accurate and TRIM5α was the only protein required for post-entry restriction, 
why would blockage of the proteasome inhibit this process?  Under the premature 
decapsidation theory it would be expected that TRIM5α would bind to the incoming core 
causing uncoating and the infection would be aborted, unable to initiate reverse 
transcription. But this is in fact the opposite of what happens, as inhibition of cellular 
proteasome function drastically increases the level of viral DNA present in the cell. 
Proponents of the premature decapsidation model have suggested that proteasome 
inhibition causes TRIM5α to be mislocalized to aggresomes in the cell, rendering it 
unable to interact with the incoming virus (Diaz-Griffero et al., 2006). In this 
environment, the incoming virus is free to proceed through the lifecycle, thus explaining 
the increased levels of viral DNA present in the cell. They cite immunofluorescence data 
showing TRIM5α localized to large protein aggregates in cells treated with proteasome 
inhibitors as evidence supporting this hypothesis. However, this argument has two 
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obvious weaknesses: (1) The cells in these experiments were treated with MG132 for a 
period of 16 hours and are significantly over-expressing TRIM5α, a protein whose 
turnover is regulated by the proteasome. It is to be expected that these cells are most 
likely filled with over-expressed TRIM5α; a protein with a multimerization domain and 
two protein-protein interaction domains, which associates with numerous other proteins 
in protein complexes known as cytoplasmic bodies, and would therefore likely be in large 
protein aggresomes after a period of 16 hours. (2) If the argument that TRIM5α was 
mislocalized allowing the incoming virus to proceed with the infection were to be true, 
than why does proteasome inhibitor treatment not substantially enhance infection in 
restrictive cells? Following fusion, the virus rapidly sheds the capsid, the target of 
TRIM5α restriction, as it proceeds through the lifecycle with little to no CA left in the 
PICs. With TRIM5α mislocalized, the virus should be free to proceed all the way through 
the early stages of infection eventually integrating into the target cell. Proteasome 
inhibition enhances HIV-1 infection in cells not expressing TRIM5α, so the virus should 
actually be more likely to infect the cell. Again, this is in fact the opposite of what 
happens as MG132 enhances restriction by TRIM5α in primate cells (Figure 3-3). Based 
on these observations it seems highly unlikely that TRIM5α blocks retroviral infection by 
simply binding to the core and directly inducing a premature uncoating event.  
 Data from my studies indicate that TRIM5α degradation correlates with retroviral 
restriction and that this degradation does not occur in a setting where proteasome 
function is compromised. Data from previous studies showed that proteasome function is 
required for TRIM5α’s ability to block HIV-1 infection pre-RT (Anderson et al., 2006; 
Wu et al., 2006). While it seemed likely that TRIM5α degradation was required for pre-
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RT restriction, what was lacking was evidence that failure of TRIM5α to be degraded 
resulted in increased reverse transcription. Deletion of the RING domain of TRIM5αrh 
resulted in a mutant that was capable of restricting HIV-1 infection but does so after 
completion of reverse transcription. When these cells were infected with HIV-1 no 
degradation was observed. Transfer of the RING domain of TRIM5αsq, which also does 
not restrict retrovirus infection prior to RT and is not degraded in response to SIVmac 
challenge, also resulted in a loss of viral-induced degradation. Taken together, these 
findings strongly indicate that degradation of TRIM5α by the cellular proteasome is 
responsible for restriction of retroviruses prior to completion of reverse transcription. 
 Based upon my findings I and others have proposed a new model for the 
mechanism of post-entry restriction by TRIM5α, proteasome-induced uncoating 
(Campbell et al., 2008; Rold and Aiken, 2008). In this model (Figure 3-8), engagement of 
the incoming capsid by TRIM5α leads to recruitment of the proteasome and degradation 
of the TRIM5α polymerized on the capsid surface. The degradation of TRIM5α results in 
removal of CA from the capsid causing a loss in stability and acceleration of the 
uncoating process, resulting in aborted infection. In the absence of proteasome function 
TRIM5α remains bound to the viral capsid and prevents infection by preventing CA 
shedding from the viral particle. DNA synthesis continues but the inability of the virus to 
shed the capsid renders the particle uninfectious. Recent data showing fused HIV-1 viral 
particles surrounded by TRIM5α in cells treated with MG132 provide support for this 
point (Anderson et al., 2008). At present, the proteasome-induced uncoating model is 
currently the best able to reconcile the numerous observations regarding restriction by 
TRIM5α as well as the findings concerning the protein content of PICs.  
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A B 
C D 
Figure 3-8. Diagram of the model proteasome-induced uncoating. (A) TRIM5α in 
the cell binds to the incoming core through interaction with the PRY/SPRY 
domain and stabilizes the capsid. (B) This binding results in the recruitment of 
proteasomes to the TRIM5α-capsid protein complex. (C) Initiation of TRIM5α 
degradation by the proteasome results in removal of a TRIM5α-CA complex from 
the capsid. This removal of small portions of CA results in a decrease in the 
overall stability of the capsid such that it can no longer maintain the structural 
integrity required to remain intact. This change in stability results in an 
accelerated uncoating and aborted infection. (D) Degradation of TRIM5α by the 
proteasome results in release of the CA from the TRIM5α-CA complex and 
hydrolysis of TRIM5α. 
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So how does the degradation of TRIM5α result in loss of capsid stability? The 
most obvious explanation would be that engagement of the capsid by TRIM5α leads to 
direct removal of CA from the core as a TRIM5α-CA complex followed by proteasomal 
degradation. However, proteins are fed into the proteasome as linear peptides rather than 
large, multi-subunit complexes. It would thus be unlikely that TRIM5α would be able to 
directly lead CA into the proteasome. What is far more likely is that binding of TRIM5α 
onto the incoming core results in recruitment of the cellular proteasome which degrades 
TRIM5α. The degradation event leads to a change in the conformation of the capsid to 
the point that it can no longer maintain the structural stability required to facilitate the 
early stages of HIV-1 replication. This “proteasome-induced uncoating” could occur via 
physical dissociation of a TRIM5α-CA complex from the core followed by release of the 
CA from TRIM5α, thus leading to destruction of the restriction factor and decapsidation 
of the core but not necessarily degradation of CA. Genetic evidence from abrogation-of-
restriction studies indicates that TRIM5α binding requires an intact or semi-intact viral 
capsid, suggesting that TRIM5α binding to CA is highly dependent on avidity resulting 
from multivalent interactions with the polymeric viral capsid.  It is thus plausible that 
once removed from the intact capsid, TRIM5α cannot engage the CA protein with 
sufficient affinity to stay bound. Alternatively, CA, once removed from the hexameric 
lattice form of the viral capsid, may not stay in the proper conformation that is required 
for TRIM5α to bind to it. Without the CA-CA interactions provided by the numerous 
hexameric subunits of the capsid influencing self-association, the small portion of CA-
CA subunits in a TRIM5α-CA complex removed during proteasome-induced uncoating 
would be expected to have less affinity for one another and dissociation would seem 
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likely. While the exact nature of how the TRIM5α degradation induces aberrant 
uncoating during post-entry restriction remains to be determined, it now seems clear that 
proteasomal degradation of TRIM5α is required.   
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CHAPTER IV 
 
 
EVIDENCE FOR A ROLE OF THE UBCH5 FAMILY OF UBIQUITIN 
CONJUGATING ENZYMES IN POST-ENTRY RETRICTION BY TRIM5α 
 
 
Introduction 
While the exact mechanism by which TRIM5α functions remains in debate, so 
does the requirement of specific regions of the protein for full function. Some researchers 
maintain that deletion of the RING domain results in little loss of restriction activity 
(Javanbakht et al., 2005), while others demonstrated that deletion of the RING domain 
has significant effects on post-entry restriction (Perez-Caballero et al., 2005a). Thus, the 
role of the RING domain in post-entry restriction is a matter of considerable interest. 
Previous work had demonstrated that the RING domain of TRIM5δ, which is identical to 
TRIM5α, has E3-ligase activity and that TRIM5α autoubiquitylates itself in vitro when 
incubated with the ubiquitin conjugating enzyme UbcH5b (Xu et al., 2003; Yamauchi et 
al., 2008). Mutations in the TRIM5δ RING domain that prevented folding, or incubating 
the RING domain with other E2 proteins, does not result in ubiquitin conjugation. These 
findings suggested a mechanism for how TRIM5α might alter the uncoating process: 
transfer of ubiquitin to an incoming capsid and targeting of the capsid to the proteasome. 
TRIM5α is itself ubiquitinated in vivo but the role this modification has on restriction, if 
any, is unclear (Diaz-Griffero et al., 2006). The detection of ubiquitin on TRIM5α and 
the autoubiquitylation activity also suggested the possibility that interaction with the 
incoming capsid resulted in polyubiquitination of TRIM5α and subsequent targeting of 
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the protein to the proteasome, a hypothesis consistent with my findings discussed in 
Chapter 3.  
Considerable efforts had been expended towards determining the regions of 
TRIM5α that were critical for restriction, but little effort had been directed towards 
determining if TRIM5α was the sole protein involved in post-entry restriction. In this 
study I sought to determine if other proteins, specifically E2 proteins, may be involved in 
post-entry restriction by TRIM5α. To address this I used two separate approaches to 
address the question. In the first approach, I used a panel of E2 expression plasmids along 
with corresponding dominant-negative (DN) mutants, expressed them in cells, and 
determined the effects on TRIM5α-mediated restriction. In the second part of the study, I 
utilized silencing RNA technology to knock down expression of a family of E2 proteins 
to determine if loss of these proteins altered the ability of TRIM5αrh to restrict infection 
by HIV-1. I determined that the presence of high levels of dominant-negative forms of 
UbcH5b and UbcH5c resulted in reduced HIV-1 restriction by TRIM5αrh. This was not 
the case when the corresponding wild-type E2s were expressed in cells. This increase in 
permissivity to infection was dose dependent, with the greatest effects occurring at the 
lowest input levels of virus. Knockdown of the same UbcH5 proteins in target cells, 
while enhancing infection, did not result in a substantial loss of HIV-1 restriction by 
TRIM5αrh. Collectively, these results suggest that ubiquitination by the UbcH5 family of 
E2 proteins in TRIM5αrh -expressing cells has a role in post-entry restriction of HIV-1. 
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Results 
 
Expression of dominant negative UbcH5 impairs restriction by TRIM5αrh 
 Incubation of GST-tagged RING domain of TRIM5δ with UbcH5b and free 
ubiquitin in vitro results in autoubiquitylation of TRIM5δ (Xu et al., 2003). As the RING 
domains of TRIM5α and δ are identical, I reasoned that the UbcH5 family of proteins 
might have a role in post-entry restriction of HIV-1 by TRIM5αrh.  The UbcH5 family of 
E2 proteins contains three isoforms: a, b, and c. UbcH5b and UbcH5c share 98% 
sequence identity while UbcH5a shares a ~90% identity to b and c. All three isoforms 
contain a conserved cysteine residue at position 85 that serves as the acceptor for the 
ubiquitin moiety. Mutation of this amino acid to alanine results in a DN version of the 
protein that lacks the ability to accept ubiquitin but does bind to the appropriate E3-
ligases. I obtained a panel of E2 expression plasmids and their corresponding DN mutants 
that had been previously characterized (Gonen et al., 1999).  Utilizing 293T cells that had 
been stably transduced to express either TRIM5αrh or TRIM5αhu, I transfected UbcH5a, b, 
and c into cells via lipofection along with a transfection control plasmid HcRedN1. Stable 
expression of TRIM5αrh in 293T cells rendered them greater than 100-fold restrictive to 
infection by HIV-1 compared to untransduced cells (Figure 2-1C). Expression of 
TRIM5αhu in 293T cells rendered them ~4-fold restrictive to HIV-1 which is consistent 
with previously published reports (Hatziioannou et al., 2004b; Perron et al., 2004). The 
cells were then infected with a predetermined dose of VSV-pseudotyped HIV-GFP virus 
such that 5% of the cells would become infected. Forty-eight hours after infection, the 
cells were fixed and analyzed by flow cytometry for both 
 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Expression of DN UbcH5b or c enhances permissivity of TRIM5αrh-
expressing cells. Cultures of TRIM5αrh or TRIM5αhu-expressing cells were 
transfected with the indicated E2 expression plasmid then cultured for 24 hours. 
The cells were then challenged with stocks of VSV-G-pseudotyped HIV-GFP (A) 
or SIV-GFP (B) and cultured for another 48 hours. Following this period cells 
were harvested and analyzed for RFP (E2 expression) and GFP (infection) by 
FACS. Data shown are representative of three independent experiments. 
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HcRED (E2 expression) and GFP (HIV infection). Analysis of the effect of E2 
expression was performed by dividing the ratio of transfected cells that became infected 
by the ratio of untransfected cells that became infected. I have termed this ratio of ratios 
the ‘permissivity index’ of the target cells. If expression of a given E2 protein has no 
effect than the ratio should be 1. A ratio of greater than 1 indicates that expression of that 
E2 in cells enhances the permissivity of the target cells to HIV-1infection. When UbcH5a, 
b, and c were expressed in TRIM5αrh-expressing cells the permissivity ratio was 
approximately 4 indicating over-expression of UbcH5 impairs restriction in these cells 
(Figure 4-1A). This effect is partially related to transfection though as transfection with 
the parental plasmid pCAGGS results in a permissivity index of almost 2. Expression of 
UbcH5aDN did not significantly alter the permissivity index of TRIM5αrh-expressing 
cells. Expression of UbcH5bDN and UbcH5cDN resulted in a rise in the ratio of infected 
cells indicating that expression of the DN forms of these plasmids impair restriction in 
TRIM5αrh-expressing cells. TRIM5αhu is not capable of efficiently restricting HIV-1; 
therefore, these cells should not be affected by expression of either form of E2 protein. 
While the expression of the DN forms of UbcH5b and c did slightly increase permissivity 
of cells, it was not to the extent of the increase seen in the TRIM5αrh-expressing cells. 
 I considered the possibility that over-expression of any E2 protein may have 
deleterious effects on post-entry restriction by TRIM5αrh. To investigate this, I 
transfected two other unrelated E2 proteins into TRIM5αrh and TRIM5αhu-expressing 
cells to study their effects on post-entry restriction of HIV-1. Over-expression of DN 
forms of Ubc3 and E2-20K or even the wild-type form of Ubc3 had little effect on 
permissivity to HIV-1 in either TRIM5αrh or TRIM5αhu cells compared to  
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TRIM5αrh-expressing cells transfected with UbcH5cDN (compare Figures 4-1A and 4-
2A). The wild-type form of E2-20K was not utilized in these experiments due to inability 
to obtain this particular plasmid. These data indicate that over-expression of unrelated E2 
proteins does not affect TRIM5αrh-mediated post-entry restriction of HIV-1. These 
results also suggest that impairment of ubiquitination pathways involving UbcH5b and c 
impairs post-entry restriction by TRIM5αrh.  
 
Inhibition of sumoylation does not alter restriction by TRIM5αrh 
 I considered the possibility that modifications to TRIM5α may alter localization 
inside the cell thus affecting restriction. Sumoylation is a modification that can result in 
altered cellular localization. I hypothesized that TRIM5α interaction with the incoming 
core could result in sumoylation, leading to altered trafficking of the core and impairment 
of infection. To assay this, I obtained expression plasmids for the E2 protein Ubc9 and 
the corresponding DN mutant. Ubc9 is the sole E2 protein responsible for SUMO 
conjugation. I transfected these plasmids into TRIM5αrh and TRIM5αhu-expressing cells 
and assayed the effect on permissivity to HIV-1. Expression of either form of Ubc9 had 
little effect on permissivity to HIV-1 infection compared to cells transfected with empty 
plasmid alone (Figure 4-2B). These data suggest that sumoylation does not play a role in 
post-entry restriction by TRIM5α and additionally indicate the effect on restriction by the 
DN forms of UbcH5b and c observed in the previous experiments is specific to those E2 
proteins. 
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Figure 4-2. Expression of DN forms of Ubc3, E2-20K or Ubc9 do not enhance 
permissivity of TRIM5αrh-expressing cells. Cultures of TRIM5αrh or TRIM5αhu-
expressing cells were transfected with the indicated E2 expression plasmid then 
cultured for 24 hours. The cells were then challenged with stocks of VSV-G-
pseudotyped HIV-GFP and cultured for another 48 hours. Following this period 
cells were harvested and analyzed for RFP (E2 expression) and GFP (infection) 
by FACS. Data shown are representative of two independent experiments. 
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Effect of DN E2 expression on restriction by TRIM5αrh is dose dependent 
 Restriction by TRIM5α is saturable, and higher input levels of virus can mask the 
full potency of restriction. I hypothesized that altering the input dose could possibly have 
an effect on the changes in permissivity. To assay this, I transfected TRIM5αrh and 
TRIM5αhu-expressing cells with DN UbcH5c and infected the cells with a series of two-
fold dilutions of HIV or SIV-GFP. The dilutions were set such that the highest level of 
virus input would result in 20% of the cells becoming infected. As TRIM5αrh-expressing 
cells are more restrictive than TRIM5αhu-expressing cells, 100-fold less HIV-GFP virus 
was used to obtain the same level of infection. The cells were analyzed as before and the 
permissivity index was calculated to determine changes in the ability to restrict HIV-1 
infection. Decreasing the level of input virus had a strong effect on the permissivity index 
in TRIM5αrh-expressing cells transfected with DN UbcH5c. At the highest dose of virus, 
the ratio reflected no effect (r=1), but as the level of virus was decreased, a corresponding 
increase in the permissivity index was seen at each dilution (Figure 4-3A). Reducing the 
virus input had only a very slight effect on the permissivity index of nonrestrictive 
TRIM5αhu-expressing cells to HIV-1 (Figure 4-3B). Decreases in input dose of the 
unrestricted virus SIV-GFP had no effect on the permissivity index of either type of cell 
(Figure 4-3C). Therefore, the effect of impairment of UbcH5c-conjugated ubiquitination 
is specific to post-entry restriction of HIV-1 by TRIM5αrh as the effect was not observed 
in a cell line expressing the minimally restrictive TRIM5αhu or when an unrestricted virus 
was used. These data also suggest that a functioning UbcH5-mediated ubiquitination 
pathway is critical for restriction at lower, more physiological levels of viral infection.  
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Figure 4-3. Enhancement of permissivity by UbcH5DN expression is dose-
dependent. Cultures of TRIM5αrh (A) or TRIM5αhu (B)-expressing cells were 
transfected with the UbcH5cDN expression plasmid then cultured for 24 hours. 
The cells were then challenged with the indicated quantity of VSV-G-
pseudotyped HIV-GFP and cultured for another 48 hours. Following this period 
cells were harvested and analyzed for RFP (E2 expression) and GFP (infection) 
by FACS. (C) TRIM5αrh and TRIM5αhu cells transfected as in (A) and (B) but 
challenged with VSV-G-pseudotyped SIV-GFP. Data shown are representative of 
two independent experiments. 
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Knockdown of UbcH5 in TRIM5αrh cells modestly impairs restriction 
 Over-expression of proteins that may possibly interact in cells can be useful to 
screen potential candidates for study but can also result in unintended effects. I 
considered the possibility that the results obtained from my over-expression studies could 
be artifactual and that over-expression of the UbcH5 proteins altered permissivity of the 
cells to infection by impairing the ability of TRIM5α to interact with another E2 that was 
responsible for facilitating post-entry restriction. To address this, I sought to study the 
effect of depletion of UbcH5 on post-entry restriction of HIV-1 by TRIM5αrh.  
I transfected a panel of siRNA duplexes (Table 4-1) designed to target all three isoforms 
of UbcH5 into TRIM5αrh-expressing cells and obtained an approximately 90% 
knockdown of all isoforms of UbcH5 after a period of 48 hours as determined by 
quantitation utilizing Odyssey band imaging software (Figure 4-4A). The antibody 
utilized detected all isoforms of UbcH5 (Figure 4-4C) and further incubation of the cells 
to 72 hours did not result in a greater decrease in UbcH5 levels (data not shown). I also 
transfected siRNA duplexes designed to target TRIM5αrh
 I then transfected TRIM5α
 and was able to obtain between 
70-80% knockdown of the protein in the transduced cell lines.  
rh and TRIM5αhu-expressing cells with siRNA 
duplexes targeting UbcH5, TRIM5αrh, or a prescreened non-targeting siRNA. All siRNA 
transfections were normalized so that the cells each received the same concentration of 
duplexes. The transfected cells, as well as untreated cells, were then challenged with 
either HIV or SIV-GFP and the effect on post-entry restriction was determined. 
Transfection of TRIM5αrh-specific siRNA duplexes into TRIM5αrh-expressing cells 
resulted in a 4-fold loss of restriction compared to control cells (Figure 4-5A). 
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Figure 4-4. Knockdown of UbcH5 by transfection of siRNA pools. (A) Western 
blot of TRIM5αrh-expressing 293T cells transfected with individual and pooled 
siRNAs. (Lane 17 is the parental 293T cell line and does not express TRIM5α) 
LC=loading control. (B) Quantitation of UbcH5 levels in (A). Values are 
expressed as a percentage of the untreated cells in lane 16. (C) 293T cells were 
lipofected with 3μg of the indicated expression plasmid, cultured for 24 hours, 
and the lysates analyzed for UbcH5 expression. The top band is the exogenously 
expressed UbcH5 that has a higher molecular weight due to the His-epitope tag. 
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siRNA Sense Sequence Protein Targeted 
A2 GAAGAAUUGAGUGAUCUAUU UbcH5a 
A4 GCACAAAUCUAUAAAUCAGUU UbcH5a 
B2 CUAUCAGGGUGGAGUAUUUUU UbcH5b 
B4 UGAAUGAUCUGGCACGGGAUU UbcH5b 
C3 CUAAUGACAGCCCAUAUCAUU UbcH5c 
C4 ACAGUGGUCGCCUGCUUUAUU UbcH5c 
TRIM5α AAGCCUUACGAAGUCUGAAAC TRIM5α 
Negative AAGCCUUACGAAGUCUGAAAC None 
 
 
Analysis of a subset of cells from this transfection showed knockdown of 77% of the 
TRIM5αrh (Data not shown). Knockdown of UbcH5 also resulted in a loss of restriction 
of ~3 fold; however, the knockdown of UbcH5 for this experiment was greater than 95%. 
In TRIM5αhu-expressing cells knockdown of UbcH5 resulted in total loss of restriction as 
compared to the parental cell line 293T (Figure 4-5B); however, over-expression of 
TRIM5αhu in the transduced 293T cells only results in a 4-fold decrease in 
permissiveness to HIV-1. TRIM5αrh and TRIM5αhu-expressing cells treated with the 
non-targeting siRNA did not differ in terms of restriction of HIV-1 from the untreated 
cells. Transfection of siRNA duplexes targeting either UbcH5 or TRIM5αrh had no effect 
on TRIM5αrh and TRIM5αhu-expressing cells permissiveness to the unrestricted SIV-
GFP virus (Figure 4-5C). These data indicate that despite efficient knockdown of UbcH5 
in target cells, the effect on restriction was very modest. While knockdown of TRIM5αrh 
 
by ~75% also only had a limited effect on restriction in the target cells (as seen 
previously in Figure 2-10), the knockdown of UbcH5 was considerably more effective.  
Table 4-1. Table of siRNA sequence and targets. TRIM5α siRNA is described in 
Stremlau et al 2004. 
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Figure 4-5. Knockdown of UbcH5 does not significantly alter post-entry 
restriction by of HIV-1 by TRIM5αrh. Cultures of TRIM5αrh (A) or TRIM5αhu 
(B)-expressing cells were transfected with a pool of siRNAs targeting the 
indicated protein and cultured for 48 hours. The cells were then challenged with 
the indicated quantity of VSV-G-pseudotyped HIV-GFP and cultured for another 
48 hours. Following this period cells were harvested and analyzed for GFP 
expression by FACS. (C) TRIM5αrh cells transfected as in (A) but challenged with 
VSV-G-pseudotyped SIV-GFP. Data shown are representative of two independent 
experiments. 
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Knockdown of UbcH5 in cells endogenously expressing TRIM5α does not alter   
post-entry restriction  
 
 Despite knocking down considerable levels of TRIM5α in the TRIM5αrh-
transduced cells lines, the decrease of restriction of HIV-1 was not substantially changed, 
consistent with previous results (Figure 2-10). Based on the level of knockdown it 
appeared that only 25% of the TRIM5α present in the cells was still sufficient to potently 
restrict infection by HIV-1. This observation indicated the possibility that the minor loss 
in restriction resulting from knockdown of UbcH5 could possibly be due to the 
artificially high levels of TRIM5αrh present in the transduced cells. I considered the 
possibility that knockdown of UbcH5 may have a greater effect on post-entry restriction 
in cells that expressed TRIM5α at lower levels.  HeLa cells express the TRIM5αhu allele 
and restrict infection by N but not B-MLV. I transfected HeLa cells with siRNA duplexes 
targeting either UbcH5 or a non-targeting control, and assayed the effects on restriction 
of N-MLV. Knockdown of UbcH5 in the HeLa cells was very effective at ~95% decrease 
in UbcH5 levels (Figure 4-6A). However, the loss did not alter restriction of N-MLV as 
compared to control (Figure 4-6B). Knockdown of UbcH5 did not alter the levels of 
infection of the unrestricted B-MLV in HeLa cells (Figure 4-6C).   
 FRhK-4 cells are derived from rhesus macaques and express TRIM5αrh and 
restrict HIV-1. I transfected FRhK cells with siRNA duplexes targeting UbcH5, 
TRIM5αrh, or a non-targeting control and assayed for changes in restriction of HIV or 
SIV-GFP. Knockdown of TRIM5α in FRhK cells resulted in a considerable loss of 
restriction of HIV-1 as previously reported (Figure 4-7A). No change in restriction of 
HIV-1 was observed in FRhK cells treated with UbcH5 siRNAs or the non-targeting  
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Figure 4-6. Knockdown of UbcH5 does not significantly alter post-entry 
restriction of N-MLV in HeLa cells. (A) Cultures of HeLA cells were transfected 
with a pool of siRNAs targeting the indicated protein and cultured for 48 hours. 
The cells were then challenged with the indicated quantity of VSV-G-
pseudotyped N-MLV (B) or B-MLV (C) and cultured for another 48 hours. 
Following this period, cells were harvested and analyzed for GFP expression by 
FACS. Data shown are the average of two wells per data point. 
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control. Knockdown of either UbcH5 or TRIM5αrh in FRhK cells did not alter infection 
by the unrestricted SIV-GFP (Figure 4-7B). While knockdown of TRIM5αrh appeared 
effective based on the loss of HIV-1 restriction, UbcH5 was not able to be visualized on 
western blots of FRhK lysates (data not shown) leaving open the question of whether 
UbcH5 was efficiently knocked down in these cells. These observations suggest that the 
role of UbcH5 in post-entry restriction by TRIM5α may be less important in cells that 
express TRIM5α at physiological levels. 
 
Discussion 
 In this study, I found preliminary evidence for a role for the UbcH5 family of 
proteins in post-entry restriction of HIV-1 by TRIM5αrh. I demonstrated that over-
expression of DN forms of UbcH5b and c resulted in an increased likelihood of infection 
by the restricted HIV-1 but did not alter susceptibility to an unrestricted virus. The 
increase in susceptibility to HIV-1 infection was not observed when cells were 
transfected with other E2 proteins not predicted to interact with TRIM5α and over-
expression of the wild-type UbcH5 isoforms had only modest effects on permissivity to 
HIV-1. Over-expression of DN forms of UbcH5 also did not alter susceptibility of 
permissive cells to infection by HIV-1. The effect of DN UbcH5 expression on 
permissiveness of TRIM5αrh-expressing cells to HIV-1 is dependent on the input level of 
the virus. Increased effects of DN UbcH5 on permissivity to infection were seen with 
lower levels of viral inoculation. Knockdown of UbcH5 did result in a reduction of 
restriction in TRIM5αrh-transduced cell lines, but the effect was minor and was not 
observed in cells expressing endogenous, physiologic levels of TRIM5α. 
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Figure 4-7. Knockdown of UbcH5 does not significantly alter post-entry 
restriction of HIV-1 in FRhK-4 cells. (A) Cultures of FRhK-4 cells were 
transfected with a pool of siRNAs targeting the indicated protein and cultured for 
48 hours. The cells were then challenged with the indicated quantity of VSV-G-
pseudotyped HIV-1 (A) or SIVmac239 (B) and cultured for another 48 hours. 
Following this period cells were harvested and analyzed for GFP expression by 
FACS. Data shown represent the average of two independent wells. 
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 The RING domain of TRIM5α is critical for full restriction activity, as evidenced 
by the significant increase in infection in cells expressing a TRIM5αrh in which the RING 
domain is deleted or misfolded (Stremlau et al., 2004; Javanbakht et al., 2005; Perez-
Caballero et al., 2005a). Loss of RING function increases the half-life of TRIM5α in the 
cell but does not appear to alter cellular localization. TRIM5α is ubiquitinated in vivo and 
the majority of the population appears to be monoubiquitinated (Diaz-Griffero et al., 
2006; Yamauchi et al., 2008). The role for this modification is unclear, and TRIM5α rh 
restriction of HIV-1 in cells lacking a functional ubiquitin pathway is not altered in 
magnitude. Restriction of HIV-1 in such an environment may be different than the 
restriction that exists in a physiologic setting, complicating interpretation of results in 
which ubiquitination is altered through mutation or drug treatment (Anderson et al., 2006; 
Wu et al., 2006). Experiments in which I analyzed the effects of UbcH5 knockdown on 
the accumulation of viral DNA in TRIM5αrh
 During the course of my studies, another group identified a role for UbcH5b in 
the monoubiquitination of TRIM5α and suggested that the purpose of this modification is 
to regulate the shuttling of TRIM5α in and out of cytoplasmic bodies (Yamauchi et al., 
2008). If ubiquitination of TRIM5α by UbcH5 does result in changes in cellular 
localization, this might explain the reduction of restriction in cells in which ubiquitination 
was impaired by DN expression owing to an inability to transition to the site of TRIM5α-
capsid interaction. However, this does not explain why knockdown of UbcH5 did not 
also result in increased infection. It is perhaps possible that other E2 proteins are capable 
of conjugating ubiquitin onto TRIM5α and these proteins are sufficient to fulfill this role 
-expressing cells yielded results that were 
not interpretable (data not shown). 
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in the absence of UbcH5. The study by Yamauchi et al. found that MG132 treatment did 
not enhance stability of the monoubiquitinated TRIM5α, suggesting that this modification 
does not lead to proteasomal degradation. However, these experiments were not 
conducted using cells challenged with virus. It would be of interest to determine if 
impairment of UbcH5 in cells challenged with HIV-1 results in a loss of virus-induced 
TRIM5α degradation. My own experiments attempting to test this were complicated by 
an overall decrease in TRIM5α stability in response to any siRNA treatment, even in cells 
not challenged with HIV-1 (data not shown).  
 Initial evidence obtained from experiments with the over-expression of the DN E2 
proteins suggested that ubiquitination of TRIM5αrh 
 Findings from these studies indicate that impairment of function of a pathway 
involving UbcH5 may play a role in post-entry restriction of HIV-1 by TRIM5α
might have a role in post-entry 
restriction. I attempted to determine if loss of potential acceptor lysine residues in the N-
terminal domain of TRIM5α resulted in enhanced infection. Mutation of individual lysine 
residues and one tandem lysine site to arginine did not result in a loss of HIV-1 restriction 
in any of the mutant TRIM5α proteins (data not shown). After I had identified the 
degradation effect of HIV-1 infection on TRIM5α, I reanalyzed these mutants for 
degradation resulting from infection. All mutants were fully capable of being degraded in 
response to HIV-1 challenge (data not shown). While these mutants did target all of the 
individual lysines present in the N-terminal domain of TRIM5α up to the B-box domain, 
this panel of mutants is by no means comprehensive. It is possible that increased 
mutation of multiple lysine residues might have a more profound impact on TRIM5α 
degradation resulting from viral challenge.   
rh. 
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Whether this role is due to direct action by UbcH5, or if the overexpressed DN forms of 
UbcH5 simply bound to all of the TRIM5α protein in the cells thereby preventing 
interaction with the appropriate partner remains to be determined. The vast majority of 
this work was conducted prior to my characterization of viral-induced degradation of 
TRIM5α and the effect of proteasome inhibition on the timing of restriction. The more 
recent identification of these aspects of the mechanism of post-entry restriction by 
TRIM5α, along with the development of newer TRIM5α mutants that are capable of 
restricting HIV-1 without being degraded, suggest that further investigation into the role 
of UbcH5 in TRIM5α function may prove fruitful.
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Introduction 
 In the past 15 years it has become increasingly clear that the interior of the cell, 
rather than serving as an unwitting host for viral replication, is in fact a battleground in 
which there is a constant war waged between the host and virus for supremacy at the 
molecular level. Retroviruses exhibit a restricted host range due to the requirement for 
specific interactions between viral and host proteins to complete the viral lifecycle. 
Numerous host cell proteins that target the intracellular stages of retroviral infection have 
been identified (Best et al., 1996; Sheehy et al., 2002; Nisole et al., 2004; Sayah et al., 
2004; Stremlau et al., 2004; Wolf and Goff, 2007). Scanning of the chromosome on 
which the antiviral factor APOBEC3G is found shows that the gene has likely been 
duplicated 7 times on the same segment of DNA. Analysis of the rate of positive 
selection (non-synonymous nucleotide changes divided by synonymous nucleotide 
changes) has calculated that TRIM5α and APOBEC3G are two of the most highly 
selected genes in the primate genome (Sawyer et al., 2005). The enormous selection 
pressure placed on these two particular genes, both of which target intracellular stages of 
retroviral infection, indicates that the ability to successfully inhibit retroviral infection 
inside the cell has likely provided significant fitness advantage to the host. The enhanced 
selection of genes that target retroviral infection at a cellular level also suggests that this 
strategy has been successful, perhaps more successful, than control of retroviral infection 
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at the level of the host immune system. Considering this possibility, our enhanced 
understanding of how these factors inhibit viral replication offers us not only the 
opportunity for a greater understanding of the molecular biology of both the host and 
virus, but also the potential for the development of new therapies targeting stages of viral 
replication that have clearly been the target of host cell defenses selected by eons of 
evolution. 
 Our understanding of the early stages of HIV-1 replication is relatively poor 
compared to our understanding of other aspects of the viral lifecycle. Recent advances in 
molecular biology and technology have opened the door for the development of new 
techniques to answer questions about how HIV-1 accomplishes the seemingly difficult 
tasks of converting its genome into a form suitable for integration into the host, 
trafficking through the dense network of the cellular cytoplasm, and obtaining entry into 
the nucleus. The identification of APOBEC3G and TRIM5α now indicates that the virus 
must additionally contend with attempts by the cell to sabotage these processes along the 
way. The understanding that both proteins target the early stages of viral replication 
indicates that this is a point at which the virus is clearly most vulnerable. Therefore, 
enhanced understanding of how the HIV-1 accomplishes its early replication, and how it 
avoids the barriers established by the host cell, offers the potential for more effective 
treatments to help those infected with HIV-1. 
  
The mechanism of post-entry restriction or retroviruses by TRIM5α 
 So how now, at the conclusion of my graduate studies, do I consider my findings 
to have impacted the field of HIV-1 uncoating and more broadly, HIV-1 research? Prior 
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to the publication of my studies, the predominant theory regarding the mechanism of 
post-entry restriction by TRIM5α posited that TRIM5α functioned independently of any 
other proteins to induce accelerated uncoating of the incoming virus. This hypothesis was 
supported by evidence of an increased loss of what was consistently referred to as 
pelletable retroviral capsids in cells expressing a restrictive TRIM5α (Stremlau et al., 
2006; Perron et al., 2007). This theory was proposed by the lab having identified 
TRIM5α as the protein responsible for post-entry restriction in primate cells and as such, 
carried considerable weight and was viewed by many as the likely explanation of 
TRIM5α function. While initial studies showing the increased viral DNA accumulation 
as a result of proteasome inhibition provided an interesting observation, this effect was 
not considered relevant to the context of normal function by TRIM5α as inhibition of the 
proteasome does not typically occur in cells. The changes in the timing of infection 
resulting from inhibition of the proteasome indicated the possibility that something was 
being degraded during the process of restriction, but numerous efforts by several labs had 
failed to conclusively identify the potential candidate. Thus, due in part to a lack of 
evidence to the contrary, the theory of premature decapsidation was well embraced. 
 My findings of viral-induced TRIM5α degradation, and the requirement of the 
proteasome for this effect, was the first identification of a candidate protein whose 
change in stability might explain the alterations in post-entry restriction due to 
impairment of proteasome degradation. This finding, coupled with data showing 
relatively stable TRIM5α-capsid complexes inside MG132 treated cells, do not support 
the theory that TRIM5α acts alone to block HIV-1 infection (Campbell et al., 2008; Rold 
and Aiken, 2008). These findings in concert have led to a redefinition of how many in the 
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HIV-1 field view post-entry restriction. The proposed mechanism of proteasome-induced 
uncoating is now considered to be the most likely explanation of TRIM5α function.  
My work has also led to a redefinition of the process of saturation of restriction by 
incoming viruses. All work previously had speculated that saturation occurred due to an 
overwhelming number of capsids as compared to restriction factor, such that there was 
not enough TRIM5α present to bind to additional incoming cores. These studies also 
speculated on the possibility of a rate-limiting step following binding such that there was 
insufficient activity of another cellular pathway to facilitate the steps required subsequent 
to binding of TRIM5α to the capsid that were necessary to inhibit viral infection. These 
results were all highly speculative, and the proposed pathway was not defined. My data 
showing that degradation of TRIM5α is inversely correlated to infection now provides a 
potential explanation of the saturability of restriction that appears far more complete and 
better reconciles the data from numerous studies. The simplicity of the supposition that 
the limiting cellular protein in post-entry restriction is the restriction factor itself indicates 
both a mechanism to explain why restriction is saturable and why this saturability is 
stable for a period of several hours (Besnier et al., 2002). Proteasomal degradation of 
TRIM5α as a result of binding to the incoming core also connects the interaction of the 
restriction factor with a downstream cellular pathway that would be predicted to 
significantly impair the ability of the incoming virus to infect the target cell. 
My observation that TRIM5αsq is not degraded in response to infection also 
reconciles why this particular allele of TRIM5α behaves so differently in comparison to 
all other alleles of TRIM5α that have thus been characterized so far. The lack of 
degradation as a result of SIV challenge potentially explains the lack of saturability of 
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TRIM5αsq by VLPs and the accumulated levels of viral DNA in target cells expressing 
this protein. My findings showing that transfer of the RING domain of TRIM5αsq to 
TRIM5αrh eliminates degradation in response to virus exposure have, in concert with the 
TRIM5αrhΔRING mutant, identified a domain that is required for degradation as a result 
of infection and provide a connection between TRIM5α degradation and restriction prior 
to completion of reverse transcription. While these findings do not explain why 
TRIM5αsq behaves so differently from other TRIM5α alleles, they do identify TRIM5αsq, 
and more specifically the RING domain of this allele, 
My studies addressing the role of the UbcH5 family of proteins in post-entry 
restriction by TRIM5α, while interesting, provide somewhat less conclusive answers than 
my other findings. It is important to note that, while the studies of UbcH5 are placed last 
in the sequential order of this dissertation, they were in fact my first endeavor towards 
investigating of the workings of TRIM5α. In light of my later findings (which are 
described in the earlier chapters), it would seem that I unintentionally placed the cart 
before the horse in the order of my investigations. Frequently in scientific research there 
is the accepted realization that hindsight is 20/20 and I am no less subject to this truth 
than any other. Clearly, had I known then what I know now, my studies of UbcH5 would 
have taken a different tack. While I did attempt to make connections between UbcH5 and 
my later findings, these attempts were unsuccessful. I therefore think that there is still 
potential for the future study of UbcH5 in post-entry restriction by TRIM5α and that this 
as a potential tool for the study of 
how TRIM5α degradation results in aborted infection. Future studies should investigate 
this aspect of TRIM5α biology and further define the role of the TRIM5α RING domain 
in post-entry restriction. 
 115 
 
would be a suitable endeavor for future investigations. If further investigation were 
possible I would attempt to more in-depth experiments investigating knockdown of 
UbcH5 in target cells and the effect of this on the accumulation of viral DNA in cell 
expressing TRIM5α. In pilot experiments where I measured the levels of late-RT 
products in TRIM5αrh-expressing cells in which I had knocked down UbcH5 the results 
were not interpretable. I consider it a strong possibility that knockdown of UbcH5 or over 
expression of a DN UbcH5 in target cells might result in an alteration in the timing of the 
block to HIV-1 infection imposed by TRIM5αrh
The lack of effect that I observed in terms of degradation in the case of the 
TRIM5α mutants in which the lysine residues were mutated also provides a potential area 
for future work. While the failure of these individual mutants to restore stability in 
response to viral challenge indicates that these lysines are not individually the targets of 
potential polyubiquitination, a more extensive elimination of potential acceptor lysines 
might be more informative. Additionally the changes made to each lysine were to 
. If such a change in timing was observed 
than I can foresee at least two potential explanations: (1) One or more members of the 
UbcH5 family are responsible for transfer of ubiquitin to TRIM5α as a result of TRIM5α 
oligomerization on incoming retroviral cores that ultimately leads to proteasome-induced 
uncoating and degradation of TRIM5α. (2) Members of the UbcH5 family are responsible 
for the specific monoubiquitination of TRIM5α in cells that targets the protein to the 
appropriate position in the cytoplasm in order to interact with incoming cores and loss of 
this enzymatic pathway impairs the ability of TRIM5α to interact with incoming cores. 
The latter possibility would be consistent with previously published reports on 
monoubiquitination of TRIM5α (Yamauchi et al., 2008).   
 116 
 
arginine, a choice made in order to conserve the charged nature of the amino acids. It is 
possible that the importance of the lysine residues is to provide an important charged 
surface for interactions with a cognate protein rather than to serve as acceptor sites for 
protein modification. Recent studies investigating the deleterious effects of charge 
alterations on the outer surface of the TRIM5α B-Box domain make this possibility seem 
increasingly likely (Diaz-Griffero et al., 2007).  
 
TRIM protein biology 
Our knowledge of how TRIM proteins function inside the cell is limited in light 
of the fact that there are such an extensive number of these types of proteins in the cell. 
As most of the 51 TRIM transcripts can be alternatively spliced, the number of these 
proteins potentially expressed in a cell is predicted to be in the hundreds. Despite this 
prolific expression, our understanding of the role of these proteins is typically limited to 
the diseases that result due to inherited mutations in the coding sequences. Even the 
identification of these mutations and the diseases that they cause has offered little 
understanding of TRIM biology inside the cell. The chromosomal translocation event that 
results in a fusion protein between TRIM19 (PML) and retinoic acid receptor alpha 
(RARα) that results in acute promyelocytic leukemia (APL) has been identified for three 
decades, yet in that time we have only gained limited insight into how PML facilitates the 
steps required for lymphocytic differentiation (Rowley et al., 1977). A number of recent 
studies indicate that a variety of TRIM proteins may be involved in intracellular host 
defenses against viral infection (Turelli et al., 2001; Stremlau et al., 2004; Gack et al., 
2007; Wolf and Goff, 2007; Barr et al., 2008; Eldin et al., 2009). This body of evidence 
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indicates that further study of TRIM biology is likely to have significant impact on our 
understanding of cellular biology, host-pathogen interactions, and innate immunity. My 
work has served to elucidate a cellular pathway by which one of these proteins functions 
to enhance host resistance to retroviral infection, thus furthering our understanding of our 
own cellular biology in addition to advancing or understanding of HIV-1. My studies can 
thus serve as a foundation for future work on the nature of TRIM protein function in cells. 
 
Conclusion 
 My work has provided greater insight in our understanding of a critical host-
pathogen interaction and has contributed to a new mechanistic hypothesis to explain post-
entry restriction of retroviruses by TRIM5α. I have helped shed light on an important 
host-defense mechanism against retroviruses that may have significant implications on 
HIV-1 research, gene therapy protocols, and pharmaceutical development. My work may 
help facilitate the advancement of knowledge in the field of HIV-1 uncoating, providing 
important insight into an aspect of the viral lifecycle that is presently obscure. Lastly, I 
have helped to enhance our understanding of a molecular pathway connecting the binding 
of TRIM5α to an incoming core to the formers proteasomal degradation. This pathway 
was heretofore uncharacterized and as such, my data has contributed to a greater 
understanding of cellular biology. I am pleased with the progress I have made in my 
graduate work at Vanderbilt and look forward to my future efforts to enhance our 
understanding of HIV-1 biology. 
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CHAPTER VI 
 
 
MATERIALS AND METHODS 
 
 
Plasmids 
pLPCX-TRIM5α rh (rhesus macaque), pLPCX-TRIM5αhu (human), pLPCX-TRIM5αsp 
(spider monkey), pLPCX-TRIM5αsq (squirrel monkey), and pLPCX-TRIM5α tam
 R9-G89V was made by PCR mutagenesis of the wild type HIV-1 provirus R9 utilizing 
site-specific primers and verified by sequencing. pHIV-G89V-GFP was made by transfer 
of the BssHII-EcoRI fragment of R9-G89V into the BssHII-EcoRI sites of pHIV-GFP 
and verified by restriction digest. pHCMV-G was provided by J. Burns (Yee et al., 1994). 
pBABE-eGFP was created by transfer of the BamHI-EcoRI fragment from peGFP 
 (tamarin 
monkey) were generous gifts from Dr. J. Sodroski (Stremlau et al., 2004; Song et al., 
2005). pCIG-N and pCIG-B were generous gifts from J. Stoye (Bock et al., 2000). pNL4-
3 was obtained from the NIH AIDS Research and Reference Reagent Program and the 
env gene inactivated as previously described (Aiken, 1997).  pHIV-GFP (He et al., 1997), 
pSIV-GFP (Cowan et al., 2002), and pCL-ampho (Naviaux et al., 1996) were gifts from 
D. Gabuzda, P. Bieniasz, and B. Naviaux, respectively. Ubc3, UbcH5a, UbcH5b, 
UbcH5c, Ubc3(C93A), UbcH5a(C85A), UbcH5b(C85A), UbcH5c(C85A), and E2-
20K(C87A) were all expressed from the His-epitope tagged expression plasmid pCAGGS 
and were all generous gifts from Dr. K. Iwai (Gonen et al., 1999). UbcH9 and the 
corresponding DN form were generous gifts from Dr. Z. Shen (Liu et al., 1999).  
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(Clontech) into the BamHI-EcoRI sites of pBABE-puro (Morgenstern and Land, 1990).  
pBABE-rhTRIM5α and pBABE-huTRIM5α were generated by PCR amplification of the 
rhesus and human TRIM5α sequences from pLPCX-TRIM5αrh and pLPCX-TRIM5αhu  
using primers TRIM5α-1(S)-Eco 5’- 
GATCGAATTCAGCTACTATGGCTTCTGGAATCCTG-3’ and pTM1-TRIMHA-R 5’-
GTCTCGAGTCAAGCGTAGTCTGGGACG-3’ (EcoRI and XhoI sites underlined). The 
PCR products were digested and ligated into the EcoRI and SalI sites in pBABE-puro.  A 
TRIMCyp cDNA was generated from oligo dT-primed owl monkey kidney cell cDNA 
and PCR amplified using the TRIM5α-1(S)-Eco and primer 5’ 
CTAGCTCGAGTACAGAAGGAATGATCTGG-3’ (XhoI site underlined) specific to 
the 3’-UTR of the human cyclophilin A gene. This amplification results in a Arg to Gly 
substitution at codon 4 as compared to the original TRIMCyp cDNA. The product was 
ligated into the EcoRI-XhoI sites of plasmid CMX-PL1. The Myc-His6 tag was added to 
TRIMCyp by PCR amplification of CMX-PL1-TRIMCyp with TRIM5α-1(S)-Eco and 
primer 5’ GTCTCGAGAGAGCTTGGTGAGCACAGAGTCATGG-3’ (XhoI site 
underlined). This product was then digested with EcoRI and XhoI and ligated into 
pcDNA 3.1/myc-His A (Invitrogen). The TRIMCyp containing the myc-(His)6 epitope 
tag was then amplified from TRIMCyp-pcDNA3.1/myc-His A using TRIM5α-1(S)-Eco 
and the primer pcDNA3.1 HIS-Sal 5’-
ACGTCGACTTTCAATGGTGATGGTGATGATGACC-3’, and the product digested 
with EcoRI and SalI and ligated into the corresponding sites in pBABE-puro. pBABE-
TRIM5αsq was made by amplification of pLPCX-TRIM5αsq with the primers TRIM5α-
1(S)-Eco and sqHA extend 1 5’-GTATGGGTAGCCAGAGCTTGGTGAGACCAG-3’. 
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This product was then amplified with TRIM5α-1(S)-Eco and the primer sqHAextend 2 
5’-CAAGCGTAGTCTGGGACGTCGTATGGGTAGCCGCCAG-3’. This product was 
the amplified with TRIM5α-1(S)-Eco and pTM1-TRIMHA-R and digested and ligated 
into the EcoRI and SalI sites in pBABE-puro. SRRRCyp was made by amplification of 
pLPCX-TRIM5αsq with the primers Sq RING B 5’-CACAAAGGGCAGCTTCTC-3’ and 
the TRIM5α-1(S)-Eco and amplification of pBABE-rhTRIM5α with the primers Rh 
LBCS 5’-GAGAAGCTGCCCTTTGTG-3’ and pTM1-TRIMHA-R. These products of 
these reactions were then joined by sewing reaction using primers TRIM5α-1(S)-Eco and 
pTM1-TRIMHA-R to form SqRING-RhLBCS (SRRRRHA). This PCR product was 
digested and ligated into the EcoRI and SalI sites in pBABE-puro. This plasmid was then 
amplified with TRIM5α-1(S)-Eco and the primer SqCyp R 5’-
CCAGTAGCGTTGGACTTCTGTC-3’. The CypA domain of pBABE-TRIMCyp was 
amplified using primers pcDNA3.1 HIS-Sal and SqCyp F 5’-
GAAGAAGTCCAACGCTACTGG-3’. The products of these two reactions were joined 
by sewing reaction using primers TRIM5α-1(S)-Eco and pcDNA3.1 HIS-Sal and the 
resulting product was ligated into the EcoRI and SalI sites in pBABE-puro. RSSSCyp 
was made by amplification of pBABE-rhTRIM5α  with the primers Rh RING B 5’-
CACACAGGGCAGCTTCTC-3’ and the TRIM5α-1(S)-Eco and amplification of 
pBABE-TRIM5αsq with the primers Sq LBCS 5’-GAGAAGCTGCCCTGTGTG -3’ and 
pTM1-TRIMHA-R. These products of these reactions were then joined by sewing 
reaction using primers TRIM5α-1(S)-Eco and pTM1-TRIMHA-R to form RhRING-
SqLBCS (RSSSSHA). This PCR product was digested and ligated into the EcoRI and 
SalI sites in pBABE-puro. This plasmid was then amplified with TRIM5α-1(S)-Eco and 
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the primer SqCyp R 5’-CCAGTAGCGTTGGACTTCTGTC-3’. The CypA domain of 
pBABE-TRIMCyp was amplified using primers pcDNA3.1 HIS-Sal and SqCyp F 5’-
GAAGAAGTCCAACGCTACTGG-3’. The products of these two reactions were joined 
by sewing reaction using primers TRIM5α-1(S)-Eco and pcDNA3.1 HIS-Sal and the 
resulting product was ligated into the EcoRI and SalI sites in pBABE-puro. All constructs 
were verified via bidirectional DNA sequencing.  
  
Chemicals 
 MG132 and cycloheximide were purchased from Sigma-Aldrich and used at final 
concentrations of 25 μM and 50 μM, respectively.  Cyclosporin A was purchased from 
CalBiochem used at 2.5 μM final concentration.  Epoxomicin was purchased from 
Boston Biochem and used at 10 μM. The cathepsin inhibitor E64 was purchased from 
Sigma-Aldrich and was used at 40 μM. 
 
siRNAs 
siRNAs targeting UbcH5a, b, and c were ordered as part of the SMARTpools from 
Dharmacon. The negative siRNA was the Dharmacon siCONTROL Non-targeting 
siRNA#1. siRNAs targeting TRIM5αrh 
FRhK-4 cells were purchased from the American Type Culture Collection.  Cells were 
cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 
have been previously described (Stremlau et al., 
2004). 
 
Cells and Viruses 
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1% penicillin/streptomycin. VSV-G-pseudotyped HIV-1NL4.3, HIV-GFP, and SIV-GFP 
viruses were produced by calcium phosphate transfection of 293T cells with proviral 
plasmid DNA (23 μg) and pHCMV-G (7 μg).  N- and B-tropic MLV virus stocks were 
prepared by co-transfection of 23 μg pCIG-N or pCIG-B plasmids with pHCMV-G (7 μg) 
onto the cell line 293TeGFP.  This cell line is a clone generated from 293T cells 
previously transduced with the retroviral vector pBABE-eGFP and isolated by limiting 
dilution and selected for high levels of GFP expression. Transfected cells were washed 
after 24 hours and replenished with fresh media.  Supernatants were harvested 48-72 
hours after transfection, clarified by passing through 0.45 μm filters, and stored in 
aliquots at -800C. Retrovirus stocks for transduction of TRIM5α alleles were harvested 
from 293T cells transfected with the plasmids pCL-ampho (10 μg), the appropriate 
TRIM5α vector (15 μg), and pHCMV-G (5 μg). Viruses were collected 48 hours after 
transfection and used to transduce 293T cells. All 293T cell lines expressing TRIM5α 
proteins were polyclonal cell populations obtained by selection of transduced cells with 
puromycin. TRIMCyp-expressing cells were obtained by isolation of a single cell clone 
via limiting dilution. HIV-1 was strongly restricted in these cells, and restriction was 
prevented by the addition of 5 μg/ml cyclosporin A (CsA). Cf2 cells expressing 
TRIM5α rh and TRIM5αsq
293T or Cf2 cells were seeded in 6-well plates at a density of 1 to 1.25 x 10
ΔRING were provided by Dr. J. Sodroski.  
 
Infection Protocol 
6 cells/well 
and incubated overnight. Prior to infection, cultures were treated for 1 hour in 50 μM 
cycloheximide to block protein synthesis. In experiments involving proteasome inhibitors, 
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cells were incubated with both cycloheximide and the appropriate inhibitor for 1 hour 
prior to infection. Viral stocks containing cycloheximide, polybrene (5 μg/mL), CsA (2.5 
μM), and proteasome inhibitors were prewarmed to 370C prior to addition to cells. After 
culturing for 1 hr, media from zero hour timepoints was removed and 1 ml of PBS was 
added. Cells were then detached from the plate by flushing, pelleted, washed in PBS, 
repelleted, and the pellets frozen at -800C. In experiments utilizing Cf2 cells the cells 
were placed in fresh D10 media at a 1:1 volume, pelleted then washed in PBS. Cells that 
were challenged with virus had media removed and replaced with viral stock and were 
returned to 370C.  Individual cultures were harvested hourly using same procedure as 
previously described for the zero hour timepoints. All cell pellets were frozen at -800C 
prior to analysis. For experiments utilizing FRhK-4 the cells were seeded in 6 well plates 
at a density of 3 x 105 cells/well and incubated overnight. Prewarmed viral stocks 
containing polybrene (5μg/mL) were added the following day with a well harvested at the 
time of viral addition serving as the zero hour timepoint. Cells were incubated with the 
viral stock for the indicated time period then trypsinized, placed in fresh D10 media at a 
1:1 volume, pelleted, washed in 1mL complete D10 media to inactivate trypsin, 
repelleted, washed 2 times in 1 mL PBS, then frozen at -800
 For experiments studying viral DNA accumulation, 293T cells were plated at 2 x 
10
C. In experiments with 
FRhK-4 cells involving MG132, the cells were incubated with inhibitor for one hour 
prior to viral addition with the zero hour timepoint being an uninfected well harvested 
after 1 hour pretreatment. 
5 cells per well in 12 well plates. Following overnight culture, cells were pretreated for 
1 hour with MG132 or RT inhibitor then infected with HIV-GFP in the presence of the 
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relevant drug. Cells were cultured for 5 hours in the presence of virus and drug after 
which virus and drug were removed and cells were harvested or had fresh D10 media 
added and cultured for an additional 5 or 10 hours. Cells infected in the presence of AZT 
had the drug present for the entire 15 hours. Cells were harvested by flushing, pelleted, 
washed 2X in PBS, then frozen at -800C. DNA was harvested from cells as previously 
described (Dismuke and Aiken, 2006). Briefly, cell pellets were resuspended in 200 μL 
of PBS and DNA isolated using DNeasy kit (Qiagen) following the manufacturer’s 
instructions.  Viral DNA was quantified by real-time PCR using a MX-3000p 
thermocycler (Stratagene) utilizing TaqMan chemistry (ABI).  Viral DNA products (U5-
Gag) were detected using the forward primer MH531 5'- 
TGTGTGCCCGTCTGTTGTGT-3', reverse primer MH532 5'- 
GAGTCCTGCGTCGAGAGAGC-3', with the probe LRT-P 5'-(FAM)-
CAGTGGCGCCCGAACAGGGA-(TAMRA)-3' as previously described (Butler et al., 
2001).  Thermal cycling conditions were 2 minutes at 50°C, 10 minutes at 95°C, and 40 
cycles of 95°C for 15 seconds and 60°C for 60 seconds. 
 
siRNA Knockdown of TRIM5αrh 
 FRhK-4 cells were seeded at a density of 2 x 10
for FRhK degradation studies 
5 cells per well in 6-well plates 
and incubated overnight. 24 hours later, TRIM5αrh-specific siRNA, or the non-targeting 
control siRNA were diluted to a concentration of 3 μM in 1X siRNA buffer then 
transfected into cells using Dharmafect 1 transfection reagent and OptiMEM I (Gibco) 
according to manufacturers protocol (Dharmacon). Cells were then incubated overnight 
and retransfected with siRNAs again the following day utilizing the identical protocol. 48 
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hours after the first siRNA transfection the cells were removed from the 6-well plates and 
plated onto a 10 cm dish in complete D10 media at a ratio of 1 well to 1 10cm dish and 
incubated for either 24 or 48 hours. 24 hours later, one 10 cm dish of either TRIM5αrh-
specific siRNA treated cells or non-targeting control treated cells were trypsinized and 
replated in 24 well plates at a density of 2 x 105 cells/well then incubated overnight. The 
following day the remaining two 10 cm dishes of siRNA treated cells were trypsinized, 
diluted 1:1 in D10 media, pelleted, washed 1X in D10 media to inactivate trypsin, 
repelleted, washed 2X in 1mL PBS per wash, repelleted, then frozen at -800C. Cells that 
had been seeded the prior day in the 24 well plates were then infected with dilutions of 
HIV and SIV-GFP, incubated for 48 hours, then analyzed for GFP expression by flow 
cytometry. 
 
Transfection of E2 Plasmids 
293T cells were seeded at 1.75 x 105
293T, HeLa, and FRhK cells were seeded at 8 x 10
 cells per well in 6-well plates and incubated 
overnight. 24 hours later each well was transfected with 2μg of E2 plasmid plus 200ng of 
HcRedN1 per well using OptiMEM I and Transit 293T (Mirus) according to 
manufacturers instructions. The cells were cultured for 24 hours, infected with HIV and 
SIV-GFP, cultured for another 48 hours, then fixed and analyzed for HcRed and GFP 
expression by flow cytometry. 
 
Knockdown of UbcH5 
4 cells per well in 24 well plates. 24 
hours later, UbcH5-specific siRNAs, TRIM5αrh-specific siRNA, or the non-targeting 
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control siRNA were diluted to a concentration of 3 μM in 1X siRNA buffer then 
transfected into cells using Dharmafect 1 transfection reagent and OptiMEM I (Gibco) 
according to manufacturers protocol (Dharmacon) and cultured overnight. 24 hours later 
the cells were replated at 2 x 104 cells per well in 24 well plates (titrations) or pooled (2 
wells) and placed 1 well of a 6-well plate and cultured for another 24 hours. The 
following day the cells in the 24 well plates were infected with dilutions of HIV and SIV-
GFP, cultured for another 48 hours, then fixed and analyzed for HcRed (RFP) and GFP 
expression by flow cytometry. The cells in the 6-well plates were harvested 24 hours later 
(at the same time as the cells in the 24 well plates were exposed to virus) by flushing 
(293T) or trypsin (HeLa and FRhK), diluted 1:1 in fresh D10 (HeLa and FRhK), pelleted, 
washed 1X in 1mL of PBS, repelleted, and frozen a -800
Cell pellets were thawed and lysed in a solution containing 100 mM Tris-HCl (pH 8.0), 
100 mM NaCl, and 0.5% NP-40. Nuclei were pelleted via centrifugation at 16,000 xg for 
10 minutes and post-nuclear supernatants were removed. Protein levels were quantified 
via BCA assay (Pierce). Samples, normalized for total protein, were denatured in SDS 
and subjected to electrophoresis on 4-20% acrylamide gradient gels (BioRad). Proteins 
were transferred to nitrocellulose and probed with HA-epitope tag-specific rat 
monoclonal antibody (3F10, Roche) and Alexa Fluor 680 conjugated goat anti-rat IgG 
(Molecular Probes). Cells expressing TRIMCyp were probed with the myc epitope-
specific mouse monoclonal antibody (9E10, Invitrogen) and Alexa Fluor 680-conjugated 
goat anti-mouse IgG (Molecular Probes). Proteins extracted from FRhK-4 cells were 
C for protein analysis. 
 
Protein Analyses 
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probed the TRIM5α-specific mouse polyclonal antibody (IMG-5354, Imgenex) and 
Alexa Fluor 680 conjugated goat anti-mouse IgG (Molecular Probes). Cells in which 
UbcH5 were knocked down were probed with the rabbit α-UbcH5 polyclonal antibody 
(A-615, Boston Biochem) and Alexa Fluor 680-conjugated goat anti-rabbit IgG 
(Molecular Probes). All immunoblots were probed with α-actin-specific rabbit 
monoclonal antibody (A2228, Sigma) and IRDye800-conjugated goat anti-rabbit IgG 
(Rockland). Dilutions of antibodies were 1:1000 and 1:5000 for primary and secondary 
respectively with the exception of IMG-5354 which was used at a dilution of 1:2000. 
Bands were detected by scanning blots with the LI-COR Odyssey Imaging System using 
both 700 and 800 channels, and integrated intensities were determined using the LI-COR 
Odyssey band quantitation software with the median top-bottom background subtraction 
method.  The TRIM5α band intensities were then normalized to the signals from the 
corresponding β-actin bands. All signals were then expressed as a percentage of the initial 
TRIM5α/actin band intensity ratio. 
 
Genes used in this study 
TRIM5α rh (AY523632); TRIM5αhu (AF220025); TRIMCyp (AY646198); TRIM5αtam 
(AY740615); TRIM5αsp (AY740616); TRIM5αsq 
 
(AY740614). 
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Abstract
The host protein TRIM5a inhibits retroviral infection at an early post-penetration stage by targeting the incoming viral
capsid. While the detailed mechanism of restriction remains unclear, recent studies have implicated the activity of cellular
proteasomes in the restriction of retroviral reverse transcription imposed by TRIM5a. Here, we show that TRIM5a is rapidly
degraded upon encounter of a restriction-susceptible retroviral core. Inoculation of TRIM5a-expressing human 293T cells
with a saturating level of HIV-1 particles resulted in accelerated degradation of the HIV-1-restrictive rhesus macaque TRIM5a
protein but not the nonrestrictive human TRIM5a protein. Exposure of cells to HIV-1 also destabilized the owl monkey
restriction factor TRIMCyp; this was prevented by addition of the inhibitor cyclosporin A and was not observed with an HIV-
1 virus containing a mutation in the capsid protein that relieves restriction by TRIMCyp IVHIV. Likewise, human TRIM5a was
rapidly degraded upon encounter of the restriction-sensitive N-tropic murine leukemia virus (N-MLV) but not the
unrestricted B-MLV. Pretreatment of cells with proteasome inhibitors prevented the HIV-1-induced loss of both rhesus
macaque TRIM5a and TRIMCyp proteins. We also detected degradation of endogenous TRIM5a in rhesus macaque cells
following HIV-1 infection. We conclude that engagement of a restriction-sensitive retrovirus core results in TRIM5a
degradation by a proteasome-dependent mechanism.
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Introduction
Retroviruses exhibit a restricted host range due to the
requirement for specific interactions between viral and host
proteins to complete the viral life cycle. Also limiting retroviral
tropism are several recently identified intracellular antiviral factors
([1–5]); reviewed in [6–10]). The prototypical restriction activity,
Fv1, was first detected in the 1970s as differential susceptibility of
inbred mice strains to the Friend leukemia virus [11–13]. Fv1
blocks infection of murine leukemia viruses (MLV) at a stage
following fusion but prior to integration [14,15]. The block to
infection can be overcome at high multiplicities of infection (m.o.i.)
or by pretreatment of target cells with non-infectious virus like
particles (VLPs) [11,16]. Susceptibility to Fv1 restriction is
determined by the sequence of the viral capsid protein (CA)
[17–19]. The gene encoding Fv1 was identified in 1996 by
positional cloning [1]; yet the molecular mechanism by which Fv1
inhibits MLV infection remains poorly defined.
Recent investigations have identified additional restriction
activities present in human and simian cells that govern the
tropism of lentiviruses, including human and simian immunode-
ficiency viruses (HIV and SIV) [20–25]. Like Fv1, these
restrictions target the incoming viral capsid [23,25–27]. One
factor, TRIM5a, is responsible for post-entry restriction of HIV-1
in many simian cell lines [3,28–31]. Expression of the rhesus
macaque TRIM5a protein (TRIM5arh) in human cells renders
them highly restrictive to infection by HIV-1 [3]. Unlike Fv1,
TRIM5a acts at a stage prior to completion of reverse
transcription [3,20,23,24]. The human genome encodes a
TRIM5a protein (TRIM5ahu) that restricts multiple retroviruses
including N-tropic MLV (N-MLV), feline immunodeficiency virus
(FIV), and equine infectious anemia virus (EIAV) but does not
efficiently restrict HIV-1 [29,30,32–37]. TRIM5a cDNAs have
now been cloned from multiple primate species; these differentially
restrict infection by HIV-1, HIV-2, and SIV [28,31].
Shortly after the identification of TRIM5a, a second HIV-1
restriction factor was identified in owl monkeys [4,5]. This protein,
TRIMCyp, is the apparent result of a LINE1-mediated retro-
transposition event in which the cyclophilin A (CypA) mRNA was
inserted into the TRIM5 locus resulting in a functional fusion
protein [4]. TRIMCyp potently inhibits HIV-1 infection by
interacting with an exposed loop on the surface of the CA via the
CypA domain. The discovery of TRIMCyp provided a simple
explanation for the ability of cyclosporin A (CsA), which inhibits
CypA binding to CA, to render owl monkey cells permissive to
HIV-1 infection [38]. Mutations in the CypA binding loop that
result in a failure to bind CypA also result in a loss of restriction by
TRIMCyp [4,5]. More recently, novel TRIM5-CypA proteins
have also been identified in other primate species [39–42].
TRIM5a and TRIMCyp are members of the tripartite motif
family of proteins, which encode RING, B-Box, and coiled-coil
(RBCC) domains [43]. TRIM5a is the longest of the three
isoforms (a, c, and d) generated from the TRIM5 locus by
alternative splicing of the primary transcript. While all three
TRIM5 isoforms contain identical RBCC domains, the a-
transcript also encodes the B30.2/SPRY domain required for
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recognition of the incoming viral capsid and restriction specificity
[29,30,33,34,36,44–46]. The coiled-coil domain promotes the
multimerization of TRIM5a molecules that is required for efficient
restriction [44,47,48]. While the precise function of the B-Box
domain is unclear, deletion of this region results in total loss of
restriction potential thus indicating its importance [44,49]. The
RING domain of TRIM5a is also required for full restriction
activity, as mutants that lack this domain or in which proper folding
is impaired are severely impaired for restriction and have altered
cellular localization [3,44,49]. Substitution of RING domains from
other human TRIM proteins results in changes in both the timing of
restriction (i.e. pre- vs. post-reverse transcription) and the intracel-
lular localization of the restriction factor [37,50–52].
RING domains are commonly associated with ubiquitin ligase
(E3) activity facilitating specific transfer of ubiquitin from various
ubiquitin-conjugating (E2) proteins to substrates (reviewed in
[53,54]). Polyubiquitylation of proteins commonly targets them for
intracellular degradation by proteasomes. TRIM5a can be
ubiquitylated in cells [55], but a role for this modification in
TRIM5a stability or restriction has not been established. The d
isoform of TRIM5, which encodes an identical RING domain to
TRIM5a, exhibits E3 activity in vitro and mutation of the RING
domain abolishes this activity [56]. The presence of a RING
domain on TRIM5a suggested that the restriction factor might
function by transferring ubiquitin to a core-associated viral
protein, thus targeting it for proteasomal degradation. However,
such a modification has not been detected, and the magnitude of
restriction imposed by TRIM5a was not altered in cells in which
the ubiquitination pathway was disrupted [57]. Nonetheless,
recent studies have shown that proteasome inhibitors relieve the
TRIM5a-dependent inhibition of reverse transcription, yet a block
to HIV-1 nuclear entry remains [58,59].
Based on these findings implicating the proteasome in
TRIM5a-dependent retroviral restriction, we hypothesized that
restriction by TRIM5a leads to proteasomal degradation of a
TRIM5a-viral protein complex. Here we show that inoculation of
TRIM5a-expressing cells with a restricted retrovirus results in
accelerated degradation of TRIM5a itself. Destabilization of
TRIM5a was tightly correlated with the ability of the restriction
factor to block infection by the incoming virus. Proteasome
inhibitors prevented HIV-1-induced degradation of TRIM5arh
when added to cells prior to virus inoculation. These data suggest a
functional link between proteasomal degradation of TRIM5a and
the ability of TRIM5a to restrict an incoming retrovirus.
Results
Exposure of Cells to HIV-1 Destabilizes TRIM5a
We hypothesized that TRIM5a itself might be degraded as a
consequence of the post-entry restriction process. To test this,
TRIM5arh-expressing 293T cells were cultured in the presence of
cycloheximide to arrest protein synthesis and then challenged with
VSV-G-pseudotyped HIV-1 particles. At various times post-
infection, cells were harvested for analysis of TRIM5a levels by
quantitative immunoblotting. In control cells not exposed to virus,
the TRIM5a level declined at a slow rate, eventually leveling off to
55% of the original level after 4 hours (Figure 1A). By contrast,
inoculation with HIV-1 induced a more rapid decrease in the
TRIM5a level resulting in 85% loss after 4 hours. Analysis of data
from 4 experiments indicated that the decay of TRIM5a was
significantly faster in the HIV-1-inoculated cultures relative to the
control (Figure 1B). The stability of TRIM5a in our cells differs in
terms of time as compared to previously published reports using
Hela cells [55]. In additional studies we observed a similar
destabilizing effect of HIV-1 exposure on TRIM5arh in HeLa cells
(data not shown).
Exposure of target cells to saturating levels of virus or VLPs can
overcome restriction by TRIM5a. To determine whether the
decay of TRIM5arh was related to saturation of restriction, we
inoculated TRIM5arh–expressing cells with various doses of a
GFP-encoding virus in the presence of cycloheximide for a fixed
period of time and harvested the cells to quantify TRIM5a levels.
To probe the relationship between saturation of restriction and
TRIM5a degradation, a portion of the harvested cells were
replated and cultured for 48 hours, and the extent of infection
determined by flow cytometric analysis of GFP expression. The
results showed that the ability to detect degradation of TRIM5arh
was strongly dependent on the dose of virus used (Figure 1C).
Furthermore, the TRIM5a level following inoculation was
inversely related to the overall extent of infection (Figure 1D).
These results indicate that HIV-1-induced degradation of
TRIM5a is correlated with saturation of restriction, likely due to
a requirement to engage most of the restriction factor to detect the
loss of the protein.
Human TRIM5a Stability is Not Affected by HIV-1
Human TRIM5a does not efficiently restrict HIV-1 infection.
To further probe the link between restriction and TRIM5a
destabilization, we analyzed the stability of the human TRIM5a
protein following challenge of cells with HIV-1. As previously
shown in Figure 1, HIV-1 challenge of TRIM5arh-expressing
293T cells resulted in a more rapid loss of the protein vs. mock-
infected cells (Figure 2A and B). TRIM5ahu was intrinsically less
stable than TRIM5arh, as indicated by its more rapid decay in the
mock-infected cultures (Figure 2B and C). However, inoculation
with HIV-1 did not result in further destabilization of TRIM5ahu,
indicating that the HIV-1-induced degradation of TRIM5arh is
not a nonspecific cellular response to the viral challenge. These
results suggest that the loss of TRIM5arh depends on its ability to
recognize the HIV-1 core.
Author Summary
Recent studies have identified several cellular proteins that
restrict infection by a variety of retroviruses. One of these
restriction factors, TRIM5a, is partially responsible for the
differences in susceptibility of monkeys and humans to SIV
and HIV-1, respectively. TRIM5a inhibits retrovirus infection
soon after penetration into the target cell by associating
with the viral protein CA, which forms the polymeric
capsid shell of the viral core. Although the detailed
mechanism of restriction is unknown, TRIM5a is postulated
to alter the stability of the viral core, resulting in a failure to
complete reverse transcription. The activity of cellular
proteasomes, which are responsible for intracellular
protein degradation, has also been implicated in TRIM5a-
dependent attenuation of retroviral reverse transcription.
In this study, we show that cellular TRIM5a is rapidly
degraded in cells exposed to a restriction-sensitive
retrovirus but not in cells infected with an unrestricted
virus. Virus-induced degradation of TRIM5a was depen-
dent on cellular proteasome activity, as inhibition with
drugs blocking proteasome function also inhibited degra-
dation of TRIM5a. These results provide additional support
for a role of proteasomal degradation in TRIM5a-depen-
dent retrovirus restriction and suggest a novel mechanism
by which binding of TRIM5a to the viral capsid prevents
infection.
TRIM5a Is Degraded upon Restriction of HIV-1
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Exposure to Restriction-Sensitive HIV-1 Destabilizes
TRIMCyp
The owl monkey restriction factor TRIMCyp restricts HIV-1
by binding to an exposed loop on the surface of CA. Restriction
can be prevented by addition of CsA or amino acid substitutions in
CA that reduce CypA binding. We therefore asked whether
TRIMCyp would also be destabilized following encounter of HIV-
1. 293T cells expressing TRIMCyp were treated with cyclohex-
imide and then challenged with VSV-G pseudotyped HIV-1
particles. As a control, parallel cultures were inoculated in the
presence of a CsA concentration known to abolish TRIMCyp
restriction of HIV-1. In the control mock-inoculated cells,
TRIMCyp was stable in the cells during the six-hour time course
(Figure 3A). Challenge with HIV-1 resulted in accelerated loss of
TRIMCyp. In the cultures containing CsA, the HIV-1-induced
loss of TRIMCyp was markedly reduced (Figure 3B).
Figure 1. Destabilization of TRIM5a upon challenge of cells
with HIV-1. (A) Immunoblot analysis of TRIM5a in cells challenged
with HIV-1. 293T cells expressing HA-tagged TRIM5arh were pretreated
for 1 hour with cycloheximide at 37uC. Cells were then challenged with
stock solutions of HIV-1(VSV) or media alone (Mock). (B) Quantitation of
TRIM5a levels utilizing Odyssey Band imaging software. The TRIM5a
levels are expressed as a percentage of the ratio of TRIM5a:actin signal
to the zero hour sample TRIM5a:actin signal. Shown are the mean
values and standard deviations obtained in four independent
experiments. h.p.i. =Hours post infection. (C) Immunoblot analysis of
TRIM5a in cells challenged with HIV-1. 293T cells expressing HA-tagged
TRIM5arh were pretreated for 1 hour with cycloheximide at 37uC. Cells
were then challenged with media alone (Mock) or the indicated amount
of pseudotyped HIV-GFP expressed as quantity of p24 (CA) for a period
of three hours. (D) Relationship of TRIM5a level to permissivity of target
cells. A portion of the cultures harvested in (C) were recultured for
48 hours and subsequently analyzed for GFP expression by flow
cytometry. Shown are the mean values for the two replicates for both
TRIM5a levels and extent of infection.
doi:10.1371/journal.ppat.1000074.g001
Figure 2. Rhesus macaque, but not human TRIM5a, is less
stable in cells challenged with HIV-1. (A) 293T cells expressing HA-
tagged TRIM5arh or TRIM5ahu were pretreated for 1 hour with
cycloheximide then exposed to VSV-G pseudotyped HIV-1 or media
alone as in Figure 1. TRIM5a was detected by immunoblotting with HA-
specific antibody. Integrated intensity values for the individual bands
are shown in Figure S1. (B and C) Quantitation of TRIM5arh (B) and
TRIM5ahu levels utilizing Odyssey imaging software. Data shown are
from one representative of three independent experiments.
doi:10.1371/journal.ppat.1000074.g002
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Next we asked whether the HIV-1-induced degradation of
TRIMCyp is correlated with the specificity of restriction. HIV-1
containing the G89V mutation in the CypA binding loop of CA is
incapable of binding CypA and is also not restricted by
TRIMCyp. However, this viral mutant is susceptible to TRIM5arh
restriction. Parallel cultures of 293T cells expressing either
TRIMCyp or TRIM5arh were treated with cycloheximide and
then challenged with equivalent quantities of VSV-G pseudotyped
HIV-GFP particles or the G89V CA mutant virus. As seen in
Figure 3C, exposure to wild type HIV-1 induced accelerated loss
of both TRIMCyp and TRIM5arh. By contrast, exposure to the
G89V mutant particles resulted in loss of TRIM5arh but not
TRIMCyp. These results indicate that exposure of cells to HIV-1
results in destabilization of TRIMCyp by a mechanism requiring
recognition of the incoming HIV-1 core by the restriction factor.
Human TRIM5a is Destabilized Upon Encounter of N-
tropic MLV
TRIM5ahu cannot restrict HIV-1 or B-tropic MLV but potently
restricts N-MLV. To further test the link between TRIM5a
destabilization and retrovirus restriction, we challenged 293T cells
stably expressing TRIM5ahu with N- and B-tropic MLV viruses
and measured TRIM5a levels following infection. The GFP-
transducing N- and B-tropic MLV stocks were first titrated on
nonrestrictive CrFK cells (Figure S2, detailed in Text S1) then
normalized to ensure equivalent dosing. Mock-treated cells lost
TRIM5ahu at a slow rate (t1/2,2.5 h; Figure 4A). Challenge with
B-MLV did not significantly affect the rate of TRIM5ahu decay
(Figure 4A). By contrast, cells challenged with an equivalent
quantity of N-MLV showed accelerated loss of TRIM5ahu (t1/2
,1 h) (Figure 4A and 4B). The relative band intensities of the
TRIM5a levels for this experiment were calculated and are
represented in the graph in Figure 4B. These results, together with
the TRIM5a and TRIMCyp data, establish a strong correlation
between virus-induced TRIM5a destabilization and the specificity
of restriction.
Figure 3. TRIMCyp is destabilized in cells challenged with HIV-
1. (A) 293T cells expressing the myc-His6 tagged TRIMCyp were
pretreated for 1 hour with cycloheximide. Cells were then challenged
with HIV-1(VSV) and either ethanol carrier (HIV-1) or CsA (HIV-1+CsA), or
with media alone (Mock). All stocks contained cycloheximide. (B)
Quantitation of TRIMCyp levels as described in the legend to Figure 1B.
Data in this figure are from one of two independent experiments. (C)
293T cells expressing either myc-His6 tagged TRIMCyp or HA-tagged
TRIM5arh were pretreated for 1 hour with cycloheximide. Cells were
then challenged for 5 hours with stock solutions of VSV-G pseudotyped
HIV-GFP (WT), VSV-G pseudotyped HIV-GFP with the G89V capsid
mutation (G89V), or medium alone (M). (D) Quantitation of TRIMCyp
and TRIM5a levels as described in legend to Figure 1B. Data in (D) are
expressed as the mean values of four determinations from two
experiments, with error bars representing one standard deviation.
doi:10.1371/journal.ppat.1000074.g003
Figure 4. Human TRIM5a is destabilized upon challenge of cells
with N-tropic but not B-tropic MLV. (A) 293T cells expressing HA-
tagged TRIM5ahu were pretreated for 1 hr with cycloheximide and
exposed to stocks of VSV-G-pseudotyped N- or B-tropic MLV or media
alone (Mock). Integrated intensity values for the individual bands are
shown in Figure S3. (B) Quantitation of TRIM5a levels utilizing Odyssey
Band imaging software. Data shown are from one representative of
three independent experiments.
doi:10.1371/journal.ppat.1000074.g004
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Virus-induced TRIM5a Destabilization is Correlated with
Lentiviral Restriction in Old and New World Monkeys
TRIM5a proteins from different primates differ in their ability to
restrict specific lentiviruses. For example, tamarin monkey TRIM5a
(TRIM5atam) restricts SIVmac but not HIV-1, while spider monkey
TRIM5a (TRIM5asp) restricts both viruses. To further test the
correlation between virus-induced loss of TRIM5a and antiviral
specificity, we stably expressed the TRIM5atam and TRIM5asp
proteins in 293T cells and challenged them with equivalent titers of
VSV-pseudotyped HIV-1 and SIVmac239 GFP reporter viruses (as
determined by titration on permissive CrFK cells). The cell lines
were found to restrict the respective viruses by at least ten-fold (data
not shown). Immunoblot analysis of post-nuclear lysates revealed
that TRIM5arh was specifically destabilized when challenged with
HIV-1 but not upon SIVmac challenge (Figure 5A). By contrast, the
SIV-restrictive TRIM5atam was destabilized only in response to
SIVmac challenge (Figure 5A). TRIM5asp, which restricts both
viruses, was degraded in response to challenge with either virus
(Figure 5A and B). These results further strengthen the correlation
between the specificity of retrovirus restriction and virus-induced
destabilization of TRIM5a.
HIV-1-Induced Destabilization of TRIM5a Requires
Proteasome Activity
Amajor mechanism for cellular protein degradation is via the 26S
proteasome. Previous studies have shown that the turnover of
TRIM5a is dependent on cellular proteasome activity. Furthermore,
inhibition of proteasome activity overcomes the early block to
reverse transcription imposed by TRIM5a. We asked whether HIV-
1-induced destabilization of TRIM5arh is dependent on proteasome
activity. As previously reported [55], treatment of cells with the
proteasome inhibitor MG132 resulted in an accumulation of
TRIM5a protein (Figure 1, 0 H.p.i.). MG132 also prevented the
HIV-1-induced destabilization of TRIM5arh (Figure 6A and B).
Additional studies revealed that epoxomicin, a more specific
proteasome inhibitor, also blocked the HIV-1-induced degradation
of TRIM5arh (data not shown). By contrast, infection by HIV-1 in
the presence of the S-cathepsin inhibitor E64 did not prevent HIV-1-
induced TRIM5arh degradation (data not shown), suggesting that
endosomal proteases are not responsible for TRIM5arh destabiliza-
tion. We conclude that the virus-induced degradation of TRIM5a is
dependent on cellular proteasome activity.
To determine whether HIV-1-induced destabilization of
TRIMCyp depends on proteasome activity, we challenged
TRIMCyp-expressing 293T cells with either restricted HIV-GFP
or unrestricted HIV.G89V-GFP in the presence or absence of
MG132. As shown in Figure 6C, MG132 prevented the HIV-1-
induced loss of TRIMCyp. Infection with the unrestricted G89V
virus did not alter TRIMCyp stability, while addition of MG132
stabilized the restriction factor.
HIV-1-Induced Destabilization of Endogenous TRIM5a in
Primate Cells
All of the previous experiments studying TRIM5a stability were
conducted in transduced 293T cell lines in which TRIM5a was
detected by virtue of a hemagglutinin epitope tag. In this setting, it
Figure 5. Destabilization of primate TRIM5a proteins is correlated with restriction of HIV-1 and SIVmac239. (A) 293T cells expressing
HA-tagged TRIM5arh, TRIM5atam (tamarin monkey), TRIM5asp (spider monkey), and were pretreated for 1 hour with cycloheximide then exposed to
stocks of VSV-G pseudotyped HIV-GFP, SIV-GFP, or media alone (Mock). (B). Quantitation of relative TRIM5a levels. Data shown are from one
representative of three independent experiments.
doi:10.1371/journal.ppat.1000074.g005
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was necessary to treat the cells with cycloheximide to detect virus-
induced degradation of the restriction factor, potentially leading
to artifacts due to general inhibition of protein synthesis. Virus
titration experiments demonstrated markedly greater restriction
in the transduced cells vs. rhesus macaque FRhK-4 cell line,
indicating that the 293T cells overexpress TRIM5arh (our
unpublished observations). Furthermore, while cycloheximide
treatment had only a minor effect on restriction in FRhK-4
cells, the drug markedly reduced restriction in 293T cells (Figure
S4). To probe the physiological relevance of our observations
made in 293T cells, we sought a means of detecting endogenous
TRIM5a protein in rhesus macaque cells. Using a monoclonal
antibody against native TRIM5a for immunoblotting, we
detected a band that was consistent in terms of molecular
weight with TRIM5arh that was also absent in cells lacking
TRIM5arh (data not shown). To confirm that the band is
TRIM5a, we transfected FRhK-4 cells with either a TRIM5arh -
specific siRNA duplex or a non-targeting control siRNA duplex
and quantified the intensity of this band by immunoblotting. As
shown in Figure 7A and B, transfection with TRIM5arh-specific
siRNA resulted in a 72% decrease in intensity of the relevant
band vs. FRhK-4 cells treated with the non-targeting control.
Cells treated with the TRIM5arh-specific also exhibited a tenfold
increase in permissiveness to infection with HIV-1 (data not
shown). HIV-1 infection of FRhK-4 cells was not altered by
treatment with the non-targeting siRNA control. As expected,
treatment with either siRNA duplex did not affect permissiveness
to SIV infection (data not shown). These results indicated that
the monoclonal antibody is capable of detecting endogenous
TRIM5arh in FRhK-4 cells. They further demonstrated that the
transduced 293T cells express a 3.3 fold higher level of TRIM5a
than FRhK-4 cells (Figure 7B).
We next sought to determine if endogenous TRIM5arh was
destabilized by HIV-1 in rhesus macaque cells. FRhK-4 cultures
were inoculated with HIV-1 in the presence or absence of
cycloheximide and the stability of TRIM5arh in response to
infection was analyzed by immunoblotting. Initial experiments
showed no effect of cycloheximide treatment on TRIM5arh
levels in HIV-1-exposed cells (data not shown); therefore the
drug was removed in all subsequent experiments. We observed
that TRIM5arh levels were stable in FRhK-4 cells over the
4 hour period (Figure 7C and D). Infection with HIV-1 resulted
in accelerated decay of endogenous TRIM5arh in rhesus
macaque cells without any requirement of inhibition of protein
synthesis.
We next sought to determine if the loss of TRIM5arh was
specifically due to restriction or was a non-specific effect
resulting from viral infection. In the absence of cycloheximide
we infected FRhK-4 cells with equivalent titers of HIV-1 or
SIVmac239 GFP reporter viruses. As seen in Figure 8A and B,
infection with HIV-1 resulted in a potent loss of TRIM5arh while
infection with SIV resulted in only a slight loss of TRIM5arh as
compared to the control cells. We conclude that infection by HIV-1
results in a rapid loss of TRIM5arh in target cells and that this loss is
directly related to the ability of TRIM5arh to restrict infection by the
incoming virus.
HIV-1-Induced Destabilization of Endogenous TRIM5a
Requires Active Proteasomes
We sought to determine if inhibition of proteasome function
would restore TRIM5arh stability in rhesus macaque cells. FRhK-
4 cells were exposed to HIV-1 in the presence or absence of
MG132 for a period of four hours, and the levels of TRIM5arh
were measured by immunoblotting. As can be seen in Figure 8C
Figure 6. HIV-1-induced destabilization of TRIM5a is blocked
by the proteasome inhibitor MG132. (A and B) 293T cells
expressing HA-tagged TRIM5arh were cultured for 1 hour with
cycloheximide and DMSO (Mock) or MG132 then exposed to HIV-
1(VSV) with DMSO or MG132 (open or filled circles, respectively) or D10
media containing DMSO or MG132 (open or filled diamonds,
respectively). Panel B shows quantitation of TRIM5a levels utilizing
Odyssey imaging software. Data in this figure are from one of two
independent experiments. (C). 293T cells expressing myc-His6-tagged
TRIMCyp were cultured for 1 hour with cycloheximide and DMSO or
MG132. The cells were then exposed for 5 hours to; VSV-G-pseudo-
typed HIV-GFP with either DMSO or MG132, VSV-G-pseudotyped HIV-
GFP with the G89V capsid mutation (G89V) with either DMSO or MG132,
or media alone containing DMSO or MG132 (Mock). (B) Quantitation of
TRIMCyp levels utilizing Odyssey imaging software. Data in this figure
are expressed as the average of the duplicate determinations, with the
error bars depicting the range of values.
doi:10.1371/journal.ppat.1000074.g006
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and D, MG132 stabilized TRIM5arh in HIV-1-exposed cells.
Flow cytometry analysis of GFP signal in a small subset of the
infected cells showed no difference in infection levels resulting
from inhibition of proteasome function, which is consistent with
previously published results. These results indicate that HIV-1-
induced destabilization of TRIM5arh in rhesus macaque cells
requires proteasome activity. They further suggest that the results
we observed with TRIM5a-transduced 293T cells are unlikely to
be an artifact of cycloheximide treatment.
Figure 7. HIV-1 specifically induces destabilization of TRIM5a
in rhesus macaque cells. (A) Duplicate cultures of 293T-TRIM5arh and
FRHK-4 cells were transfected on two consecutive days with siRNAs
specific for TRIM5arh (TRIM5a) or a non-targeting control siRNA (NTC).
72 hours after the second transfection, proteins were extracted and
analyzed by immunoblotting with a TRIM5a–specific monoclonal
antibody. (B) Quantitation of TRIM5arh levels in siRNA-transfected cells
by Odyssey imaging software. TRIM5arh levels following siRNA
knockdown are expressed as the average of the duplicate determina-
tions with the error bars depicting the range of values. (C) FRhK-4 cells
were challenged with HIV-GFP(VSV) or media alone (Mock). Zero hour
timepoint represents TRIM5a levels in uninfected cells. (D) Quantitation
of TRIM5arh levels. Results shown are from one representative of three
independent experiments.
doi:10.1371/journal.ppat.1000074.g007
Figure 8. HIV-1-induced turnover of TRIM5a in primate cells
specific to restriction and is blocked by the proteasome
inhibitor MG132. (A) Duplicate cultures of FRhK-4 cells were exposed
to stocks of VSV-G-pseudotyped HIV-GFP (HIV), SIV-GFP (SIV), or media
alone (Mock) for a period of 4 hours then harvested and TRIM5arh levels
quantified by immunoblotting. The zero hour sample corresponds to
uninfected cells. (B) Quantitation of TRIM5arh levels in (A) utilizing
Odyssey imaging software. (C) Duplicate cultures of FRhK-4 cells were
treated for 1 hour with DMSO or MG132, then exposed for 4 hours to:
VSV-G-pseudotyped HIV-GFP with either DMSO or MG132, or media
alone containing DMSO or MG132 (Mock). (D) Quantitation of TRIM5arh
levels utilizing Odyssey imaging software. Data in this figure are
expressed as the averages of the two determinations, with the error
bars spanning the range of values.
doi:10.1371/journal.ppat.1000074.g008
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Discussion
While it is well established that TRIM5a limits the host range of
many retroviruses, the precise mechanism of restriction remains
undefined. TRIM5a can specifically associate with assemblies of
HIV-1 CA-NC protein in vitro, and genetic evidence indicates that
TRIM5a and TRIMCyp require an intact or semiintact viral
capsid for binding [60,61]. However, the detailed molecular
consequences of the binding interaction to the viral core remain
poorly defined. Two lines of evidence have implicated the
ubiquitin-proteasome system in restriction. First, the d isoform of
TRIM5, which has a RING domain identical to that of TRIM5a,
exhibits E3 activity in vitro [56]. Deletion or mutation of the RING
domain in TRIM5a results in significant loss of restriction efficacy
[44,49]. TRIM5a is ubiquitinated in cells, although a role of this
modification in retrovirus restriction has not been established [55].
Second, inhibition of proteasome activity alters the stage at which
TRIM5a-mediated restriction occurs [58,59]. The latter observa-
tion led us to hypothesize that the proteasome may participate in
restriction by degrading a complex of TRIM5a with one or more
incoming viral proteins. To test this, we asked whether exposure of
cells to HIV-1 alters the stability of TRIM5arh. We observed that
inoculation with HIV-1 results in an accelerated turnover of the
restriction factor. Similar effects were observed in both 293T and
HeLa cells (data not shown), suggesting that TRIM5a destabili-
zation is not specific to a unique cell type. HIV-1 challenge
resulted in destabilization of TRIM5arh but not TRIM5ahu.
Likewise, TRIM5ahu was destabilized by inoculation of cells with
restriction-sensitive N-MLV particles but not by unrestricted B-
MLV. Similar results were seen in cells expressing the HIV-1-
specific restriction factor TRIMCyp. Treatment of target cells with
CsA, which blocks TRIMCyp restriction of HIV-1, or infection
with virus containing mutations that prevent CypA binding
[4,5,38], did not affect TRIMCyp stability. Specific loss of
TRIM5a from cells expressing different primate alleles of the
protein also correlated very well with the ability of those alleles to
restrict HIV or SIV. The HIV-1-induced destabilization of
TRIM5arh and TRIMCyp was prevented by inhibition of cellular
proteasome activity. Destabilization of TRIM5arh by HIV-1 was
also observed in a primate derived cell line without the need of
cycloheximide to inhibit protein synthesis. This destabilization was
specific for the restricted HIV-1 and was not observed in cells
infected with an unrestricted virus. Inhibition of proteasome
function restored TRIM5arh stability in response to infection by
HIV-1 in the rhesus macaque cells. We conclude that TRIM5-
related restriction factors are targeted for degradation by a
proteasome-dependent mechanism following encounter of a
restriction-sensitive retroviral core.
TRIM5a forms heterogenous structures in cells referred to as
cytoplasmic bodies (CBs). While the role of CBs in restriction is
unclear, TRIM5a protein in these structures rapidly exchanges with
soluble TRIM5a, indicating that the protein is highly dynamic
within cells [62]. We observed that most of the cellular TRIM5a can
be degraded in response to exposure to a restriction-sensitive
retrovirus, which implies that a majority of cellular TRIM5a
molecules can engage incoming viral cores. If the CB-associated
TRIM5a is inaccessible to incoming virus, our observation that a
restricted virus can induce degradation of the majority of the
TRIM5amolecules suggests that this protein rapidly redistributes to
a compartment accessible to incoming virus.
TRIM5a and TRIMCyp are subject to proteasome-dependent
turnover under steady-state conditions, yet its rapid turnover is not
a prerequisite for restriction activity [55,63]. Accordingly,
proteasome inhibitors do not overcome restriction ([57]; Figure
S5). Nonetheless, the effect of virus exposure on TRIM5a stability
had heretofore not been reported. While alterations of specific
individual portions of TRIM5a may alter its intrinsic stability, our
results indicate that TRIM5a encounter with a restricted core
results in degradation of the restriction factor by a proteasome-
dependent mechanism.
Retrovirus uncoating is a poorly characterized process, but can be
defined as the disassembly of the viral capsid following penetration of
the viral core into the target cell cytoplasm. Studies of HIV-1 CA
mutants indicate that the stability of the viral capsid is properly
balanced for productive uncoating in target cells: mutants with
unstable capsids are impaired for viral DNA synthesis, suggesting
that premature uncoating is detrimental to reverse transcription
[64]. Thus a plausible mechanism for restriction is that binding of
TRIM5a to the viral capsid inhibits infection directly by physically
triggering premature uncoating in target cells [65,66]. In this model,
TRIM5a, perhaps with one or more cofactors, promotes the
physical decapsidation of the virus core independently of proteolysis.
Consistent with this view are studies demonstrating that TRIM5a
restriction is associated with decreased recovery of sedimentable CA
protein in lysates of acutely-infected cells [65,66]. However, these
studies fell short of demonstrating that the sedimentable CA protein
was associated with intact viral cores. Furthermore, a recent study
reported that treatment of cells with proteasome inhibitors prevented
TRIM5a-dependent loss of particulate CA protein [67], indicating
the potential involvement of proteasome activity in TRIM5a-
induced virus uncoating.
Other studies further implicate the activity of the proteasome in
TRIM5a-dependent restriction. Inhibition of proteasome activity
rescues HIV-1 reverse transcription in TRIM5a-expressing cells,
revealing a downstream block to nuclear import mediated by the
restriction factor [58,59]. Engagement of the viral capsid by
TRIM5a may lead to proteasomal degradation of a TRIM5a-CA
complex, resulting in functional decapsidation of the viral core and
a premature uncoating phenotype. Consistent with this model,
TRIM5a restriction has been associated with decreased intracel-
lular accumulation of HIV-1 CA [68]. In addition, a recent study
of MLV particle-mediated RNA cellular transfer reported reduced
accumulation of viral CA protein in cells in a manner that was
correlated with restriction by TRIM5a, and this effect was
reversed by proteasome inhibition [69]. Unfortunately, our own
efforts to detect an effect of TRIM5a on the stability of the
incoming HIV-1 CA have thus far yielded negative results; thus we
are reluctant to conclude at this stage that a specific component of
the viral core is degraded as a complex with TRIM5a. Another
potential mechanism is that proteasomal engagement of TRIM5a
bound to the virus core results in physical dissociation of CA from
the core followed by its release from TRIM5a, thus leading to
destruction of the restriction factor and decapsidation of the core
but not necessarily degradation of CA [70]. Genetic evidence from
abrogation-of-restriction studies indicates that TRIM5a binding
requires an intact or semiintact viral capsid [60], suggesting that
TRIM5a binding to CA is highly dependent on avidity resulting
from multivalent interactions with the polymeric viral capsid. It is
thus plausible that CA is released from TRIM5a following forced
uncoating. This model is attractive in its ability to reconcile most,
if not all, of the reported data regarding the mechanism of
restriction by TRIM5a.
HIV-1 infection in many primate cell lines exhibits biphasic
titration curves, and restriction can be abrogated in trans by high
concentrations of VLPs, indicating that virus restriction is
saturable. While it is generally assumed that the saturation occurs
via sequestration of the restriction factor by the incoming virus,
our results reveal another potential mechanism. Degradation of
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TRIM5arh by HIV-1 was tightly correlated with cellular suscepti-
bility to infection by incoming virus, suggesting that loss of restriction
at high virus input may occur via degradation of the restriction factor
itself. Consistent with this view, treatment with MG132 resulted in a
three-fold decrease in HIV-1 infection of FRhK-4 as well as OMK
cells, while infection by unrestricted SIV was inhibited only
marginally (Figure S5). This result, coupled with our observations
of proteasome-dependent degradation of TRIM5a proteins in
restrictive cells, suggests that depletion of TRIM5a via the
proteasome contributes to the saturability of restriction.
The potential involvement of ubiquitylation in virus-induced
degradation of TRIM5a degradation warrants further study. The
autoubiquitylation of TRIM5d observed in vitro suggests that
TRIM5a may be ubiquitylated in trans upon polymerization of the
restriction factor on a retroviral capsid. However, we have been
unable to detect accumulation of cellular ubiquitylated TRIM5a
species following HIV-1 inoculation either in the presence or absence
of proteasome inhibitors (our unpublished observations). While many
cellular proteins are regulated by ubiquitin-dependent proteolysis,
ubiquitin-independent proteasomal degradation is also well docu-
mented (reviewed in [71]). Most E3 ligases are not degraded
following ubiquitylation of a substrate, yet notable exceptions exist.
The E3 enzyme Mdm2 is degraded following its ubiquitylation of its
target, p53 [72], and the stability of several E3 ligases is related to
their ubiquitylation status resulting from autoubiquitylation [73–75].
It will therefore be of interest to determine whether HIV-1-induced
degradation of TRIM5a is dependent on host cell ubiquitylation and
the TRIM5a RING domain.
The early post-entry stage of infection remains a fundamentally
obscure part of the retrovirus life cycle. Our results provide novel
evidence for a role for proteasome activity in TRIM5a restriction.
Further mechanistic studies of TRIM5a may reveal novel
approaches to antiviral therapy and fundamental insights into
the molecular details of HIV-1 uncoating.
Materials and Methods
Plasmids
pLPCX-TRIM5arh (rhesus macaque), pLPCX-TRIM5ahu
(human), pLPCX-TRIM5asp (spider monkey), and pLPCX-
TRIM5atam (tamarin monkey) were generous gifts from Dr. J.
Sodroski [3,31]. pCIG-N and pCIG-B were generous gifts from J.
Stoye [76]. pNL4-3 was obtained from the NIH AIDS Research
and Reference Reagent Program and the env gene inactivated as
previously described [77]. pHIV-GFP [78], pSIV-GFP [23], and
pCL-ampho [79] were gifts from D. Gabuzda, P. Bieniasz, and B.
Naviaux, respectively. R9-G89V was made by PCR mutagenesis
of the wild type HIV-1 provirus R9 utilizing site-specific primers
and verified by sequencing. pHIV-G89V-GFP was made by
transfer of the BssHII-EcoRI fragment of R9-G89V into the
BssHII-EcoRI sites of pHIV-GFP and verified by restriction
digest. pHCMV-G was provided by J. Burns [80]. pBABE-eGFP
was created by transfer of the BamHI-EcoRI fragment from
peGFP (Clontech) into the BamHI-EcoRI sites of pBABE-puro
[81]. pBABE-rhTRIM5a and pBABE-huTRIM5a were generat-
ed by PCR amplification of the rhesus and human TRIM5a
sequences from pLPCX-TRIM5arh and pLPCX-TRIM5ahu
using primers TRIM5a-1(S)-Eco 59- GATCGAATTCAGCTAC-
TATGGCTTCTGGAATCCTG-39 and pTM1-TRIMHA-R 59-
GTCTCGAGTCAAGCGTAGTCTGGGACG-39 (EcoRI and
XhoI sites underlined). The PCR products were digested and
ligated into the EcoRI and SalI sites in pBABE-puro. A TRIMCyp
cDNA was generated from oligo dT-primed owl monkey kidney
cell cDNA and PCR amplified using the TRIM5a-1(S)-Eco and
primer 59-CTAGCTCGAGTACAGAAGGAATGATCTGG-39
(XhoI site underlined) specific to the 39-UTR of the human
cyclophilin A gene. This amplification results in a Arg to Gly
substitution at codon 4 as compared to the original TRIMCyp
cDNA. The product was ligated into the EcoRI-XhoI sites of
plasmid CMX-PL1. The Myc-His6 tag was added to TRIMCyp
by PCR amplification of CMX-PL1-TRIMCyp with TRIM5a-
1(S)-Eco and primer 59-GTCTCGAGAGAGCTTGGTGAGCA-
CAGAGTCATGG-39 (XhoI site underlined). This product was
then digested with EcoRI and XhoI and ligated into pcDNA 3.1/
myc-His A (Invitrogen). The TRIMCyp containing the myc-(His)6
epitope tag was then amplified from TRIMCyp-pcDNA3.1/myc-
His A using TRIM5a-1(S)-Eco and the primer pcDNA3.1 HIS-Sal
59-ACGTCGACTTTCAATGGTGATGGTGATGATGACC-
39, and the product digested with EcoRI and SalI and ligated into
the corresponding sites in pBABE-puro. All constructs were
verified via bidirectional DNA sequencing.
Chemicals
MG132 and cycloheximide were purchased from Sigma-
Aldrich and used at final concentrations of 25 mM and 50 mM,
respectively. Cyclosporin A was purchased from CalBiochem used
at 2.5 mM final concentration. Epoxomicin was purchased from
Boston Biochem and used at 10 mM. The cathepsin inhibitor E64
was purchased from Sigma-Aldrich and was used at 40 mM.
Cells and Viruses
FRhK-4 cells were purchased from the American Type Culture
Collection. Cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum and 1% penicillin/
streptomycin. VSV-G-pseudotyped HIV-1NL4.3, HIV-GFP, and
SIV-GFP viruses were produced by calcium phosphate transfection
of 293T cells with proviral plasmid DNA (23 mg) and pHCMV-G
(7 mg). N- and B-tropic MLV virus stocks were prepared by co-
transfection of 23 mg pCIG-N or pCIG-B plasmids with pHCMV-G
(7 mg) onto the cell line 293TeGFP. This cell line is a clone generated
from 293T cells previously transduced with the retroviral vector
pBABE-eGFP and isolated by limiting dilution and selected for high
levels of GFP expression. Transfected cells were washed after
24 hours and replenished with fresh media. Supernatants were
harvested 48–72 hours after transfection, clarified by passing
through 0.45 mm filters, and stored in aliquots at280uC. Retrovirus
stocks for transduction of TRIM5a alleles were harvested from 293T
cells transfected with the plasmids pCL-ampho (10 mg), the
appropriate TRIM5a vector (15 mg), and pHCMV-G (5 mg).
Viruses were collected 48 hours after transfection and used to
transduce 293T cells. All 293T cell lines expressing TRIM5a
proteins were polyclonal cell populations obtained by selection of
transduced cells with puromycin. TRIMCyp-expressing cells were
obtained by isolation of a single cell clone via limiting dilution. HIV-
1 was strongly restricted in these cells, and restriction was prevented
by the addition of 5 mg/ml cyclosporin A (CsA).
Infection Protocol
Cells were seeded in 6-well plates at a density of 1 to 1.256106
cells/well and incubated overnight. Prior to infection, cultures
were treated for 1 hour in 50 mM cycloheximide to block protein
synthesis. In experiments involving proteasome inhibitors, cells
were incubated with both cycloheximide and the appropriate
inhibitor for 1 hour prior to infection. Viral stocks containing
cycloheximide, polybrene (5 mg/mL), CsA (2.5 mM), and protea-
some inhibitors were prewarmed to 37uC prior to addition to cells.
After culturing for 1 hr, media from zero hour timepoints was
removed and 1 ml of PBS was added. Cells were then detached
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from the plate by flushing, pelleted, washed in PBS, repelleted, and
the pellets frozen at 280uC. Cells that were challenged with virus
had media removed and replaced with viral stock and were
returned to 37uC. Individual cultures were harvested hourly using
same procedure as previously described for the zero hour
timepoints. All cell pellets were frozen at 280uC prior to analysis.
For experiments utilizing FRhK-4 cells the cells were seeded in 6
well plates at a density of 36105 cells/well and incubated
overnight. Prewarmed viral stocks containing polybrene (5 mg/
mL) were added the following day with a well harvested at the
time of viral addition serving as the zero hour timepoint. Cells
were incubated with the viral stock for the indicated time period
then trypsinized, placed in fresh D10 media at a 1:1 volume,
pelleted, washed in 1 mL complete D10 media to inactivate
trypsin, repelleted, washed 2 times in 1 mL PBS, then frozen at
280uC. In experiments with FRhK-4 cells involving MG132, the
cells were incubated with inhibitor for one hour prior to viral
addition with the zero hour timepoint being an uninfected well
harvested after 1 hour pretreatment.
siRNA Knockdown of TRIM5arh
293T and FRhK-4 cells were seeded at a density of 26105 cells
per well in 6-well plates and incubated overnight. 24 hours later,
TRIM5arh-specific siRNA [3], or a non-targeting control siRNA
(Dharmacon), were diluted to a concentration of 3 mM in 16siRNA
buffer then transfected into cells using Dharmafect 1 transfection
reagent and OptiMEM I (Gibco) according to manufacturers
protocol (Dharmacon). Cells were then incubated overnight and
retransfected with siRNAs again the following day utilizing the
identical protocol. 48 hours after the first siRNA transfection the
cells were removed from the 6-well plates and plated onto a 10 cm
dish in complete D10 media at a ratio of 1 well to 1 10 cm dish and
incubated for either 24 or 48 hours. 24 hours later, one 10 cm dish
of either TRIM5arh-specific siRNA treated cells or non-targeting
control treated cells were trypsinized and replated in 24 well plates at
a density of 26105 cells/well then incubated overnight. The
following day the remaining two 10 cm dishes of siRNA treated
cells were trypsinized, diluted 1:1 in D10 media, pelleted, washed 16
in D10 media to inactivate trypsin, repelleted, washed 26 in 1 mL
PBS per wash, repelleted, then frozen at280uC. Cells that had been
seeded the prior day in the 24 well plates were then infected with
dilutions of HIV and SIV-GFP, incubated for 48 hours, then
analyzed for GFP expression by flow cytometry.
Protein Analyses
Cell pellets were thawed and lysed in a solution containing
100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 0.5% NP-40.
Nuclei were pelleted via centrifugation at 16,0006g for 10 minutes
and post-nuclear supernatants were removed. Protein levels were
quantified via BCA assay (Pierce). Samples, normalized for total
protein, were denatured in SDS and subjected to electrophoresis
on 4–20% acrylamide gradient gels (BioRad). Proteins were
transferred to nitrocellulose and probed with HA-epitope tag-
specific rat monoclonal antibody (3F10, Roche) and Alexa Fluor
680 conjugated goat anti-rat IgG (Molecular Probes). Cells
expressing TRIMCyp were probed with the myc epitope-specific
mouse monoclonal antibody (9E10, Invitrogen) and Alexa Fluor
680-conjugated goat anti-mouse IgG (Molecular Probes). Proteins
extracted from FRhK-4 cells were probed the TRIM5a-specific
mouse polyclonal antibody (IMG-5354, Imgenex) and Alexa Fluor
680 conjugated goat anti-mouse IgG (Molecular Probes). All
immunoblots were probed with b-actin-specific rabbit monoclonal
antibody (A2228, Sigma) and IRDye800-conjugated goat anti-
rabbit IgG (Rockland). Dilutions of antibodies were 1:1000 and
1:5000 for primary and secondary respectively with the exception
of IMG-5354 which was used at a dilution of 1:2000. Bands were
detected by scanning blots with the LI-COR Odyssey Imaging
System using both 700 and 800 channels, and integrated
intensities were determined using the LI-COR Odyssey band
quantitation software with the median top-bottom background
subtraction method. The TRIM5a band intensities were then
normalized to the signals from the corresponding b-actin bands.
All signals were then expressed as a percentage of the initial
TRIM5a/actin band intensity ratio.
Genes used in this study
TRIM5arh (AY523632); TRIM5ahu (AF220025); TRIMCyp
(AY646198); TRIM5atam (AY740615); TRIM5asp (AY740616).
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